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The characteristic motor symptoms of Parkinson disease (PD) are primarily 
the result of the progressive loss of dopaminergic (DA) neurons of the substantia nigra 
(SN). The common genetic variants responsible for sporadic PD, the mechanisms by 
which these variants exert their effects, and the origins of the preferential 
degeneration of SN DA neurons remain largely unknown.  
We first aimed to identify common, non-coding PD-associated variants. We 
examined the chromatin of embryonic midbrain DA neurons and identified >100,000 
regions of open chromatin, many of which are transcriptional enhancers, as 
demonstrated by a series of transgenic reporter assays. Among these enhancers, one, 
in intron 4 of the familial PD gene SNCA, directed reporter expression in 
catecholaminergic neurons from transgenic mice and zebrafish. Sequencing this 
enhancer in 986 PD patients and 992 controls revealed two common variants, 
rs2583959 and rs2737024, associated with elevated PD risk.  
We next assessed how these and other common disease-associated variants 
influence transcription and disease risk. We developed a regulatory vocabulary of 
midbrain DA neurons to identify key transcription factors (TFs) and ranked >7,000 
disease-associated variants on their capacity to disrupt TF binding. We tested ~20 
prioritized variants using in vitro luciferase reporter assays. Established neuronal cell 
culture models are not valid cellular surrogates for embryonic DA neurons and 
resisted in vitro validation. Instead, we employed alternative strategies for evaluating 
TF and protein binding disruption, like protein binding arrays. Additionally, we 
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characterized an embryonic mouse-derived SN DA neuron cell culture model, SN4741, 
and evaluated its potential as a cellular surrogate for testing our variant predictions.  
 Finally, we queried the developmental origins of the preferential degeneration 
of SN DA neurons in PD. We examined single-cell transcriptomes from ~1,200 
midbrain DA neurons in a mouse model of PD and characterized subpopulations of 
neurons, genes, and pathways disrupted in PD at an early post-natal time point. The 
PD mutation induces precocious maturation of neuroblasts into mature SN neurons, 
accompanied by striking dysregulation of genes involved in mitochondrial function. 
We propose a model suggesting a developmental origin of PD involving disrupted 
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Chapter 1: Introduction 
1.1 A model complex disease: Parkinson disease 
Parkinson disease is the second most common neurodegenerative disease, 
affecting 1% of the population over the age of 601. It is characterized by progressive 
motor symptoms, like tremor, bradykinesia, rigidity, and postural instability2. It is 
often preceded, over the course of decades, by a variety of non-motor phenotypes like 
insomnia, REM sleep disorders, depression and anxiety, anosmia, and constipation3. 
These motor symptoms are primarily the result of the degeneration of dopaminergic 
(DA) neurons, particularly in the substantia nigra4. This degeneration of nigral DA 
neurons and the presence of protein aggregates of α-synuclein, called Lewy bodies, are 
the pathological hallmarks of Parkinson disease (Figure 1.1).  
Parkinson disease is a complex disease, likely arising from a combination of 
environmental and genetic factors. In terms of the genetic causes, both familial and 
sporadic forms exist, with familial cases representing less than 15% of cases5. Of these 
familial cases, 30% can be attributed to highly penetrant, monogenic mutations6. Both 
autosomal dominant (e.g.: SNCA7, LRRK28,9, and VPS3510) and autosomal recessive 
(e.g.: PARKIN11, DJ-112, PINK113) mutations have been identified. Interestingly, at 
the SNCA locus, in addition to six autosomal dominant missense mutations causing 
disease7,14–18, duplications19 and triplications20 of the gene results in disease, with the 
severity of the phenotype and age of onset commensurate with the number of gene 
copies21.  
Sporadic Parkinson disease is more common than familial forms of the disease 
and often exhibits a later onset of phenotypes (familial age: 59.3 ± 11.3 vs sporadic 
2 
 
age: 66.5 ± 11.8)22. For sporadic cases, there exists a genetic component of risk, with a 
narrow-sense heritability of ~0.209 (95% confidence interval [CI]: 0.148-0.271)23. 
Genome-wide association studies (GWASs) have been applied to elucidate the genetic 
basis of sporadic Parkinson disease and has implicated approximately 90 loci in 
conferring risk, finding both novel loci but those containing many of the familial 
Parkinson disease genes24. For example, the most significant signal in sporadic 
Parkinson disease has consistently been located at the SNCA locus (odds ratio (OR) = 
0.760, p-value = 4.16x10-73)25, which given its role in Lewy bodies and the pathogenesis 
of Parkinson disease suggests common mechanisms are fundamental to both familial 
and sporadic forms.  
Unfortunately, given the reliance of GWAS on linkage disequilibrium (LD), the 
causative variants at the implicated loci and the genes they disrupt are obscured. 
Further confounding the study of these loci, the majority of GWAS-implicated variants 
fall in non-coding sequences26, where the mechanism by which they confer risk is less 
straightforward than in coding variants. To begin prioritizing non-coding variants at 
GWAS implicated loci, functional fine-mapping has often been employed27. Here, the 
lead variant indicted by GWAS plus those in high LD are intersected with genomic 
annotations, like ChIP-seq, to identify variants that are more likely to be functional 
(Figure 1.2). Underlying this technique is the assumption that these non-coding 
variants confer risk by altering gene expression through disruption of a functional 




1.2 Enhancers and transcriptional regulation 
Enhancers are a cis-acting, non-protein coding DNA element that regulate 
gene transcription. Enhancers were first described in 1981, when a fragment of non-
coding DNA from the SV40 viral genome was observed to increase transcription of a 
reporter gene in HeLa cells by several hundred-fold28. Early studies into the general 
properties of enhancers found them to boost transcription of target genes in a tissue-
specific manner that is irrespective of orientation (e.g.: forward strand or reverse 
strand), distance, or position relative to the target gene28. Gene regulation by 
enhancers is highly dynamic across cell state (e.g.: cell type, developmental time, 
environmental or genetic perturbation)29,30 and each gene is often under the regulation 
of multiple enhancers31,32, each at various strengths of activity. This combinatory 
control allows for the intricacy and complexity of gene expression patterns. 
 Enhancers achieve this intricate transcriptional regulation largely through 
three mechanisms: transcription factor binding, DNA looping, and chromatin 
accessibility changes.  
 At the sequence level, enhancers contain transcription factor binding sites33. 
The number of sites34, the affinity of transcription factors for that sequence35, and the 
availability of transcription factors to bind these motifs all modulate an enhancer’s 
activity36. Classically, it was believed that the transcription factors recruited to the 
enhancer would interact with RNA polymerase II at the target gene promoter to 
initiate gene transcription37,38. Recently, it has been suggested that the polymerase 
initiates transcription in the absence of the transcription factors or enhancer, but 
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instead is paused and requires the transcription factors and enhancer to promote 
transcriptional elongation39,40.  
 Regardless the model, there is a requirement for the enhancer to interact with 
its cognate gene promoter. This is achieved through DNA looping41,42. There is a higher 
order 3D structure of DNA that regulates gene expression through the formation of 
loops in which an enhancer is brought into close physical proximity to its target 
promoter43. This DNA looping structure is formed and maintained by the cohesin 
complex44,45 and the contacts between the enhancer and the promoter are likely 
bridged by the Mediator complex46. Alterations in the chromatin conformation, either 
by the formation or dissolution of different complements of DNA loops, allow for the 
dynamic regulation of gene expression42,47.  
 The compaction of the chromatin is also an important factor in regulating 
transcription. DNA is packaged tightly around histone octamers at regular 146bp 
intervals to form nucleosomes48. This packaging not only compacts the DNA into the 
nucleus but it also regulates gene activity by restricting transcription factor binding 
and therefore, transcription. For an enhancer to function, the underlying DNA 
containing the transcription factor binding sites must be made accessible49,50. 
Chromatin accessibility can be modulated by pioneering transcription factors and 
DNA remodelling proteins in a cell type specific manner51. Pioneer transcription 
factors are a class of proteins that have a strong DNA binding affinity which are able 
to recognize their motifs even when the sequence is partially occluded by the histone 
packaging52,53. Once bound, pioneer transcription factors can recruit chromatin 
remodelers or other transcription factors to promote DNA accessibility54–56. Chromatin 
remodellers are ATP-dependent proteins that shuffle or remove histones to establish 
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nucleosome-free DNA that is accessible to non-pioneering transcription factors or 
other DNA binding proteins, like RNA polymerase II57. Only once the DNA is 
accessible, looped such that open enhancers are brought into proximity with their 
target promoters, and bound by transcription factors and other complexes, effectively 
regulated transcription can be realized (summarized in Figure 1.3).  
1.3 Regulatory variation and human phenotypes  
 While protein-coding mutations have traditionally been the focus of searches 
for disease-associated variation, non-coding, regulatory variation is frequently the 
culprit in both rare, Mendelian and common, complex diseases.  
 An early example of disease-causing mutations disrupting enhancer element 
activity is in ß-thalassaemia, where translocations and deletions of a series of 
enhancers upstream of the ß-globin gene cluster (the locus control region) ablates ß-
globin gene expression, leading to disease58. We see another classic example of rare 
enhancer variants leading to disease in autosomal dominant pre-axial polydactyly. 
Here, point mutations in an enhancer of SHH, located over 1Mb away in an intron of 
a neighbouring gene59, disrupt the expression of SHH in the developing limb bud, 
disrupting the normal morphogen gradient specifying digit location along the antero-
posterior axis60. Rare, highly penetrant point mutations in enhancers have been 
identified in other disorders like mutations in PTF1A in pancreatic agenesis61, de novo 
mutations in PAX6 in aniridia62,63, and TBX5 in congenital heart defects64.  
 There are also examples of common variants impacting variants and 
contributing to disease, as in a common variant occurring in an enhancer in intron 1 
of RET that increases risk for Hirschsprung disease in a sex-specific manner65. Many 
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common enhancer variants associated with common disease have been identified by 
GWAS. GWAS have identified thousands of risk loci, many of which do not contain 
protein-coding causal variants26,66, suggesting a role for regulatory variants in 
conferring disease risk. These non-coding variants can be prioritized through 
intersections with disease-relevant, tissue-specific enhancer catalogues combined 
with mechanistic studies to identify the causative SNP at a locus. By these methods, 
common obesity-associate enhancer variants were found to regulate IRX3 
expression67,68. Similarly, genetic fine-mapping studies in combination with genetic 
editing experiments identified an enhancer variant of EDN1 that is associated with 
five vascular diseases, as identified by GWAS69.  
While these success stories exist, our ability to prioritize variants through 
intersections with enhancer catalogues are limited by our ability to identify 
enhancers; the specificity of enhancers to tissue types, developmental time, 
pathological status, and environmental conditions, remain barriers to prioritizing the 
causative non-coding variant at many GWAS-identified loci.  
1.4 Identifying and validating enhancers  
Unlike with coding sequences, we cannot reliably predict enhancers from DNA 
sequence alone. Machine learning algorithms have recently been employed to attempt 
to learn enhancer sequence composition in order to predict enhancers from sequence 
alone70–74. These algorithms are still limited in their predictions, especially given the 
lack of quality training sets and the complexity of the sequence encoded by degenerate 
and combinatorial transcription factor binding site sequences. Sequence conservation 
has also been used to predict enhancers under the expectation that enhancers are 
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functional elements and therefore will be conserved across species at higher rates 
than background, non-functional, non-coding DNA75–79. This approach has been 
effective in finding a variety of enhancers however, fails to identify a large proportion 
of functional non-coding sequences and also misses enhancers that are recent in the 
human evolutionary history80–82.  
Most enhancer searches have shifted away from sequence analysis and have 
instead focused on molecular methods to identifying enhancers. These methods 
generally rely on exploiting the properties of enhancers to aid their searches.  
Exploiting that enhancers are bound by transcription factors, ChIP-seq 
(chromatin immunoprecipitation) is used to assay transcription factor binding sites 
genome-wide, a proportion of which will be enhancers83. Often ChIP-seq is also used 
to pull down against histone marks characteristic of enhancers (e.g.: H3K27Ac and 
H3K4me1)84–86 or enhancer associated proteins, like EP300, a transcriptional 
activator87,88.  
We can also exploit the requirement of enhancers to physically interact with 
target promoters as a means to identify enhancers. Using chromatin conformation 
capture techniques, we can identify sequences that physically interact with a 
promoter. Using 4C-seq, we can use a promoter of interest as the anchor/viewpoint 
and identify all sequences that interact with it, likely including enhancers89. On a 
larger scale, we can perform promoter-capture HiC to identify all sequences 
interacting with all promoters90,91, under the assumption that a large fraction of non-
coding interacting sequences are likely to be enhancers.  
8 
 
The increased chromatin accessibility in active enhancers is the main feature 
currently being exploited to identify enhancers genome-wide. Classic methods of 
probing DNA accessibility include DNase I hypersensitivity site sequencing (DNaseI-
seq)92,93 and FAIRE-seq (formaldehyde-assisted isolation of regulatory elements)94. 
DNaseI-seq relies on open chromatin being more susceptible to degradation by 
DNaseI. FAIRE-seq relies on open chromatin being more readily solubilized after 
crosslinking and sonication. 
Both of these methods have successfully identified extensive catalogues of 
enhancers however, they both rely on assaying a large number of cells (on the order 
of tens of millions). This cell number requirement often precludes the study of rare 
populations of cells or in studying specific cell types rather than a whole tissue. As 
such, these techniques are often limited to use in cell culture models, in order to meet 
the input requirements, prohibiting the study of enhancers in their in vivo context, or 
in assaying across developmental time or in an appropriate or perturbed environment.  
To overcome these limitations, the assay of transposase accessible chromatin 
with sequencing, ATAC-seq, has recently been developed95. Like DNaseI-seq and 
FAIRE-seq, ATAC-seq relies on a specific property of open chromatin for assay, 
specifically that open chromatin is more susceptible to fragmentation by a hyperactive 
transposase. With this method, the cell input requirements are orders of magnitude 
less, requiring 500 to 50,000 cells, with the ability to assay open chromatin in single-
cells also now a possibility. 
None of these methods for identifying enhancers solely identify enhancers – 
other sequences of the genome may interact with transcription factors or DNA-binding 
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proteins, or are in contact with a promoter, or reside in open chromatin. Once we have 
generated these catalogues, there remains the burden of proof in verifying these 
sequences as capable of regulating transcription.  
The main methods to validating enhancer activity generally rely on assaying 
reporter activity, in which the candidate enhancer sequence is placed upstream of a 
minimal reporter that directs expression of a reporter gene. In cell culture, this is 
often a luciferase assay. Luciferase assays use the firefly luciferase and renilla genes 
to quantitatively measure fluorescence activity being directed by a putative 
enhancer96. This is a medium throughput assay with dozens of enhancers routinely 
tested at once. Scaling this up, massively parallel reporter assays (MPRAs) are a 
related, higher throughput assay, where instead of measuring luciferase fluorescent 
activity, the transcription of a reporter gene is measured by RNA-seq, allowing the 
assay of tens of thousands of sequences simultaneously97–100.  
Both of these methods are in vitro, transient expression assays. As such, they 
are unable to assess the cell type specificity of enhancer activity, are limited to 
assaying a single cell type and cannot assess the impact of developmental time or 
environmental perturbation on enhancer activity. Reporter assays in transgenic 
animals overcome these issues. These assays usually involve random integration of 
an enhancer-promoter-reporter construct into the animal’s genome. Often, the 
reporters used in in vivo reporter models are lacZ expression with ß-gal staining (“blue 
mice”)101,102 or fluorescence activity – often used in zebrafish given their relative 
translucency throughout development103.  
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These assays allow for the measurement of enhancer activity across 
developmental time, tissues, and perturbation. These assays are informative for the 
deep understanding of an enhancer but do not scale well to assaying large numbers of 
enhancers simultaneously. Unfortunately, neither the in vitro or in vivo reporter 
assays generally measure enhancer activity using the endogenous locus or promoter 
and as such do not preserve one of the core principles enhancers use in regulating 
gene expression: chromatin looping.  
A recent method in probing enhancer activity seeks to overcome these 
limitations through genome editing at the endogenous locus, usually by CRISPR-
Cas9104–106. Here, the native locus is edited to disrupt an enhancer, either by modifying 
the chromatin state107, introducing a variant67,108,109 or through its wholesale 
deletion110,111, and changes to gene expression and chromatin conformation are 
measured. If the editing occurs in an in vivo model, the animal model can be examined 
for disease-related phenotypes and disease susceptibility can be tested. This method 
of validating enhancer activity remains low throughput but is commonly used in 
confirming enhancer activity or in assessing the effect of an enhancer variant on the 
cognate gene expression in vivo.  
1.5 Evaluating gene expression 
Enhancers regulate gene expression. Our ability to measure gene expression 
is fundamental to our understanding of how DNA gives rise to phenotypes. To 
measure gene expression, we can examine either the ultimate gene product, proteins, 
or we can consider the intermediary product, RNA.  
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Proteins are the culmination of all regulatory steps from transcription to 
translation and are the ultimate agents conferring phenotypes. Common strategies 
for measuring protein abundance include antibody-based methods, including western 
blot112,113 and enzyme-linked immunosorbent assay (ELISA)114, or spectrometry-based 
methods, like liquid chromatography mass spectrometry (LC/MS)115. While these 
methods are able to measure protein abundance with high sensitivity, they can be low 
throughput, rely on the availability and specificity of an appropriate antibody against 
the protein of interest (western, ELISA), are technically demanding (LC/MS), or 
require a large amount of sample (e.g.: western blots can require ~10-100µg of total 
protein116) precluding measurement of protein levels for rare populations of cells117.  
Measuring RNA levels avoid these issues but relies on the assumption that 
transcript levels correlate with protein levels, which has been called into 
question118,119. However, measuring the transcriptome is the favoured method for 
evaluating gene expression due to the relative ease of the protocols, the scale of data 
generated, and the low input requirements (i.e.: as low as single cells). Methods for 
measuring RNA levels, from low- to high-throughput, include northern blot120, RT-
qPCR121–123, microarrays124–126, and RNA-seq127–131. RNA-seq is a relatively new 
technology that generally involves RNA conversion to cDNA and ligation of 
sequencing adapters followed by next generation sequencing. The reads are aligned 
to either the transcriptome or genome and gene expression is quantified, novel 
splicing events or isoforms are uncovered, and non-coding RNAs (e.g.: miRNAs, 
lncRNAs, eRNAs) are identified132. RNA-seq allows for the quantification and 
comparison of transcripts across cell types, tissues, individuals, time points, disease 
state or, environmental perturbation with high sensitivity. However, bulk RNA-seq is 
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limited to measuring average gene expression across pools of cells, potentially 
masking subpopulations of cells. In response to this shortcoming, new protocols for 
quantifying RNA expression in single cells were developed.  
 The invention of single-cell RNA-seq (scRNA-seq)133–137 has allowed for the 
measurement of transcripts from hundreds to thousands of single cells 
simultaneously, enabling the in-depth analysis of heterogeneous populations of cells. 
scRNA-seq involves the isolation of single cells (either though cell sorting138, 
combinatorial indexing139, or droplet-based techniques137), reverse transcription of 
extracted RNA into cDNA, and the production of sequencing-ready libraries with 
unique barcodes for each cell for deconvolution post-sequencing. Each cell’s sequences 
are aligned and quantified and sparse matrices of cells by gene expression are 
generated to summarize the expression data. The gene expression data is sparse given 
the low efficiency of RNA capture coupled with the low expression of many genes140. 
This scarcity of data is mitigated by the collection of a large number of cells; there is 
a tradeoff in analysing sparse data from many cells versus analysing very deep data 
from just a few samples. Once the expression is quantified across all cells, cells are 
clustered using dimensionality-reduction algorithms (e.g.: PCA141, tSNE142, UMAP143) 
into subpopulations of related cells. From these clusters, marker genes of each can be 
identified, subpopulations of cells can be assigned to biological functions or anatomical 
regions, and genes differentially expressed between clusters are identified.  
1.6 Applying scRNA-seq to biological questions  
With this technology in hand, scRNA-seq has been rapidly applied to a variety 
of biological questions. scRNA-seq has been used to uncover tissue and cellular 
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heterogeneity, identify and profile rare cell types, and compare healthy and diseased 
tissues.  
In one of the first demonstrations of scRNA-seq, the fledgling technology was 
applied to examining cancer, focusing on circulating tumour cells in a melanoma 
patient135. This marked the beginning of a slew of studies into tumoural heterogeneity 
and microenvironment, markers of disease progression or metastasis, and response to 
therapy using scRNA-seq. For example, common brain tumours, glioblastoma and 
medulloblastoma, were examined for intratumoural heterogeneity. Researchers 
identified four cellular subtypes in glioblastoma tumours and three clusters of distinct 
cells in medulloblastoma tumours144,145. Each tumour is composed of each of the 
subtypes and depending on the composition and degree of heterogeneity within a 
tumour, survival was influenced146. Like tumours, brains are incredibly complex and 
highly heterogeneous; even within a brain region, there is a large diversity of cell 
types, both neuronal and non-neuronal. scRNA-seq has been used to identify cellular 
subtypes in a variety of brain regions, like the cortex and hippocampus where 
researchers identified 47 clusters147, the temporal lobe148, and the midbrain149. Specific 
types of neurons and support cells have been assayed as well to find subtypes within 
these restricted populations. For example subsets of oligodendrocytes150 and 
dopaminergic neurons151 have been identified.  
These studies have used scRNA-seq to better understand cell type composition 
within a tissue. Even when assaying tissues that have been studied extensively, 
scRNA-seq can identify novel cell populations. In the case of blood dendritic cells and 
monocytes, which had been canonically classified into six subtypes, scRNA-seq 
suggests there are instead ten subtypes152. One of these subtypes was a novel 
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progenitor population, making up just 0.02% of cells assayed, which while rare, could 
be exploited as a new therapeutic target. Similarly, in the lung epithelia, a novel, rare 
population of cells, composed of pulmonary ionocytes, was identified by scRNA-
seq153,154. Interesting, this population of cells, representing less than 1% of airway 
epithelial cells, express high levels of CFTR, suggesting that this rare, previously 
unidentified cell population may be involved in cystic fibrosis pathogenesis.  
Clearly, scRNA-seq is an important technology in understanding disease. 
Many studies have used scRNA-seq to compare the diseased and healthy state in order 
to understand the molecular mechanisms of disease pathogenesis and progression. In 
one example, single cells were isolated from the lungs of control and influenza-treated 
mice and the host and viral transcriptomes were measured155. Doing so, nine clusters 
of cells, corresponding to the major classes of cells expected, were observed. 
Unexpectedly, each cluster of cells contained cells with high rates of viral infection, 
where previously it had been believed that only certain subpopulations of cells carried 
the burden of infection156,157. Another example comparing healthy and diseased tissues 
involved the comparison of failing and non-failing heart transcriptomes158. This 
comparison identified subpopulations of cardiomyocytes that execute a 
dedifferentiation transcriptomic profile in the disease-state, suggesting an effort for 
these cells to regenerate following stress. A subsequent paper compared 
cardiomyocytes in failing hearts and in hearts that are stressed but not yet failing, to 
examine the molecular basis of that transition159. These two studies indicate the value 
in using scRNA-seq to identify populations of cells implicated in disease.  
Bringing together all of these use cases for scRNA-seq, we can turn to a study 
that used scRNA-seq to characterize the heterogeneity of cell types in the entorhinal 
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cortex in the context of Alzheimer disease (AD)160. In this study, they identify 
subpopulations of microglia, astrocytes, neurons, oligodendrocytes, oligodendrocyte 
progenitors, and endothelial cells in the entorhinal cortex. Some of these clusters were 
novel and originated exclusively from AD brains, suggesting extensive transcriptional 
changes as a result of the disease. Examining these disease-specific clusters, groups 
of dysregulated genes, particularly transcription factor networks, are implicated in 
regulating cell fate transitions between healthy and AD subpopulations. This study 
exemplifies the power of scRNA-seq in defining the cellular heterogeneity of tissues, 
identifying new and rare cell subtypes, in the context of disease to better understand 
the mechanisms underlying pathogenesis and disease progression.  
1.7 The transcriptional origins of sporadic Parkinson disease 
We can consider sporadic Parkinson disease to be the result of variation 
leading to aberrant transcription ultimately leading to the preferential degeneration 
of midbrain dopaminergic neurons. To investigate this process, I set out to investigate 
each of these steps in depth.  
I was motivated to identify non-coding variants that are responsible for 
elevating Parkinson disease risk. In Chapter 2, I identify enhancers in midbrain 
dopaminergic neurons and focus on a novel midbrain-specific enhancer of SNCA and 
within it, reveal two common Parkinson disease-associated variants.  
I also wanted to investigate how disease-associated non-coding variants alter 
transcription in modulating risk. In Chapter 3, I identify important transcription 
factors for midbrain dopaminergic neurons and predict how thousands of variants 
associated with risk for a variety of neurodegenerative and neuropsychiatric disorders 
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alter their binding. In evaluating these predictions, I explore the suitability of a 
variety of in vitro cellular surrogates, particularly focusing on how appropriate an 
immortalized mouse substantia nigra cell line is as a surrogate for in vitro assays.  
Finally, I was curious about the predisposition of dopaminergic neurons of the 
substantia nigra to preferentially degenerate in Parkinson disease. In Chapter 4, I 
evaluate the transcriptomes of developing dopaminergic neurons of the midbrain in 
the context of a mouse model of Parkinson disease. I identify subpopulations of 
neurons of early postnatal dopaminergic neurons, including a novel population of 
substantia nigra neurons. Additionally, in comparing the diseased and healthy states, 
I observe striking dysregulation of mitochondria that we hypothesize underlies the 
precocious differentiation of neuroblasts into mature substantia nigra neurons.  
Overall, I examine how alterations in DNA sequence, transcription factor 







Figure 1.1: The pathological hallmarks of Parkinson disease 
 
There are two pathological hallmarks of Parkinson disease primarily responsible for 
the motor symptoms: the selective degeneration of midbrain dopaminergic neurons in 
the substantia nigra and the appearance of protein aggregates of alpha-synuclein, 




Figure 1.2: Genomic annotations can be used to prioritize GWAS-implicated 
variants 
 
After a GWAS is performed, the results can be summarized on a Manhattan plot, 
where each variant evaluated is plotted against the significance of its association with 
the trait. Examining each significant locus more closely, the magnitude of association 
for each SNP in the genomic region and the LD relationship with the lead SNP is 
examined and statistically likely causative variants are identified. This analysis can 
be augmented by the inclusion of functional annotations. In this example, the lead 
SNP (purple diamond) and four others in high LD (red dots) are the most statistically 
significant variants however, the two variants to the left also overlap a functional 
element (pink box) and are therefore more likely to be causative and are prioritized 











Figure 1.3: Enhancers regulate transcription 
 
Chromatin accessibility, conformation, and transcription factor binding are factors 
influencing enhancer activity. In its inactive state, chromatin is tightly compacted 
around nucleosomes (grey circles), and as such is inaccessible for protein binding. For 
enhancers to be active, nucleosomes must be disassembled or shuffled out of the region 
such that the DNA is accessible. Through the actions of cohesin (pink hoop) and 
mediator (green cloud), an enhancer is brought into proximity with its target promoter 
through chromatin looping. To form this bridge between the enhancer and promoter, 
the mediator complex interacts with both the paused RNA polymerase II and 
transcription factors (green, purple, orange, and red circles) that are bound to short 
sequence motifs at the enhancer (stripes in the black box). Once in proximity, current 
models suggest that the enhancer promotes gene expression by signaling RNA 
polymerase II (blue), already bound at the gene’s promoter, to exit its paused state 




Chapter 2: Chromatin-based analyses of 
dopaminergic neurons1 
2.1 Applying chromatin data to investigate non-coding variation in 
Parkinson disease 
Parkinson disease (PD) is a common progressive neurodegenerative disorder 
characterized by preferential and extensive degeneration of dopaminergic (DA) 
neurons in the substantia nigra4,161. This loss of midbrain (MB) DA neurons disrupts 
the nigrostriatal pathway and results in the movement phenotypes observed in PD. 
While this disorder affects approximately 1% of people over 70 years old worldwide162, 
the mechanisms underlying genetic risk of sporadic PD in the population remains 
largely unknown. Familial cases of PD with known pathogenic mutations are better 
understood but account for ≤10% of PD cases163.  
The α-synuclein gene (SNCA) is commonly disrupted in familial PD through 
missense mutations predicted to promote misfolding7,15,16 or genomic multiplications, 
resulting in an over-expression paradigm20. The SNCA locus has also been shown by 
genome-wide association studies (GWAS) to harbour common variation modulating 
risk of sporadic PD25. In the same way, common variation at over 40 additional loci 
have been implicated in PD23, but the genes modulated and causal variants 
responsible for elevating risk remain largely undetermined.  
                                                     
1 This work has been published in the American Journal of Human Genetics and adapted for use in this thesis. 
McClymont, S.A. et al. (2018). Parkinson-associated SNCA enhancer variants revealed by open chromatin in mouse 




That most GWAS-implicated variants are non-coding26 is a major source of this 
uncertainty, obstructing the identification of: 1) the causative variant at a locus; 2) 
the context in which the variation is acting and; 3) the mechanism by which a variant 
asserts its effect on disease risk.  
GWAS are inherently biologically agnostic and their exploitation of linkage 
disequilibrium (LD) structure frequently results in many variants being implicated at 
any one locus, with no one variant prioritized over those in LD. One method to 
prioritize non-coding variants is to examine the chromatin status at that locus26,164,165. 
Accessible chromatin is more likely to be functional and variants therein may impact 
that activity, more so than those variants residing in inaccessible chromatin. Recent 
studies have prioritized neuropsychiatric variants through examination of the 
chromatin status of iPSC-derived neurons or post-mortem whole brain tissues166,167. 
However, chromatin accessibility is dynamic, often varying across cell types and 
developmental time, therefore understanding and isolating the in vivo cellular context 
in which variation acts is critical to increase our ability to prioritize variants and 
query their methods of action26,168–170.  
Exploiting the preferential vulnerability of MB DA neurons in PD, we have 
prioritized DA neurons as the biological context in which a fraction of PD-associated 
variation likely acts. DA neurons in other brain regions, such as the forebrain (FB), 
provide a related substrate that is less vulnerable to loss in PD. We sought to use 
chromatin data from ex vivo populations of DA neurons to investigate the 
contributions of non-coding variation to PD risk. To maximize the specificity of the 
biological context, we generated chromatin signatures of purified mouse MB and FB 
DA neurons. We examined the resulting regulatory regions for their ability to direct 
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in vivo reporter expression and developed a regulatory sequence vocabulary specific 
to DA neurons. In doing so, we identified a novel MB DA regulatory element that falls 
within intron 4 of SNCA and demonstrate its ability to direct reporter expression in 
catecholaminergic neurons of transgenic mice and zebrafish. Furthermore, this 
enhancer harbours two common variants falling in a haplotype that we determine to 
be associated with PD risk. We demonstrate these enhancer variants impact protein 
binding and we propose a model for how the variants and the haplotype at large 
contribute to SNCA regulatory control. This work illustrates the power of cell context-
dependent guided searches for the identification of disease associated and functional 
non-coding variation. 
2.2 ATAC-seq identifies open chromatin in midbrain and forebrain 
dopaminergic neurons 
To identify open chromatin regions (OCRs) in DA neurons, we performed 
ATAC-seq95 on ~50,000 fluorescent-activated cell sorting (FACS)-isolated cells (per 
replicate) from microdissected regions of the MB and FB of embryonic day 15.5 (E15.5) 
Tg(Th-EGFP)DJ76Gsat BAC transgenic mice171 (Figure 2.1A). This mouse line 
expresses EGFP under the control of the tyrosine hydroxylase (Th) locus, labeling 
catecholaminergic neurons (i.e.: DA, noradrenergic, and adrenergic neurons). To 
confirm capture of the corresponding catecholaminergic neurons, we performed RT-
qPCR on the isolated reporter-labeled cells, establishing them to be enriched for DA 
neuronal markers relative to unlabeled populations from the same dissected tissues 
(Supplementary Figure 2.1).  
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To evaluate the ATAC-seq libraries, we examined in silico quality control 
measures (Supplementary Figure 2.2), evaluated the called peaks and read pile-ups 
with the Integrative Genomics Viewer (IGV)172,173, and quantified the correlation 
between brain regions and within replicates. A representative browser trace at the Th 
locus in both MB and FB libraries is presented in Figure 2.1B. Replicates are well 
correlated: MB library replicates have an average correlation of 0.72 (Figure 2.1C), 
and FB replicates are more correlated at r = 0.86 (Figure 2.1D). Given the robust 
correlation between replicates, we pooled all reads from the same brain region and 
called peaks on this unified set to increase our power to detect regions of open 
chromatin. As a result, we identified 104,217 regions of open chromatin in the MB DA 
neurons and 87,862 regions in the FB. MB and FB libraries are moderately well 
correlated (average r = 0.64; Supplementary Figure 2.3), with approximately 60% 
of MB OCRs also represented in the FB libraries. 
To assess these catalogues for characteristics of functionality, we examined the 
sequence constraint underlying the called regions of open chromatin, excluding peaks 
that overlap promoters. Promoters are typically accessible93 and thus, we aimed to 
reduce the inflation of sequence conservation due to highly conserved promoter-
overlapping ATAC-seq peaks. Despite removal of these highly conserved peaks, we 
observed a high degree of sequence constraint underlying open chromatin peaks 
compared to background (Figure 2.1E). The fact that elements in these libraries of 
putative cis-regulatory elements (CREs) are constrained, highlights their likely 
functional significance.  
To further examine the OCR catalogues for biological relevance, we explored 
the gene ontology (GO) terms of nearby genes. While CREs are not restricted to acting 
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solely on the nearest gene, this restriction is often used as a proxy in the absence of 
other information. To bolster our predictions, we have also generated bulk RNA-seq 
data on these same populations of sorted cells (Supplementary Figure 2.4) and used 
these data to examine the GO terms of the nearest expressed gene (RPKM ≥ 1). While 
still imperfect, implementing this as a proxy for function results in GO terms enriched 
for neuronal functions in both MB and FB OCR catalogues (Figure 2.1F, G). Thus, 
we establish these OCR catalogues are enriched for putative CREs likely directing the 
expression of genes with key roles in neuronal biology.  
2.3 Candidate regulatory regions are capable of directing expression 
in vivo  
Although our OCR catalogues appear to be enriched for functional elements on 
the basis of sequence conservation and GO, both of these metrics are indirect 
surrogates for true measures of function. To more directly measure the biological 
relevance of the catalogues and to identify enhancers, we assessed the capability of 
the candidate CREs to direct expression in vivo. 
We took advantage of the large repository of elements that have already been 
tested in lacZ reporter assays in vivo and catalogued in the VISTA enhancer 
browser174 (accessed September 4, 2016). Overlap between our catalogues and all 
2,387 elements in the VISTA enhancer browser, which were scored for their ability to 
direct lacZ reporter expression in E11.5 mice, was quantified (Supplementary Table 
2.1). Of the 1,264 elements in VISTA identified as enhancers, 786 were present in the 
MB catalogue and 719 were present in the FB catalogue (Figure 2.2A). Examining 
the overlap of the FB and MB catalogues with enhancers demonstrated to direct 
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expression in either non-neuronal or neuronal tissues, we observed that 42-47% of 
enhancers reported to direct expression in non-neuronal tissues are present in the 
catalogues. By contrast, 71-76% of enhancers that direct expression in one or more 
regions of the brain overlapped the FB and MB catalogues (Figure 2.2B) confirming 
an abundance of brain enhancers in our catalogues. Stratifying these confirmed 
neuronal enhancers on the basis of their expression patterns in VISTA, we observed 
an abundance of MB-specific enhancers in our MB catalogue, and an abundance of 
FB-specific enhancers in our FB catalogue, with 77% of MB- and FB-specific 
enhancers in VISTA captured in our MB and FB catalogues, respectively (Figure 
2.2C). Collectively, these data establish that our region-specific OCR catalogues 
capture region-specific, active CREs with high efficiency.  
To extend our assessment of the biological activity of sequences within these 
OCR catalogues, we focused on an additional five candidate CREs not already tested 
in the VISTA browser and evaluated their ability to act as enhancers in lacZ reporter 
mice and in transgenic zebrafish TdTomato reporter assays. All five regions were 
represented by robust peaks in both the MB and FB catalogues (Supplementary 
Figure 2.5). Two regions, one in the first intron of Kcnq3 and the other downstream 
of Foxg1, were additionally prioritized using H3K27Ac ChIP-seq from a variety of 
tissues from E11.5 and E15.5 embryonic mice, seeking to limit our selection to 
candidate enhancers predicted to have neuronal-specific activity. The remaining three 
candidate CREs were selected on their proximity to genes important in DA neuron 
biology. We selected sequences at Foxa2 and Nr4a2, as both are key transcription 
factors (TFs) in the development and maintenance of DA neurons175–178. The final 
region, located in an intron of Crhr1, was selected as this locus has been implicated in 
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PD by GWAS25 and our group has recently prioritized this gene as a candidate for PD 
risk179. All selected sequences were lifted over to hg19, facilitating the identification 
and assay of their corresponding human sequence intervals. 
When tested in transgenic reporter mice at E11.5 (Supplementary Figure 
2.5), two of the five regions (those near KCNQ3 and FOXA2) were validated as 
enhancers (Figure 2.2D, H). Recognizing that a disparity exists between the 
developmental time at which we generated the catalogues (E15.5) and when the mice 
were assayed (E11.5), which may compromise validation rates, we also assayed each 
sequence across multiple time points in zebrafish. All assayed regions except that at 
KCNQ3 directed reporter expression in mosaic transgenic zebrafish (Figure 2.2E, F, 
G, H). All five regions displayed enhancer activity in vivo in neuronal tissues in one 
or both transgenic assays. Our transgenic animal experiments corroborate the results 
of the retrospective VISTA enhancer browser intersection; implying that our OCR 
catalogues are biologically active and enriched for sequences capable of driving neural 
expression in vivo.  
2.4 A midbrain-specific enhancer directs expression in 
catecholaminergic neuron populations  
Having established the biological robustness of the OCR catalogue, we moved 
to exploit these data to investigate how non-coding variation therein may be 
contributing to PD risk. We established two complementary strategies. First we 
sought globally to examine the overlap of PD GWAS SNPs23,25 and those in LD (r2>0.8) 
with our DA OCR catalogues. In doing so, we identify 129 unique PD-associated 
variants at 20 GWAS associated loci that are present in one or both of our OCR 
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catalogues (34 specifically overlap the MB catalogue, 14 specifically overlap the FB 
catalogue, and 81 overlap both).  
Second, we examined the chromatin landscape surrounding familial PD genes, 
focusing on those with no obvious overlaps in the first strategy. In this, we turned our 
attention to the SNCA locus. Despite this locus being the most significant hit in PD 
GWASs23,25, the LD structure surrounding the lead SNP (rs356182) is such that no 
variants in LD are apparent at our r2 cut-off and the lead SNP itself is not overlapped 
by either our MB or FB catalogue. Given α-synuclein’s established role in PD 
pathogenesis and the strength of GWAS signal at SNCA, we prioritized this locus for 
a closer, more targeted, inspection.  
We first noted that Snca expression differs significantly between the MB and 
FB DA neurons in our bulk RNA-seq (Figure 2.3B). Examining the chromatin 
accessibility at the Snca locus, the MB and FB are largely the same with the exception 
of one robust peak in intron 4 (mm9: chr6:60,742,503-60,744,726) that is present in 
the MB and completely absent in the FB (Figure 2.3A). DNase hypersensitivity site 
(DHS) linkage93,180 suggests that this putative CRE interacts with the SNCA 
promoter. Given the MB-specificity of this putative CRE and indications that it 
interacts with the SNCA promoter, we anticipated that this region may be a driving 
force behind the MB-specific expression of Snca.  
To test this hypothesis, we assayed whether the central portion of this putative 
CRE, when lifted over to hg19 (chr4:90,721,063-90,722,122), is capable of directing 
appropriate reporter expression in transgenic zebrafish and mouse reporter assays. 
Stable transgenesis of zebrafish indicates that this CRE directs reporter expression 
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at 72 hours post fertilization in the locus coeruleus, a key population of 
catecholaminergic neurons preferentially degenerated in PD181, and along the 
catecholaminergic tract through the hindbrain, which is largely composed of DA 
neurons182 (Figure 2.3C). Additionally, we observe reporter expression throughout 
the diencephalic catecholaminergic cluster with projections to the subpallium, which 
is analogous to mammalian dopaminergic projections from the ventral midbrain to 
the striatum183. Reporter expression in these transgenic zebrafish is largely consistent 
with an enhancer active in catecholaminergic populations.  
To further evaluate this CRE in a mammalian system, we generated lacZ 
reporter mice and examined reporter activity across developmental time. Whole 
mount E12.5 reporter mice indicate this enhancer directs exquisitely restricted 
expression in Th+ populations, including the dorsal root ganglia, extending into the 
sympathetic chain, and throughout the cranial nerves (particularly the trigeminal). 
Additional diffuse staining is noted throughout the MB and FB (Figure 2.3D). 
Specifically examining the brains of lacZ animals at E15.5, reporter expression is 
identified in the MB and hypothalamus, with strong expression through the 
amygdala/piriform cortex and along the anterior portion of the sympathetic chain 
(Figure 2.3E); similar reporter patterns are seen at P7 (Figure 2.3F). At P30, we 
detect reporter activity in the amygdala, hypothalamus, thalamus, periaqueductal 
grey area, brain stem, and importantly, in the substantia nigra and ventral tegmental 
area (Figure 2.3G). By contrast, in aged lacZ reporter mice (574 days old, ~19 
months), we only detect strong reporter expression in the brain stem and observe 
weak reporter expression in the amygdala (Figure 2.3H). Collectively, the regions in 
which we detect reporter activity reflect those compromised in PD; Lewy bodies 
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(aggregates of α-synuclein) have been detected in the locus coeruleus, sympathetic 
chain, amygdala, hypothalamus, ventral tegmental area, periaqueductal grey area of 
PD patients184–188, and critically the preferential degradation of the substantia nigra 
is the pathological hallmark of PD progression4. This enhancer directs region-specific 
appropriate expression throughout development in key locations concordant with 
SNCA activity in PD pathogenesis.  
2.5 Enhancer variants are significantly associated with Parkinson 
disease risk  
Following confirmation of this CRE’s regulatory activity in brain regions 
associated with PD, we next inspected this sequence for PD-associated variation. We 
sequenced across this interval in 986 PD patients and 992 controls and identified 14 
variants (Supplementary Table 2.2), 4 of which were common and present in both 
cases and controls with a minor allele frequency greater than 5%. Of these, two tightly 
linked variants (r2 = 0.934; Supplementary Table 2.3), rs2737024 (OR = 1.25, 95% 
CI = 1.09-1.44, p-value = 0.002) and rs2583959 (OR = 1.22, 95% CI = 1.06-1.40, p-value 
= 0.005), were significantly associated with PD (Table 2.1). These data support a role 
for variation within the enhancer in conferring PD risk.  
Finally, we set out to refine the haplotype structure and understand how this 
identified variation may be interacting with other variants at this locus. A panel of 
common variants had previously been genotyped across SNCA and PD-associated 
haplotypes were identified189. After genotyping our patients and controls for a subset 
of this panel of variants in addition to all enhancer-associated variants identified by 
sequencing (Supplementary Table 2.4), we identified a single haplotype that was 
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significantly associated with PD (p-value = 0.003), with a higher observed frequency 
in PD patients (28.3%) compared to controls (23.4%; Table 2.2). This haplotype 
implicates some of the same variants as in Guella et al.189 (rs356220, rs737029) but 
also implicates rs356225 and rs356168, and the two enhancer-associated variants. 
Additionally, within the 1000 Genomes data, we observe that moderate LD structure 
exists between the lead GWAS variant (rs356182) and the enhancer variants (r2 = 
0.418, D’ = 0.745) in the general European population. Despite the moderate LD, the 
risk allele of rs356182 falls in the PD-associated haplotype that we identify 94% of the 
time. Thus, it is likely that at least part of the risk captured by rs356182 can be 
attributed to these enhancer variants and the implicated haplotype reported here. 
Further, this does not preclude additional variants from being present and 
contributing to the risk captured by the lead SNP, as the rs356182 risk allele can 
occur in the absence of the enhancer associated variants (i.e.: ~31% of EUR individuals 
with the rs356182 risk allele do not carry the risk alleles of the PD-associated 
enhancer variants). A schematic of the variants, open chromatin regions, chromatin 
interactions93,180, and LD structure at this locus is presented in Figure 2.4. Of the 
variants whose minor alleles define this PD-associated haplotype, including rs356182, 
only the two enhancer associated variants and rs2737029 are identified as eQTLs for 
SNCA expression in any tissue in the GTEx database. Collectively, these data identify 
a catecholaminergic enhancer harbouring common variation that is part of a larger 
haplotype associated with PD risk, likely by modulating SNCA activity. 
2.6 Deleting the disease-associated enhancer 
  To confirm that this enhancer governs expression of SNCA, we deleted the 
enhancer in the SK-N-SH human neuroblastoma cell line, which is often used as an 
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in vitro model of DA neurons190, with the goal of quantifying expression changes of 
nearby genes following the enhancer deletion. We designed four guide RNA pairs on 
either side of the enhancer, along with a repair template for co-transfection to allow 
for screening and selection of enhancer-deletion clones. The repair template contained 
a fluorescent marker, mCherry, for screening, and a selectable blasticidin-resistance 
cassette, all bound by loxP sites and arms of homology, to promote homology-directed 
repair following double-strand break by CRISPR-Cas9 (Figure 2.5A).  
Unfortunately, upon transfection of the necessary plasmids for the enhancer 
deletion, the majority of transfected cells died within 24 hours, while control cells did 
not (mock transfection, transfection of the repair template alone). We considered the 
possibility that the strong SV40 promoter directing expression of the blasticidin-
resistance gene might be interfering with transcription of SNCA at this locus and 
over-expressing toxic SNCA products; as such, we also generated an empty repair 
template, containing just the loxP sites and arms of homology for co-transfection with 
our guide RNA combinations (Figure 2.5A). Under these conditions, we continue to 
observe massive cell death within 24 hours of transfection of the editing components. 
These experiments indicate either a technical issue with editing SK-N-SH cells, which 
we have tried to control for, or that this locus is required for cell viability in cell 
culture.  
To address this possibility, we have turned to an in vivo model and have 
generated enhancer deletion mouse lines, where we designed a pair of guide RNAs 
against the endogenous mouse Snca enhancer locus (Figure 2.5B). These edited mice 
appear to be viable and healthy. With this model, we will extract MB DA neurons and 
assess the impact of the enhancer deletion on Snca expression. Additionally, with this 
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in vivo model in hand, we can assay more complex phenotypes and examine the mice 
for PD risk and susceptibility. We will be treating the mice with lipopolysaccharide, 
an inflammatory agent known to induce Parkinson-like phenotypes in mice191,192, and 
assessing the mice for a variety of movement phenotypes, using the rotarod or pole-
descent tests, and evaluating by histology the degree of degeneration of MB DA 
neurons as compared to non-enhancer deleted mice (Figure 2.5C). These experiments 
are designed to illuminate the role of this disease-associated enhancer in both 
regulating cognate gene expression and in modulating the risk of Parkinson disease. 
2.7 Discussion 
The identification and prioritization of biologically pertinent non-coding 
variation associated with disease remains challenging. Recent studies by our and 
other groups have emphasized the importance of cellular context in the identification 
of sequences harbouring biologically pertinent variation and the genes they regulate. 
To this end, we used chromatin signatures from ex vivo isolated DA neurons to reveal 
biologically active sequences that harbour non-coding variation contributing to PD 
risk. We generated robust OCR catalogues for both MB and FB DA neurons, confirmed 
their capacity to act as enhancers, and notably, identified two variants located within 
a MB-specific enhancer that are associated with an increase in PD risk.  
In contrast to strategies predicated solely on dissection of post-mortem tissues 
or on the differentiation of cultured cells, we leveraged the use of transgenic reporter 
mice to specifically isolate Th-expressing neurons from discrete neuroanatomical (FB 
and MB) domains. While our approach assays a more refined population of DA 
neurons than would be achieved via gross dissection, recent single-cell RNA-seq 
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analyses of these same cells make clear that even within these highly restricted MB 
and FB populations there exist two primary cellular phenotypes179. The “homogenous” 
MB and FB populations each are comprised of an immature neuroblast population 
and a more mature, domain specific, post-mitotic population of DA neurons. As such, 
our OCR catalogues capture the chromatin accessibility from both of these states. 
These catalogues are demonstrably biologically relevant for our purposes, but future 
studies requiring even greater homogeneity may wish to consider single-cell ATAC-
seq to refine these domains further193.  
In our in silico validation of the catalogues, we established them to be enriched 
for both sequence constraint and biological relevance in a manner consistent with 
function and their FB/MB origin. Furthermore, these sequences are frequently 
domain appropriate enhancers, with each catalogue capturing a large fraction (77%) 
of previously validated MB and FB enhancers. Although an abundance of regions are 
shown to direct neuronal expression compared to those annotated as negative or non-
neuronal, it is interesting to note that almost half of the sequences previously 
documented not to direct expression in vivo are also represented in one or both of our 
catalogues.  
Given the frequently dynamic nature of CRE activity, this overlap with 
negative regions likely results from temporal differences in these assays. Our data 
indicates these regions are accessible at E15.5 but the lacZ reporter assays were 
carried out at E11.5; regions that have been annotated as negative at E11.5 may be 
active at later time points and, as such, appear in our catalogues. As we moved from 
these unbiased functional comparisons to more highly selected ones, the potential 
impact of temporal differences became more pronounced. In mouse transgenic 
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reporter assays, two of five assayed putative CREs direct detectable expression of lacZ 
in neuronal populations. Consistent with the temporally dynamic nature of CREs, 
when these same regions are tested in zebrafish across multiple developmental time 
points, we observe four of the five sequences to act as neuronal enhancers.  
Taken collectively, these data establish a robust biological platform in which 
PD-associated variation can be evaluated. To this end, an obvious candidate to 
interrogate was an apparent MB-specific open chromatin domain within intron 4 of 
the known PD-associated gene, SNCA. We assayed the activity of this putative CRE 
in zebrafish and across the life course of mice and found it to be active in key 
catecholaminergic structures injured in PD (e.g.: the substantia nigra and locus 
coeruleus), from mid-gestation until at least P30. Thereafter, the utilization of this 
enhancer in the brain is diminished and by late life appears restricted to the 
brainstem and amygdala. By the time of clinical presentation, PD patients have 
already lost a significant proportion (≥30%) of their nigral DA neurons4,194; the 
observed biology of this CRE is consistent with a progressive pathogenic influence 
acting early in life, rendering these populations preferentially vulnerable to loss over 
an extensive period of time. 
Sequencing this interval in PD cases and controls revealed two common 
variants (rs2737024 and rs2583959) therein, individually associated with an 
increased risk of PD. Furthermore, we identify a larger haplotype containing these 
variants, also significantly associated with PD risk. While none of the other SNPs in 
this haplotype overlap with CREs identified in the DA neuron catalogues, variant 
rs356168 has significant functional evidence of its activity and contribution to PD 
risk109. The same DHS correlation analysis93,180 that suggests an interaction between 
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the SNCA promoter and our identified CRE, also suggests an interaction between the 
SNCA promoter and the rs356168 variant. Additionally, ChIA-PET data180,195 
indicates that sequence encompassing this variant may interact with our enhancer, 
suggesting a potential co-operative mode of action; a paradigm recently proposed by 
Gupta and colleagues69 at the EDN1 locus. We propose that the variants within the 
enhancer, independently or in concert with other variation within the identified 
haplotype, may act throughout the lifespan to render key populations of 
catecholaminergic neurons vulnerable, thus increasing PD risk in individuals 
harbouring this variation.  
This work emphasizes the value of biologically informed, cell context-
dependent guided searches for the identification of disease associated and functional 
non-coding variation. Given the extent of non-coding GWAS-identified variation, the 
need for strategies to prioritize variants for functional follow-up is greater than ever. 
Here, we generate chromatin accessibility data from purified populations of DA 
neurons to generate catalogues of putative CREs. We have demonstrated how these 
data can be used to reveal non-coding variation contributing to PD risk; focusing on a 
single region of open chromatin at the SNCA locus, we uncover PD-associated 
variation therein and propose a model through which this sequence can contribute to 
normal DA neuronal biology and PD risk. There remains a plethora of information 
still to be explored in these catalogues, either through further single locus 
investigations or through massively parallel assays. For example, our MB DA neuron 
OCR catalogue overlaps variants at 20 of 49 (41%) PD-associated loci23,25, all of which 
can be investigated further for their mechanisms by which they impact PD risk. Our 
work establishes a powerful paradigm, leveraging transgenic model systems to 
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systematically generate cell type specific chromatin accessibility data and reveal 
disease-associated variation, in a manner that can be progressively guided by 






Tg(Th-EGFP)DJ76Gsat mice (Th-EGFP) were generated by the GENSAT 
Project196 and purchased through the Mutant Mouse Resource and Research Centers 
Repository. Colony maintenance matings were between hemizygous male Th-EGFP 
mice and female Swiss Webster (SW) mice, obtained from Charles River Laboratories. 
This same mating scheme was used to establish timed matings, generating litters for 
assay; day on which vaginal plug is observed, E0.5. Adult AB zebrafish lines were 
maintained in system water according to standard methods197. All work involving 
mice and zebrafish (husbandry, colony maintenance, procedures, and euthanasia) 
were reviewed and pre-approved by the institutional care and use committee. 
Neural dissociation and FACS  
Pregnant SW mice were euthanized at E15.5 and the embryos were removed 
and immediately placed in chilled Eagle’s Minimum Essential Media (EMEM) on ice. 
Embryos were decapitated and brains were removed into Hank’s Balanced Salt 
Solution without Mg2+ and Ca2+ (HBSS w/o) on ice. Under a fluorescent microscope, 
EGFP+ brains were identified and microdissected to yield the desired forebrain (FB) 
and midbrain (MB) regions desired. Microdissected regions were placed in fresh HBSS 
w/o on ice, and pooled per litter for dissociation.  
Pooled brain regions were dissociated using the Papain Dissociation System 
(Worthington Biochemical Corporation). The tissue was dissociated in the papain 
solution for 30 minutes at 37°C, with gentle trituration every 10 minutes using a 
sterile Pasteur pipette. Following dissociation, cells were passed through a 40µm cell 
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strainer into a 50mL conical, centrifuged for 5 minutes at 300g, resuspended in 
albumin-inhibitor solution containing DNase, applied to a discontinuous density 
gradient, and centrifuged for 6 minutes at 70g. The resulting cell pellet was 
resuspended in HBSS with Mg2+ and Ca2+ and submitted to fluorescent-activated cell 
sorting (FACS). Aliquots of 50,000 EGFP+ cells were sorted directly into 300µL HBSS 
with Mg2+ and Ca2+ with 10% FBS for ATAC-seq. Aliquots containing ≥50,000 EGFP+ 
cells were sorted into kit-provided lysis buffer for RNA-seq. This procedure was 
repeated such that a single aliquot of cells from each region per litter were submitted 
to either ATAC-seq or bulk RNA-seq three times over for each region.  
ATAC-seq library preparation and quantification 
ATAC-seq library preparation generally follows the steps as set out in the 
original ATAC-seq paper95 with minor modifications. Aliquots of 50,000 EGFP+ cells 
were centrifuged for 5 minutes at 4°C and 500g, washed with 50µL of chilled PBS and 
centrifuged again for 5 minutes at 4°C and 500g. The cell pellet was resuspended in 
lysis buffer, as set out in the protocol, and cells were left to lyse for 5 minutes at 4°C 
before being centrifuged for 10 minutes at 4°C at 500g. The resulting nuclei pellet was 
tagmented, as written, using the transposase from the Nextera DNA Library 
Preparation Kit. Following transposition, DNA was purified with the MinElute 
Reaction Clean-up Kit (Qiagen) and eluted in 10µL elution buffer.  
Libraries were amplified according to the original ATAC-seq protocol95. The 
qPCR surveillance steps were modified such that the additional number of cycles of 
amplification were calculated as ¼ maximum intensity, so as to limit PCR duplication 
rates in the final libraries. Amplified libraries were purified with Ampure XP beads 
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(Beckman Coulter) following the Nextera DNA Library Prep Protocol Guide. Libraries 
were quantified using the Qubit dsDNA High Sensitivity Assay (Invitrogen) in 
combination with the Agilent 2100 Bioanalyzer using the High Sensitivity DNA Assay 
(Agilent). 
ATAC-seq sequencing, alignment, and peak calling 
Individual ATAC-seq libraries were sequenced on the Illumina MiSeq to a 
minimum depth of 15 million, 2x75bp reads per library.  
Quality of sequencing was evaluated using FastQC (v0.11.2). Reads were 
aligned to mm9 using Bowtie2198 (v2.2.5), under --local mode. Reads aligning to the 
mitochondrial genome, unknown and random chromosomes, and PCR duplicates were 
removed prior to peak calling (SAMtools199). Peaks were called on individual libraries 
and on a concatenated file combining all MB or all FB libraries (“Joint”) using 
MACS2200 (v2.1.1.20160309) “callpeak” with options: --nomodel --nolambda -B -f 
BAMPE --gsize mm --keep-dup all. Peaks overlapping blacklisted regions called by 
ENCODE and in the original ATAC-seq paper were removed95,195. Peaks were 
examined for their genomic distribution using CEAS in the Cistrome pipeline201,202. 
The fragment lengths were extracted from the SAM files and plotted using a custom 
script. Mouse (mm9) transcriptional start site (TSS) co-ordinates were extracted from 
the UCSC Genome Browser203 and deepTools204 was used to quantify the pileup of 
reads over TSSs. 
RNA-seq library preparation and quantification 
Total RNA was extracted using the Purelink RNA Micro Kit (Invitrogen). 
Following FACS isolation into kit-provided lysis buffer, samples were homogenized 
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and RNA extraction proceeded using manufacturer’s recommendations. Total RNA 
integrity was determined using the Agilent 2100 Bioanalyzer using the RNA Pico Kit 
(Agilent). RNA samples were sent to the Sidney Kimmel Comprehensive Cancer 
Center Next Generation Sequencing Core at Johns Hopkins for library preparation, 
using the Ovation RNA-Seq System V2 (Nugen), and sequencing. 
RNA-seq sequencing, alignment, and transcript quantification  
Libraries were pooled and sequenced on Illumina’s HiSeq 2500 in Rapid Run 
mode with 2x100bp reads to an average depth of >90 million reads per library. Quality 
of sequencing was evaluated using FastQC. FASTQ files were aligned to mm9 using 
HISAT2205 (v2.0.1-beta) with --dta specified.  
Aligned reads from individual samples were quantified against a reference 
transcriptome using the Rsubread package206–208 (v1.22.3) function “featureCounts” 
with the following options: isPairedEnd = TRUE, requireBothEndsMapped = TRUE, 
isGTFAnnotationFile = TRUE, useMetaFeature = TRUE. The GENCODE vM9 GTF 
was downloaded209 (date: March 30, 2016) and lifted over from the mm10 to the mm9 
genome using CrossMap (v0.2.2) with default parameters210. This was used for 
quantification, in which gene-level raw counts were converted to RPKM values and 
means for each region were calculated. 
RNA-seq and ATAC-seq relationship  
The highest 1,000 expressed genes and the lowest 1,000 expressed genes 
(RPKM ≥ 1) in both the MB and FB were identified and their transcriptional start 
sites (Ensembl) extracted from the UCSC Table Browser203. Intervals of 1, 10, and 
100kb surrounding these TSSs were intersected with the ATAC-seq libraries, and the 
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overlap quantified211 and plotted. These same TSSs were provided to deepTools204, and 
the ATAC-seq signal over these highest and lowest expressed genes was quantified 
and plotted. Additionally, the 1,000 highest and lowest ATAC-seq peaks (by q-value) 
were extracted and the expression of the nearest gene was quantified and plotted as 
a final metric to relate the RNA-seq and ATAC-seq datasets.  
cDNA synthesis and RT-qPCR for DA neuron markers 
RNA was extracted using the RNeasy Mini Kit (Qiagen), after sorting 50,000 
cells directly into Buffer RLT. Aliquots of 50,000 non-fluorescing cells were also 
collected and processed in parallel. 100ng of each RNA sample was submitted to first 
strand cDNA synthesis using the SuperScript III First-Strand Synthesis System for 
RT-PCR (Invitrogen), following the Oligo(dT) method.  
Primers (Supplementary Table 2.5) were designed using Primer-BLAST212 
under default parameters with the requirement for exon-exon junction spanning 
specified. qPCR was performed using Power SYBR Green Master Mix (Applied 
Biosystems). Reactions were run in triplicate, following default SYBR Green Standard 
cycle specifications on the Viia7 Real-Time PCR System (Applied Biosystems). 
Relative quantification followed the 2-ΔΔCT method, normalizing results to Actb in the 
EGFP- aliquot of cells for each region, respectively.  
Correlation analysis between regions and within replicates 
Peaks from all six ATAC-seq libraries and the two “Joint” ATAC-seq libraries 
were concatenated together, sorted on the basis of chromosomal location, merged into 
a unified peak set211, and converted to Simplified Annotation Format. Reads from each 
BAM file overlapping this unified peak set were quantified with the Rsubread package 
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“featureCounts” command, with the following options: isPairedEnd = TRUE, 
requireBothEndsMapped = FALSE. Read counts were normalized for each library 
using conditional quantile normalization213, accounting for library size, peak length, 
and peak GC content. Pearson correlation co-efficients were calculated from this 
normalized count matrix and visualized using corrplot214 and RColorBrewer215 and 
LSD216.  
Sequence constraint analysis 
Average phastCons217 were calculated for the “Joint” peak file for both the MB 
and FB libraries using Cistrome202. Beforehand, peaks with overlap of exons or 
promoters (defined here as +/-2,000bp from the transcriptional start site) were 
removed. The exon and promoter BED files were downloaded from the UCSC table 
browser203 (Mouse genome; mm9 assembly; Genes and Gene Predictions; RefSeq 
Genes track using the table refGene).  
Gene ontology of nearest expressed gene 
The Genomic Regions Enrichment of Annotations Tool218 (GREAT; v3.0.0) 
predicted the GO term enrichment in the catalogues. Beforehand, peaks were 
processed to: a) remove peaks overlapping commonly open regions; b) select the top 
20,000 peaks and; c) overlap the nearest expressed gene’s transcriptional start site 
(TSS).  
First, regions that are commonly open were defined as those regions of the 
genome that are open in >30% of ENCODE DNase hypersensitivity site (DHS) assays 
in mouse tissues. These ubiquitously open regions were removed from the peak files. 
Next, to limit the number of regions submitted to GREAT such that the binomial 
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distribution for calculating fold enrichment values was still valid, peak files were 
limited to the top 20,000 peaks on the basis of q-value.  
Finally, in order to limit ourselves to the nearest expressed gene, we supplied 
a list of the TSSs of the nearest expressed gene that are in the GREAT database. Only 
genes that are in this list with RPKM > 1 were considered as expressed. The nearest 
expressed gene to each of the top 20,000 peaks was identified. Each peak is associated 
with its nearest expressed gene and to ensure that GREAT only considered these 
nearest genes for analysis, we submitted these nearest expressed gene’s TSSs as a 
proxy for each peak. These proxy peaks were submitted to GREAT using the NCBI 
build 37 (mm9) assembly, under whole genome background regions, with the single 
nearest gene as the association rule, including curated regulatory domains.  
Quantification of overlap between CRE catalogues and the VISTA Enhancer 
Browser 
All elements tested in vivo were downloaded from the VISTA Enhancer 
Browser on September 4, 2016. These regions were stratified into those annotated as 
positive or negative. BED co-ordinates of these regions were extracted and intersected 
with the ATAC-seq catalogues. Positive regions were further stratified into those with 
annotations for only forebrain, only midbrain, only hindbrain, combinations of regions 
(“Multiple regions”), all three regions (“Whole brain”), summing to the “Neuronal” 
category, or were annotated as positive but driving expression in none of those three 




Testing five putative CREs for in vivo reporter activity 
Prioritized regions were PCR amplified (Supplementary Table 2.5) from 
human gDNA and cloned into either pENTR for mouse lacZ assays (Invitrogen) or 
pDONR221 for zebrafish assays (Invitrogen). Regions were sequence validated and 
LR cloned (Invitrogen) into either an hsp68-lacZ vector or pXIG vector, with a 
TdTomato cassette in place of GFP.  
Generation of transgenic mice and E11.5 embryo staining was performed as 
previously described78,101,219 using FVB strain mice. Embryos expressing the lacZ 
reporter gene were scored and annotated for their expression patterns by multiple 
curators. For a construct to be considered positive, a minimum of three embryos per 
construct were required to demonstrate reporter activity in the same tissue. Mouse 
transient transgenic assays were approved by the Lawrence Berkeley National 
Laboratory Animal Welfare and Research Committee. 
Generation of transgenic zebrafish was performed as previously described103 in 
AB zebrafish. At 3 days post fertilization (dpf) and 5dpf, reporter expression patterns 
were evaluated. For a construct to be considered as positive, ≥25% of mosaic embryos 
had to display reporter activity in one or more anatomical structures. Positive 
zebrafish were quantified for reporter activity in five anatomical regions (forebrain, 
midbrain, hindbrain, amacrine cells, spinal cord).  
Intersection of CRE catalogues and PD-associated GWAS variants 
Lead SNPs from the two most recent meta-analyses23,25 were submitted to 
rAggr and SNPs in LD were identified (1000 Genomes, Phase 3, EUR populations; 
minimum MAF = 0.05, r2 ≥ 0.8; maximum distance 5,000kb). These variants were 
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intersected211 with the CRE catalogues, after they were lifted over to hg19 co-
ordinates, and the overlap extracted and quantified.  
In vivo validation of the MB-specific enhancer 
The MB-specific peak was PCR amplified (Supplementary Table 2.5) from 
human genomic DNA and TA cloned into pCR8 (Invitrogen). Regions were sequence 
validated and LR cloned (Invitrogen) into either an hsp68-lacZ vector or a modified 
pXIG vector, with a TdTomato cassette in place of GFP.  
For zebrafish transgenesis, the modified pXIG vector was injected into 1-2 cell 
stage embryos as previously described103 in AB zebrafish. TdTomato reporter 
expression was assayed at 72 hours post fertilization (hpf) and 5dpf; mosaic embryos 
positive for TdTomato expression were selected and raised to adulthood and founders 
were identified. Progeny of founders were screened at 72hpf for reporter activity.  
For mouse transgenesis, the generated hsp68-lacZ vector was purified in a 
double CsCl gradient (Lofstrand Labs Ltd) and stable mouse transgenesis was 
performed in C57BL/6 mice by Cyagen Biosciences Inc. Multiple founder lines were 
generated. For lacZ staining, embryos were collected at E12.5, and mouse brains were 
isolated at E15.5, P7, P30, and P574. Brains were roughly sectioned in 1mm sections 
at P7 and P30 and animals were perfused at P574 and fixed brains were sectioned 
(200µm) with a vibratome. Specimens were subsequently fixed for 2 hours on ice in 
1% formaldehyde, 0.2% glutaraldehyde, 0.02% Igepal CA-630 in PBS. Following 
fixation, tissues were permeabilized over 3x15 minute washes in 2mM MgCl2 and 
0.02% Igepal CA-630 in PBS at room temperature. Embryos/tissues were incubated 
overnight at 37°C in staining solution, containing 320µg/mL X-Gal in N,N-dimethyl 
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formamide, 12mM K-ferricyanide, 12mM K-ferrocyanide, 0.002% Igepal CA-630, 
4mM MgCl2 in PBS. Specimens were washed in 0.2% Igepal CA-630 in PBS over 2x30 
minutes and finally stored in 4% formaldehyde, 100mM sodium phosphate, and 10% 
methanol.  
Sequencing and genotyping PD patients and controls at SNCA 
A total of 986 individuals with PD and 992 controls who were seen at the Mayo 
Clinic in Jacksonville, FL were sequenced across the putative enhancer and genotyped 
for 25 variants across the SNCA locus. The variants chosen for genotyping were 
confirming those identified by sequencing of the enhancer as well as assessing those 
identified in Guella et al189. For PD cases, median age at blood draw was 69 years 
(Range: 28-97 years), median age at PD onset was 67 years (Range: 28-97 years), and 
631 cases (64.0%) were male. Median age at blood draw in controls was 67 years 
(Range: 18-92 years) and 415 subjects (41.8%) were male. Individuals with PD were 
diagnosed using standard clinical criteria220. All subjects are unrelated non-Hispanic 
Caucasians of European descent. The Mayo Clinic Institutional Review Board 
approved the study and all subjects provided written informed consent. 
Genomic DNA was extracted from whole blood using the Autogen FlexStar. 
Sanger sequencing of the enhancer region was performed bidirectionally using the 
ABI 3730xl DNA analyzer (Applied Biosystems) standard protocol. Sequence data was 
analyzed using SeqScape (v2.5; Applied Biosystems). Statistical analyses were 
performed using both SAS and R221. Of the variants identified within the enhancer, 
only those with minor allele frequency greater than 5% were evaluated for association 
with PD in single-variant analysis. Associations between individual variants and PD 
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were evaluated using logistic regression models, adjusted for age at blood draw and 
sex, and where variants were considered, under an additive model (i.e. effect of each 
additional minor allele). Odds ratios and 95% confidence intervals were estimated and 
a Bonferroni correction for multiple testing, due to the four common variants that 
were evaluated for association with PD, was utilized in single-variant analysis, after 
which p-values ≤ 0.0125 were considered as statistically significant. 
Genotyping the 25 SNPs across the SNCA locus was performed using the 
iPLEX Gold protocol on the MassARRAY System and analysed with TYPER 4.0 
software (Agena Bioscience). For the 25 SNPs genotyped across the SNCA locus, all 
genotype call rates were >95% and there was no evidence for departure from Hardy-
Weinberg equilibrium (all χ2 p-values > 0.05 after Bonferroni correction). Haplotype 
frequencies in cases and controls was estimated using the haplo.stats package222 
function “haplo.group”. Associations between haplotypes and risk of PD were 
evaluated using score tests of association223 using the “haplo.score” function. Tests 
were adjusted for age at blood draw and sex, haplotypes occurring in less than 1% of 
subjects were excluded, and only individuals with no missing genotype calls for any 
variants were included. A Bonferroni correction for multiple testing was applied, after 
which p-values ≤ 0.0042 were considered as statistically significant, due to the 12 
different common haplotypes that were observed and tested for association with PD 
risk.  
LD structure/r2 values at the SNCA locus in the 1000 Genomes EUR 
population were extracted from LDlink224 using the LDmatrix tool and plotted using 
R. The chromatin structure at SNCA was extracted from the 3D Genome Browser180, 
querying POLR2A binding in MCF-7 cells at the SNCA promoter.  
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Generating enhancer knock-out cell lines and mice 
SNCA deletion cell line 
SK-N-SH neuroblastoma cells were grown in high glucose Dulbecco’s Modified 
Eagle Medium (DMEM) supplemented with 1X penicillin and streptomycin, and 10% 
fetal bovine serum. Cells were maintained at 37°C, 5% CO2. 
Guide RNA sequences flanking the lifted over enhancer (hg19) were designed 
with CHOPCHOP225–227 and double stranded oligonucleotides with BbsI/BsaI 
compatible overhangs were synthesized by Integrated DNA Technologies (1F – 
GAAGGGACTCCTTGCTTGA; 3F – GTTGAAATCAAAGTAGTAGT; 1R – 
CTGGGAGCACAATTGGCCC; 2R – GAGCTGTGATAACCACTAA; 3R – 
TGGATTAGAACCACTGCTA; 4R - ATAACCACTAATGTTCCCT). Guides were cloned 
in pairs (1F-2R, 1F-4R, 3F-1R, 3F-3R) into a modified PX458 vector228 (pSpCas9(BB)-
2A-GFP (PX458), a gift from Feng Zhang; Addgene plasmid #: 48138), in which a 
second guide RNA scaffold sequence with BsaI restriction sites was inserted into 
PX458 by restriction digest with KpnI and XbaI.  
A repair template in a pUC57 backbone was ordered from GENEWIZ, 
containing arms of homology matching hg19: chr4:90,720,863-90,721,062 and 
chr4:90,722,123-90,722,322, two loxP sites and a custom multiple cloning site. This 
represents the “empty” repair template. This was modified by standard Gibson 
assembly229 and restriction cloning to further contain a blasticidin resistance cassette 
(pCMV/Bsd; Invitrogen #V51020), a T2A site (CMV-Cas9-2A-RFP; Sigma Aldrich 
#CAS9RFPP), and an mCherry fluorescence cassette (pmCherry; Takara #632522).  
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SK-N-SH neuroblastoma cells were plated at 300,000 cells/well in a 6-well 
plate. The cells were lipofected with the guide RNA plasmid along with a linearized 
repair template (SapI) the following day using the standard Lipofectamine 2000 
protocol (Invitrogen). Each well was transfected with 3.0µg of DNA – 1.5µg of the 
guide/Cas9 plasmid and 1.5µg of either repair template. Matching repair template 
only control and no DNA control wells were also included.  
SNCA deletion mice 
Enhancer deletion mice were generated as previously described by Watkins-
Chow et al.230, with minor modifications. RNA oligonucleotide guides corresponding 
to flanking region of interest were synthesized (Integrated DNA Technologies) (3F – 
TAATTTCTACTCTTGTAGATTGTTATTTAAAAGACATGTTTCT and 4R -
TAATTTCTACTCTTGTAGATCAGTGCCTATAAAGGGACTACTC). Guides and 
CPF1 protein (Integrated DNA Technologies) were diluted in Opti-MEM media 
(Thermo-Fisher Scientific) to a final concentration of 2µM (each guide) and 5ng/µl 
CPF1 protein. A total of 50µl of guide-CPF1 solution was electroporated into roughly 
150 C57BL/6J × FVB/N F1 hybrid zygotes, using a Nepa21 electroporator (Nepa Gene 
Co., Ltd., Japan) using manufacture’s recommended pulse conditions. Hybrid zygotes 
were subsequently allowed to rest for 30-60min at 5%CO2, and washed in M2 media 
(Sigma Aldrich) prior to being implanted using standard embryo transfer surgery 
protocols. Resulting founder mice were screened for deletion alleles using the flanking 




Data sharing and accessibility 
ATAC-sequencing, RNA-sequencing and related data is available at the Gene 
Expression Omnibus (GEO) under the accession number GSE122450.  
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2.9 Figures and supplementary materials 
Figure 2.1: Preliminary validation of ATAC-seq catalogues generated from ex 
vivo DA neurons 
 
(A) The midbrain (MB) and forebrain (FB) of E15.5 brains from Tg(Th-
EGFP)DJ76Gsat mice are microdissected, dissociated, and isolated by FACS. (B) Read 
pile-up and called peaks for the MB and FB libraries at the Th locus. (C, D) Chromatin 
accessibility, genome-wide, is correlated between replicates. (E) The sequences 
underlying MB and FB peaks display a high degree of evolutionary sequence 
constraint as measured by PhastCon scores. (F, G) Gene ontology terms of the nearest 
expressed genes to all peaks in both the MB and FB reflect the neuronal origin and 








Figure 2.2: Validation of the putative CRE catalogues in vivo 
 
(A) Of the elements annotated in VISTA as having enhancer activity, 62% and 56% of 
these are represented in the MB and FB catalogues, respectively. (B) An abundance 
of open chromatin regions in the MB and FB catalogues overlap confirmed neuronal 
enhancers (≥70%). (C) Stratifying neuronal enhancers, MB- and FB-specific 
enhancers are enriched in our MB and FB catalogues, respectively. (D-H) Testing five 
prioritized putative CREs in vivo identifies five neuronal enhancers. (D) A putative 
CRE in intron 1 of KCNQ3 directs expression in the midbrain, hindbrain, and neural 
tube of E11.5 lacZ reporter mice. It fails to direct expression in a transgenic zebrafish 
assay at either 3 or 5 days post fertilization (dpf); reporter expression present in ≤25% 
of mosaics. (E, F, G) Putative CREs downstream of FOXG1, upstream of NR4A2, and 
in an intron of CRHR1 fail to direct expression in transgenic mice, however, they 
direct robust neuronal appropriate expression in transgenic zebrafish reporter assays 
(scored for expression in MB, FB, amacrine cells (AC), hindbrain (HB), spinal cord 
(SC)). (H) A putative CRE downstream of FOXA2 directs neuronal expression in both 
transgenic mice and zebrafish assays. N mosaic zebrafish scored: ≥ 141 for 3dpf, ≥ 119 
for 5dpf. All constructs have since been deposited in the VISTA database, under the 








Figure 2.3: A MB-specific enhancer directs expression in catecholaminergic 
populations of neurons known to Parkinson disease biology 
 
(A) IGV track indicating the location of the MB-specific region of open chromatin, 
located in intron 4 of Snca. (B) Snca is differentially expressed between the MB and 
FB DA neurons. Red bar is the mean expression of the four replicates (black dots). (C) 
At 72 hours post fertilization (hpf), stable transgenic zebrafish reporter assays 
indicate this putative CRE is capable of directing reporter expression in key 
catecholaminergic neuronal populations, including the locus coeruleus (LC), the 
catecholaminergic tract (CT) of the hindbrain, and the diencephalic cluster (DC) with 
projections to the subpallium (SP). (D-G) Further studies in lacZ reporter assays in 
embryonic (E) and post-natal (P) mice indicate dynamic enhancer usage across 
developmental time. (D) This enhancer directs expression throughout the MB, FB, 
dorsal root ganglia (DRG), sympathetic chain (SC), and cranial nerves (CN) of E12.5 
mice. (E) By E15.5, reporter expression is observed in the amygdala and/or piriform 
cortex (AM/PC), sympathetic chain, MB, and hypothalamus (Hyp). (F) Patterns of 
reporter expression at P7 reflect those seen at E15.5. (G) Reporter activity is observed 
at P30 in the amygdala, hypothalamus and thalamus (Thal), brain stem (BS), 
substantia nigra (SN), ventral tegmental area (VTA), and the periaqueductal grey 
area (PAG). (H) In aged mice (P574), reporter expression is detected robustly in the 







Figure 2.4: A schematic of the chromatin interactions, LD structure, 
variation, and open chromatin at the SNCA locus 
 
Publicly available DNase hypersensitivity site (DHS) linkage analysis suggest that 
the promoter of SNCA possibly interacts with the identified MB-specific enhancer, the 
lead GWAS variant (rs356182), and a previously functionally validated variant 
(rs356168). ChIA-PET data suggests the MB-specific enhancer may interact with 
variant rs356168. Open chromatin data from DA neurons do not overlap with any 
variants at this locus/haplotype other than at the MB-specific enhancer. LD analysis 
at this locus indicates that despite the low LD structure between the lead GWAS 
variant (rs356182) and the enhancer associated variants (rs2737024 and rs2583959), 
the variants are in the same haplotype. As such the GWAS signal may, at least in 








Figure 2.5: Enhancer deletion experiments and proposed phenotyping 
 
(A) In SK-N-SH cells, the enhancer was modified by one of four guide RNA 
combinations (arrows) and exploiting homology directed repair, was replaced with one 
of two repair templates. The first repair template contained a blasticidin-resistance 
cassette (BlastR) as a selectable marker and a fluorescent marker (mCherry) for 
screening. These were flanked by loxP sites (purple triangles) and arms of homology 
(dashed crosses). The alternative repair template contained solely the arms of 
homology and the loxP sites. These deletions resulted in cell death. (B) We also deleted 
the enhancer in vivo at the endogenous mouse Snca locus. (C) These enhancer deletion 
mice and matched non-deleted controls will be subjected to an LPS injection paradigm, 
where movement phenotypes will be assessed at the day of injection and at one month, 
two months, and 6 months. At six months, the mice will be sacrificed and their brains 







Table 2.1: Two tightly linked SNPs within the enhancer are significantly 
associated with PD risk 
Variant MA MAF in PD cases (N=986) 
MAF in controls 
(N=992) 
Association with PD 
OR (95% CI) p-value 
rs7684892 A 0.063 0.069 0.93 (0.72-1.20) 0.562 
rs17016188 C 0.082 0.061 1.35 (1.04-1.75) 0.023 
rs2583959 G 0.317 0.271 1.22 (1.06-1.40)    0.005 * 
rs2737024 G 0.319 0.270 1.25 (1.09-1.44)    0.002 * 
MA = minor allele; MAF = minor allele frequency; OR = odds ratio; CI = confidence interval 
Only variants with MAF > 0.05 were considered 
ORs, 95% CIs, and p-values result from additive logistic regression models adjusted for age at blood draw and sex 
p-values ≤ 0.0125 were considered as statistically significant after applying a Bonferroni correction for multiple testing (*) 
 
 
Table 2.2: A single haplotype, containing the minor alleles of the implicated 
SNPs, is significantly associated with PD risk 






































































in PD cases 
Frequency 


















1 C C A G T T C A C T G C 0.015 0.027 0.012 
2 C G A A T T T A C T G C 0.092 0.110 0.029 
3 C C A G C C C A C T A T 0.039 0.048 0.184 
4 T C A G T T C A C T G C 0.037 0.040 0.480 
5 C G A A T T C A C T G C 0.380 0.397 0.593 
6 T C A G T T T A C T G C 0.010 0.011 0.698 
7 C G A A T C C G G T G C 0.009 0.012 0.944 
8 C C A G T C C G G T G C 0.016 0.015 0.768 
9 T C G G C C C A C T A T 0.021 0.017 0.360 
10 T C G G T C C A C C G C 0.014 0.009 0.189 
11 T C G G C C C A C C G C 0.057 0.044 0.124 
12 T C A G T C C G G T G C 0.283 0.234    0.003 * 
Only haplotypes with frequency ≥ 0.01 were considered 
Black boxes indicate the minor allele in Europeans 
p-values result from score tests for association, performed under an additive model, adjusted for age at blood draw and sex 









Supplementary Figure 2.1: RT-qPCR of key DA neuron markers 
 
Expression of key DA neuron markers (Pitx3, Th, Slc6a3) in MB FACS-isolated (A) 
and FB FACS-isolated (B) cells confirms isolation of purified MB and FB DA neurons. 
Error bars represent the fold change range after incorporation of the standard 




Supplementary Figure 2.2: in silico quality control metrics for the ATAC-
seq libraries 
 
(A) Sequencing statistics for the ATAC-seq libraries indicate all six libraries are of 
sufficient quality. (B) The genomic distribution of ATAC-seq peaks indicate a 
preference for promoters and intergenic regions. (C) The fragment length distribution 
of the ATAC-seq libraries indicate the presence of a nucleosome ladder (with one 
nucleosome fragments, perhaps, being selected against in the bead clean-up). (D) All 










Supplementary Figure 2.3: Correlation analysis of all ATAC-seq libraries 
 
Genome-wide correlation within replicates (red boxed areas) and between brain 
regions indicate there is strong correlation within a brain region across replicates, 




Supplementary Figure 2.4 Relating RNA-seq and ATAC-seq data 
 
Broad analyses indicate that highly expressed genes are under greater regulatory 
control, in that there are more proximal regulatory elements (A, B) and their 
promoters are more open (C) compared to lowly expressed genes. (D) Additionally, the 
genes closest to the strongest ATAC-seq peaks are more highly expressed than those 








Supplementary Figure 2.5: All lacZ reporter mice and the mouse genomic 
locations of the putative CREs 
 
All transgenic mouse embryos assayed for lacZ reporter activity for each of the five 
putative CREs tested in vivo (left) and the genomic location and context of those 
putative CREs (right). MB: Black track, FB: Green track. Red peaks in yellow boxes: 







Supplementary Table 2.1: Summary of counts and percent overlap with the 




















    Counts  Percentage 
        VISTA MB FB   MB FB  
Positive  1264 786 719  62 57           
 Neuronal   652 498 465  76 71 
  Forebrain  191 137 147  72 77 
  Midbrain  104 80 65  77 63 
  Hindbrain 94 66 58  70 62 
  
Multiple 
regions 156 126 112  81 72 
  Whole brain 107 89 83  83 78           
 Non-neuronal  612 288 254  47 42 
          
Negative   1123 538 529   48 47 





Supplementary Table 2.2: Allele and genotype counts and frequencies 
in PD cases and controls of all variants identified by sequencing within 
the intronic SNCA enhancer 
 
      Allele counts (frequency)   Genotype counts (frequency) 
Variant MA  Population Minor allele Major allele   Homozygous Minor Heterozygous 
Homozygous 
Major 
rs537518252 A Control 0 (0%) 1910 (100%)  0 (0%) 0 (0%) 955 (100%) 
  PD 1 (0.1%) 1909 (99.9%)  0 (0%) 1 (0.1%) 954 (99.9%) 
rs78789649 A Control 0 (0%) 1910 (100%)  0 (0%) 0 (0%) 955 (100%) 
  PD 1 (0.1%) 1909 (99.9%)  0 (0%) 1 (0.1%) 954 (99.9%) 
rs112174335 C Control 2 (0.1%) 1908 (99.9%)  0 (0%) 2 (0.2%) 953 (99.8%) 
  PD 0 (0%) 1910 (100%)  0 (0%) 0 (0%) 955 (100%) 
rs28720123 T Control 4 (0.2%) 1906 (99.8%)  0 (0%) 4 (0.4%) 951 (99.6%) 
  PD 1 (0.1%) 1909 (99.9%)  0 (0%) 1 (0.1%) 954 (99.9%) 
rs2737024 G Control 515 (27%) 1395 (73%)  76 (8%) 363 (38%) 516 (54%) 
  PD 609 (31.9%) 1301 (68.1%)  105 (11%) 399 (41.8%) 451 (47.2%) 
chr4:90721581 T>C C Control 1 (0.1%) 1909 (99.9%)  0 (0%) 1 (0.1%) 954 (99.9%) 
  PD 0 (0%) 1910 (100%)  0 (0%) 0 (0%) 955 (100%) 
rs2583959 G Control 518 (27.1%) 1390 (72.9%)  89 (9.3%) 340 (35.6%) 525 (55%) 
  PD 606 (31.7%) 1304 (68.3%)  105 (11%) 396 (41.5%) 454 (47.5%) 
chr4:90721702 G>A T Control 0 (0%) 1910 (100%)  0 (0%) 0 (0%) 955 (100%) 
  PD 1 (0.1%) 1909 (99.9%)  0 (0%) 1 (0.1%) 954 (99.9%) 
chr4:90721760 T>- - Control 0 (0%) 1910 (100%)  0 (0%) 0 (0%) 955 (100%) 
  PD 1 (0.1%) 1909 (99.9%)  0 (0%) 1 (0.1%) 954 (99.9%) 
rs189903574 A Control 0 (0%) 1910 (100%)  0 (0%) 0 (0%) 955 (100%) 
  PD 1 (0.1%) 1909 (99.9%)  0 (0%) 1 (0.1%) 954 (99.9%) 
rs17016188 C Control 116 (6.1%) 1794 (93.9%)  4 (0.4%) 108 (11.3%) 843 (88.3%) 
  PD 156 (8.2%) 1754 (91.8%)  5 (0.5%) 146 (15.3%) 804 (84.2%) 
rs28536191 G Control 2 (0.1%) 1908 (99.9%)  0 (0%) 2 (0.2%) 953 (99.8%) 
  PD 0 (0%) 1910 (100%)  0 (0%) 0 (0%) 955 (100%) 
chr4:90721974 T>A A Control 0 (0%) 1910 (100%)  0 (0%) 0 (0%) 955 (100%) 
  PD 1 (0.1%) 1909 (99.9%)  0 (0%) 1 (0.1%) 954 (99.9%) 
rs7684892 A Control 131 (6.9%) 1777 (93.1%)  9 (0.9%) 113 (11.8%) 832 (87.2%) 




























































































rs10018362 0.185 0.14 0.02 0.137 0.417 0.018 0.547 0.534 0.008 0.242 0.039 0.004 0.046 0.017 <0.001 
rs2737029 ---- 0.663 0.523 0.672 0.101 0.07 0.103 0.096 0.002 0.096 0.498 0.001 0.542 0.003 0.001 
rs356168 ---- ---- 0.675 0.985 0.085 0.063 0.078 0.078 0.001 0.072 0.307 0.001 0.341 0.002 0.001 
rs356220 ---- ---- ---- 0.686 0.12 0.03 0.002 0.002 0.002 0.101 0.373 <0.001 0.411 0.003 0.002 
rs356225 ---- ---- ---- ---- 0.082 0.062 0.078 0.078 0.001 0.073 0.31 0.001 0.344 0.002 0.001 
rs3857057 ---- ---- ---- ---- ---- 0.007 0.023 0.023 0.014 0.583 0.025 <0.001 0.028 0.027 <0.001 
rs62306323 ---- ---- ---- ---- ---- ---- 0.01 0.006 <0.001 0.008 0.047 <0.001 0.05 <0.001 0.001 
rs7689942 ---- ---- ---- ---- ---- ---- ---- 0.974 <0.001 0.005 0.022 0.007 0.026 <0.001 <0.001 
rs7684892 ---- ---- ---- ---- ---- ---- ---- ---- <0.001 0.005 0.021 0.007 0.023 <0.001 <0.001 
rs28536191 ---- ---- ---- ---- ---- ---- ---- ---- ---- 0.016 <0.001 <0.001 <0.001 0.5 <0.001 
rs17016188 ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- 0.019 <0.001 0.024 0.033 <0.001 
rs2583959 ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- <0.001 0.934 0.001 <0.001 
chr4:90721581 T>C ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- <0.001 <0.001 <0.001 
rs2737024 ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- 0.001 <0.001 
rs28720123 ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- <0.001 
rs112174335 ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- 
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Supplementary Table 2.4: Allele and genotype counts and frequencies in PD 
cases and controls of all variants genotyped from the Guella et al. panel 
 
      Allele counts (frequency)  Genotype counts (frequency) 





rs10018362 C Control 213 (11.1%) 1709 (88.9%)   9 (0.9%) 195 (20.3%) 757 (78.8%) 
  PD 228 (12.1%) 1656 (87.9%)  7 (0.7%) 214 (22.7%) 721 (76.5%) 
rs2737029 C Control 864 (41.1%) 1240 (58.9%)  161 (15.3%) 542 (51.5%) 349 (33.2%) 
  PD 869 (46.2%) 1011 (53.8%)  208 (22.1%) 453 (48.2%) 279 (29.7%) 
rs356168 G Control 910 (47.2%) 1016 (52.8%)  227 (23.6%) 456 (47.4%) 280 (29.1%) 
  PD 965 (51.2%) 919 (48.8%)  246 (26.1%) 473 (50.2%) 223 (23.7%) 
rs356220 T Control 734 (38.1%) 1190 (61.9%)  159 (16.5%) 416 (43.2%) 387 (40.2%) 
  PD 827 (43.9%) 1055 (56.1%)  190 (20.2%) 447 (47.5%) 304 (32.3%) 
rs356225 C Control 904 (47%) 1018 (53%)  223 (23.2%) 458 (47.7%) 280 (29.1%) 
  PD 966 (51.3%) 918 (48.7%)  246 (26.1%) 474 (50.3%) 222 (23.6%) 
rs3857057 G Control 137 (7.1%) 1791 (92.9%)  7 (0.7%) 123 (12.8%) 834 (86.5%) 
  PD 179 (9.5%) 1705 (90.5%)  4 (0.4%) 171 (18.2%) 767 (81.4%) 
rs62306323 T Control 241 (12.6%) 1667 (87.4%)  19 (2%) 203 (21.3%) 732 (76.7%) 
  PD 205 (10.9%) 1679 (89.1%)  10 (1.1%) 185 (19.6%) 747 (79.3%) 
rs7689942 T Control 125 (6.5%) 1801 (93.5%)  5 (0.5%) 115 (11.9%) 843 (87.5%) 





Supplementary Table 2.5 : Primer sequences used for qPCR and cloning for in vivo reporter assays 
Characterizing mouse DA neurons by qPCR 
 Forward Reverse 
Expected 
amplicon mm9 co-ordinates 
Pitx3 ACGCACTAGACCTCCCTCCAT GCTTCTTCTTCAGAGAGCCGT 203 Pitx3 exons 1, 2, 3 
Th CTGTCCACGTCCCCAAGGTTCA CAATGGGTTCCCAGGTTCCG 147 Th exons 1, 2 
Slc6a3 GAGGCCCGATAAGAGCTCAAG CCTTCTTCTTCGACTGCCTCC 111 Slc6a3 exons 1, 2 
Actb TGGCTCCTAGCACCATGAAG AGCTCAGTAACAGTCCGCCTA 188 Actb exons 5. 6 
     
Testing five putative CREs in in vivo reporter assays 
 Forward Reverse 
Expected 
amplicon hg19 co-ordinates 
KCNQ3 ATAAAGCAAGTGACCGGGGA GGCTGCTCTTGAGACATTCG 2744 chr8:133425146-133427889 
FOXG1 CGGCAAAGGAACATGGAGAG TCACATCCAGGGCCAAGAAT 2188 chr14:29242870-29245057 
NR4A2 ATCAGCCTGTGTCCTGTTCT AAGGAAGGGGCAGCTTAGAG 2447 chr2:157255824-157258270 
CRHR1 CAGGACTATGACGGCTGACT GGAACACACCCTCTCCATCA 1691 chr17:43889821-43891511 
FOXA2 GTCTGATGTTCGTTCACCCAG GCCGTTTTAAGCATTGGGAA 3288 chr20:22382513-22385800 
     
Testing the SNCA enhancer in in vivo reporter assays 
 Forward Reverse 
Expected 
amplicon hg19 co-ordinates 
SNCA GGACTCCTTGCTTGAAGGAAAAAT AGACAAAAGGAGTGCATTGATGT 1060 chr4:90,721,063-90,722,122 
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Chapter 3: Transcription factors and non-coding 
variants that disrupt their binding in dopaminergic 
neurons 
3.1 Interrogating non-coding variants and their role in disease 
 The majority of variants implicated in disease by genome-wide association 
studies are non-coding26,66. These variants are predicted to impact regulatory 
functioning of non-coding elements, like enhancers, likely through disrupting the 
binding sites of transcription factors (TFs) and other DNA-binding proteins. Learning 
the TFs active in a cell type and examining how disease-associated non-coding 
variants disrupt their activity are important for improving our understanding of 
disease.  
 Unlike with coding mutations, our ability to predict the consequences of non-
coding variation is limited. There are a variety of algorithms and software available 
to predict how coding variants will impact the structure of a protein (like CADD, 
PolyPhen, and SIFT231–233), as we have an accurate understanding of the genetic code 
(“vocabulary”) underlying protein specification. We do not have these vocabularies for 
regulatory element function. As such, there have been many efforts to learn the 
sequence control underlying regulatory element functioning, especially enhancers234–
236.  
One such effort, gapped-kmer support-vector machine (gkm-SVM73), has been 
developed by our group to begin elucidating the sequence basis of regulatory control, 
using a machine-learning algorithm. This algorithm and a related method, 
deltaSVM169, can be used in combination to predict TFs important to regulatory 
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control and anticipate how variants may impact those TFs’ binding. Functional 
validation of the predictions of variant effect is commonly performed using in vitro 
reporter assays, like luciferase assay.  
To begin predict how Parkinson disease (PD) associated variants might alter 
transcription and confer risk for PD, we first developed a regulatory vocabulary for 
midbrain (MB) dopaminergic (DA) neurons and identified four TFs conferring 
regulatory activity in these cells. With this vocabulary, we scored >7,000 variants 
associated with neurodegenerative and neuropsychiatric traits for their capacity to 
disrupt TF binding. We selected >20 of these sequences for validation by luciferase 
assay however, this has proved a challenge considering the cell-specificity of enhancer 
activity and the lack of DA neuronal cell culture models. We turn to a cell type agnostic 
approach, protein-binding arrays, as an alternative to luciferase for evaluating how 
variants impact protein binding. In a preliminary test of this technique, we identified 
four proteins, NOVA1, PEG10, SNRPA, and CHMP5, whose binding may be impacted 
by the SNCA enhancer variants. Finally, we have performed preliminary 
characterization of a possible in vitro cell surrogate, SN4741 cells, using karyotyping, 
and single-cell RNA-seq.  
3.2 Candidate regulatory elements are enriched for transcription 
factor motifs active in dopaminergic neurons2  
To identify sequence modules (kmers) predicted to contribute regulatory 
activity in MB and forebrain (FB) DA neurons, we applied the machine learning 
                                                     
2 This section and associated methods have been published in the American Journal of Human Genetics and 
adapted for use in this thesis. McClymont, S.A. et al. (2018). Parkinson-associated SNCA enhancer variants 
revealed by open chromatin in mouse dopamine neurons. The American Journal of Human Genetics, 103:874-892237. 
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algorithm, gkm-SVM73 to the MB DA neuron ATAC-seq catalogues237 generated in 
Chapter 2. The resulting regulatory vocabularies of kmers had high predictive power 
(auROCMB = 0.915, auROCFB = 0.927). We rank ordered and collapsed related kmers 
to reveal motifs enriched in the open chromatin regions (OCRs) and their 
corresponding TFs (Figure 3.1A, E, I, M). In the MB, the four most enriched motifs 
correspond to Rfx1, Foxa2, Ascl2, and Nr4a2.  
Given the degeneracy of binding motifs within TF families, we consulted the 
bulk RNA-seq data for each of the implicated TF families and examined the relative 
expression levels to prioritize which TFs are most likely producing the observed motif 
enrichments (Figure 3.1B, F, J, N). For example, the reported DNA binding domain 
is highly conserved between RFX family members and as a result the predicted 
sequence motif for each is highly similar238,239, thus we must use other means to 
identify which family member is likely acting in these cells. While no member of the 
Rfx family has been canonically associated with MB DA neurons, we anticipate Rfx3 
and Rfx7, as the two highest expressed Rfx genes, to likely be active in MB DA neurons 
and driving this motif enrichment (Figure 3.1B). Foxa1, and more specifically, Foxa2 
are both known to DA neuron biology175,240 and both are highly expressed in the MB 
DA neurons (Figure 3.1F). Regarding enrichment for the Ascl family, Ascl1 is known 
to be involved in DA neuron biogenesis241 and is more highly expressed than any other 
TF in the family (Figure 3.1J). Finally, Nr4a2 is both canonically associated with DA 
neurons and required for their development178; we observe it to be highly expressed in 
MB DA neurons (Figure 3.1N). Examining the sequences underlying the OCR 
catalogues, we identified TF families known and unknown to DA neuron biology and 
further refined the TF associations using expression data.  
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We also examined the qualities that differentiate MB OCRs from FB OCRs by 
examining the sequences underlying MB-specific and FB-specific regions. We 
developed a vocabulary that discriminates MB and FB regions with high predictive 
power (auROC = 0.926) and identified kmers enriched in MB-specific peaks where the 
top corresponding TFs are Foxa1/2 and Nr4a2 (Supplementary Figure 3.1). We 
confirmed this MB bias by again considering the bulk RNA-seq for these genes. As 
expected, these TFs are more highly expressed in the MB where Nr4a2 is present at 
12-fold higher levels in the MB (135 RPKM in the MB vs 11 RPKM in the FB) and 
Foxa1/2 are not expressed in the FB, but are present in the MB (Foxa1: 28 RPKM, 
Foxa2: 7 RPKM). Not only do we identify Foxa1/2 and Nr4a2 as more active in MB 
DA neurons than in the FB, we did so solely by comparing their role in the vocabulary 
of MB-specific OCRs versus FB-specific OCRs. 
In a parallel strategy to identify TFs actively engaging the DNA in MB DA 
neurons, we performed TF footprinting in a single deeply sequenced MB ATAC-seq 
library. Doing so, we confirm that two of the TFs prioritized by gkm-SVM leave robust 
footprints. The motif corresponding to Rfx-binding results in a dearth of cuts directly 
over predicted binding sites (Figure 3.1C). The same can be seen to a lesser extent 
for the motif corresponding to Foxa1/2 (Figure 3.1G). By contrast, motifs 
corresponding to Ascl1 or Nr4a2 fail to leave a robust mark on the chromatin 
availability (Figure 3.1K, O). It has been noted that nuclear receptors, like Nr4a2, 
only transiently interact with DNA242, and as a result, it may be that the short DNA 
residence time fails to result in a robust footprint detectable by transposition. These 
footprinting data substantiate the claim that the Rfx family of TFs and Foxa1/2 are 
active in MB DA neuron CREs.  
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We confirmed that these sequences are indeed enriched in the catalogues by 
examining the pileup of reads overlapping all genome-wide predicted motif binding 
sites for each motif identified by gkm-SVM. We see an abundance of reads over 
predicted binding sites of all four motifs (Figure 3.1D, H, L, P), with the strongest 
enrichment overlapping Rfx and Ascl1 motif sites (Figure 3.1D, L). Despite the less 
robust footprint generated at the Ascl1, this TF clearly underlies a larger than 
expected proportion of OCRs in the MB catalogue.  
The integration of a support vector machine learning algorithm as applied to 
the sequences underlying OCRs with footprinting analysis in the same chromatin 
substrate powerfully identifies TFs that are important for DA neuron biology and 
suggests the Rfx family of TFs, Foxa1/2, Ascl1, and Nr4a2 are actively influencing 
gene expression in the MB DA neurons.  
3.3 Predicting and testing the effects of regulatory variants  
Next, we sought to use this vocabulary to predict the effect of disease-
associated variants on enhancer functioning. We collected the lead SNPs plus those 
in high linkage disequilibrium (LD; r2 ≥ 0.8) from five genome-wide association studies 
(GWAS) for neurodegenerative and neuropsychiatric traits: Alzheimer disease243, 
epilepsy244, PD25, progressive supranuclear palsy245, and schizophrenia246 
(summarized in Supplementary Table 3.1). These variants were filtered for 
duplicates and those that are unable to be scored by deltaSVM (eg: multiallelic SNPs), 
after which a total of 7,719 variants were scored by deltaSVM for their impact based 
on the MB and FB DA neuron vocabularies. This calculation compares the gkm-SVM 
scores of the alternative and reference alleles and sums across the surrounding 
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sequence to predict the consequence of the variant on regulatory activity. The 
distribution of these scores are shown in Figure 3.2A. We observe a long right tail, 
representing variants that are predicted to be highly influential in TF binding.  
 The top variant identified by deltaSVM is rs1498232, associated with 
schizophrenia, which is predicted to be highly damaging to TF binding in both the MB 
and FB vocabularies (deltaSVMMB: -22.347, deltaSVMFB: -19.506). How deltaSVM 
sums the variant impact using the MB vocabulary is demonstrated in Figure 3.2B. 
This variant is predicted to be highly damaging to a RFX binding site (Figure 3.2C). 
There are ten SNPs in high LD (r2 >0.8), none of which are predicted by deltaSVM to 
strongly alter regulatory function (Figure 3.2D). Using other vocabularies our group 
has generated to assess the cell-type specificity of this variants effects, we scored these 
same variants for disrupting activity in a lymphoblastoid cell line247 (GM12878) and 
melanocytes248 (melanA). These variants are not scored as altering regulatory function 
(Figure 3.2E, F).  
We sought to test these variants using luciferase in the SK-N-SH 
neuroblastoma cell line. We cloned 500bp fragments centred on the variant to be 
tested (Figure 3.2G) upstream of a minimal E1B promoter in a luciferase expression 
vector77, containing either the reference or alternate allele. Just one of the constructs, 
and not that predicted by deltaSVM, exceeded background levels of regulatory activity 
(Figure 3.2H). The one construct exceeding background levels did not validate in a 
replication experiment (data not shown). This was disappointing but perhaps 
unsurprising given that these variants fall in a gene desert and none overlap an OCR 
in either MB or FB DA neurons. To increase the a priori probability of the variants 
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falling in an active regulatory region, we next restricted ourselves to testing variants 
that are highly rated as damaging that fall in ATAC-seq peaks.  
 Of the 7,719 variants scored by deltaSVM, 275 variants overlap either a FB or 
MB peak. Many of these variants overlap with promoters and were removed from our 
analysis, leaving 137 variants overlapping an OCR. The distribution of these scores 
(Figure 3.3A) largely reflects the distribution of the variants as a whole and remains 
skewed. We selected ten peaks containing the top 11 scored disease-associated 
variants (Figure 3.3B). A schematic of the peak locations, the intersecting variants, 
and the nearest gene is indicated in Figure 3.3C. Centering on the variants, we cloned 
500bp fragments containing the risk and non-risk alleles for these regions and 
performed luciferase reporter assay. Again, no construct exceeded background levels 
of activity (Figure 3.3D).  
 While unlikely, it could be that none of the selected sequences direct enhancer 
activity. To test this, we assayed the OCR in intron 4 of SNCA that we had already 
demonstrated to have enhancer activity in vivo in Chapter 2. We cloned the exact 
enhancer region that was tested in vivo, containing the risk and non-risk haplotypes. 
After performing luciferase assay on these constructs, again we observe no enhancer 
activity (Figure 3E). This result indicated to us that there is likely an underlying 
issue with the in vitro reporter assay – we observe no enhancer activity in a sequence 
that is demonstrably an enhancer in vivo.  
To address this, we have performed a variety of troubleshooting steps, like 
changing the promoters upstream of the luciferase reporter (E1B, TATA, SV40, 
SYN1), the promoters upstream of the renilla reporter (CMV, SV40), the lipofection 
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method (lipofectamine 3000, 2000), how the vectors are cloned (Gateway cloning, 
restriction cloning), the orientation and size of the constructs (forward and reverse, 
full enhancer and restricted to a central portion), and importantly, the cell line in 
which the construct is being tested (SK-N-SH, SH-SY-5Y, Neuro2A). No change has 
reliably demonstrated the SNCA sequence to drive expression in vitro (data not 
shown).  
 We believe these results represent a fundamental problem with these in vitro 
assays – the cells in which we are testing are not the correct cellular surrogate for 
embryonic MB DA neurons. We observed the exquisite restriction of the enhancer 
activity of the SNCA sequence in Chapter 2, it is likely that the immortalized cell 
lines are poor proxies and do not represent the restricted cell types that this enhancer 
is active in.  
3.4 Protein binding arrays are a viable alternative validation 
strategy3  
We turned to parallel strategies for assaying the effects of variants on enhancer 
activity that do not rely on cell surrogates. For a cell agnostic assay, we turned to 
protein binding arrays249. To verify the utility of this assay, we examined the proteins 
whose binding is disrupted by the SNCA enhancer variants.  
We assayed differential protein binding at the PD-associated variants at SNCA 
for >16,000 proteins249. In doing so, we identify five proteins whose binding is robustly 
                                                     
3 This section and associated methods have been published in the American Journal of Human Genetics and 
adapted for use in this thesis. McClymont, S.A. et al. (2018). Parkinson-associated SNCA enhancer variants 




impacted by these implicated variants: NOVA1, APOBEC3C, PEG10, SNRPA, and 
CHMP5 (Figure 3.4A, B, C). Of these, all are expressed at appreciable levels in both 
MB and FB DA neurons (Figure 3.4D), excluding APOBEC3C (RPKM ≤ 1). Of the 
remaining four proteins, three (PEG10, SNRPA, and CHMP5) demonstrate an 
increased binding affinity for the minor risk allele over the major allele; this direction 
of effect is consistent with the over-expression paradigm by which SNCA confers PD 
risk20. Interestingly, CHMP5 is the sole protein we identify whose binding affinity is 
impacted by variant rs2583959, and our group has recently implicated one of its 
family members, CHMP7, in conferring PD risk179, perhaps indicating a role for this 
family of proteins in PD. Although no single protein stands out, the increased affinity 
for the risk alleles of the identified enhancer variants by proteins expressed in DA 
neurons is consistent with a potential mechanistic contribution to SNCA expression 
and therefore, PD risk. 
This was a promising result indicating to us that protein binding arrays are 
appropriate as an alternative strategy for luciferase to assess how enhancer variants 
affect TF binding and thus alter enhancer activity and gene expression. However, 
these assays are inherently synthetic as they occur in the absence of a cellular 
environment and only test small fragments of DNA not in their larger endogenous 
sequence context. While this method has been demonstrably successful and we will 
continue to use protein binding arrays to assay enhancer variants in the absence of a 
better test, we continue to search for a more appropriate cellular surrogate in which 




3.5 The suitability of in vitro dopaminergic neuron surrogates: the 
SN4741 cell line 
 We have identified the cell line SN4741 as a likely in vitro cell surrogate. 
SN4741 cells are derived from E13.5 mouse DA neurons from the substantia nigra 
and contain a SV40Tag that directs the differentiation when the cell culture is shifted 
to 39°C250. We performed preliminary expression analysis by RT-qPCR to confirm 
expression of a variety of DA neuron markers. We observed increases of these markers 
under the higher temperature condition, indicating the cells are indeed differentiating 
towards a more DA state (Figure 3.5A).  
 With this promising result, we moved forward to more deeply characterize 
these cells to assess their suitability as in vitro surrogates for in vivo MB DA neurons. 
First, we performed karyotyping analysis on 20 cells to assess the chromatin 
complement of these cells (representative karyogram in Figure 3.5B). Interestingly, 
SN4741 cells appear to be an unstable triploid line (Figure 3.5C), with a variety of 
marker chromosomes. None of the 20 cells assessed had the same chromosome 
complement. This is concerning for the viability of these cells as a surrogate for a 
variety of reasons. The biggest being if the cells are genetically unstable, there may 
be large experimental batch effects as the cell populations shift across divisions.  
 To assess the consistency of the differentiation protocol, we compared the 
transcriptomes from ≥17,000 cells in the permissive (37°C) and non-permissive (39°C) 
states. Cluster analysis indicates a separation of the cells at each temperature 
(Figure 3.5D). This separation of cells by temperature is accompanied by changes to 
the cell cycle, with cells at the permissive (37°C) temperature containing cells in either 
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G2M or S phase, while cells at the non-permissive temperature (39°C) are mostly 
differentiated and in G1 phase (Figure 3.5E, F). In expression analysis, we observe 
that markers of proliferation, like Ki-67, are exclusively expressed in cells at the 
permissive temperature (Figure 3.5G), corroborating the cell cycle analysis. SN4741 
cells, when shifted to the non-permissive temperature, appear to robustly 
differentiate.  
 However, in examining expression of a variety of DA neuron markers, we fail 
to detect expression in either the permissive or non-permissive temperature. Markers, 
including Th, Nr4a2, and Slc6a3 have few to no reads assigned to them (Figure 3.5H, 
I, J). It appears that while these cells are differentiating when shifted to the non-
permissive temperature, we are unable to confirm these cells are entering a DA 
trajectory when doing so.  
3.6 Discussion  
As GWASs are applied to ever more common diseases, methods to identify non-
coding variants contributing to risk through altering regulatory activity are needed. 
Machine learning algorithms, like the one we apply here, are being explored as a 
method for predicting TFs active in a cell type and how variants might impact their 
binding. Here, we use the machine learning algorithm, gkm-SVM, to predict TFs 
active in MB DA neurons and use this vocabulary to rank >7,000 variants for their 
capacity to alter regulatory functioning. Our ability to validate these predictions is 
limited as a result of the cell type specific action of enhancers, as demonstrated by our 
luciferase assay experiments. We explored cell type agnostic approaches, like protein 
binding arrays, to great success. In testing the SNCA enhancer variants for their 
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effect on protein binding, we identified five proteins whose binding is affected, three 
of which, PEG10, SNRPA, and CHMP5, display greater affinity for the risk allele. 
Finally, we explored the suitability of the SN4741 cell line as a surrogate for in vivo 
embryonic MB DA neurons.  
In examining the sequence composition underlying the ATAC-seq peaks, we 
illuminate powerful vocabularies for both FB and MB DA neuron transcriptional 
regulatory control. Machine learning using gkm-SVM prioritizes four transcription 
factor families (Rfx, Foxa1/2, Nr4a2, Ascl1/2) as those conveying significant regulatory 
potential in the CRE catalogues. Of these, the Rfx family had not previously been 
implicated in DA neuron biology. Although several of the Rfx family members have 
been annotated as having expression in the cerebellum or fetal brain238, a role 
specifically in MB DA neurons has not previously been appreciated. By contrast, 
Nr4a2 is canonically associated with MB DA neurons177,178, is highly expressed in this 
population (139 RPKM), and was prioritized as a TF conferring regulatory potential 
in these cells; however, TF footprinting fails to provide evidence supporting its 
activity. We postulate that this lack of footprint may reflect the transient DNA 
binding dynamics of Nr4a2. Transcription factors with short DNA residence times 
often fail to reveal footprints, and nuclear receptors, such as Nr4a2, have markedly 
transient DNA interactions242.  
 We apply this vocabulary to predict how variants identified by GWASs 
conferring risk for Alzheimer disease, epilepsy, PD, progressive supranuclear palsy, 
or schizophrenia might impact regulatory activity. We prioritized >20 variants for 
validation using two strategies for prioritization; first, we examined the highest 
ranked variant and ten variants in LD and next, we examined the regulatory 
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functioning of ten MB OCRs containing highly ranked disrupting variants. Despite 
the variety of variants tested, none exceeded background levels of activity. We 
hypothesize this is the result of highly restricted enhancer activity of the regions being 
assayed and supporting this hypothesis, the sequence at SNCA that we previously 
identified as an enhancer in vivo, fails to direct reporter activity in vitro. While we 
have explored alternative strategies for interrogating enhancer variant functioning, 
ideally an in vitro cellular surrogate will be identified.  
 Towards this, we have begun characterizing the embryonic MB DA-derived 
neuronal cell line, SN4741. While initial qPCR results were promising, deeper 
characterization suggests these cells are an unstable triploid cell line that are perhaps 
not as DA as hoped. scRNA-seq in these cells fails to detect activity of key DA neuron 
markers, especially Th. However, scRNA-seq collects very sparse matrices of 
information and it may be that these markers are lowly expressed and escape 
detection by scRNA-seq. RT-qPCR is far more sensitive and those results do 
demonstrate a shift towards a DA trajectory with a shift in temperature. To assess 
how well these cells might match the ex vivo MB DA neurons, we have performed bulk 
RNA-seq and ATAC-seq at both temperatures. We have begun to explore changes 
induced by the temperature shift, but importantly, we will be focusing on comparing 






3.7 Methods  
Regulatory vocabulary development 
We applied the machine learning algorithm gkm-SVM73 to the MB and FB 
catalogues generated in Chapter 2, under default settings. We trained on the 
sequences underlying the summits ±250bp of non-ubiquitously open, top 10,000 peaks 
by signal intensity, versus five negative sets, matched for GC content, length, and 
repeat content. Weights across all five tests were averaged for all 10-mers. 
All 10-mers with weight ≥1.50 were clustered on sequence similarity using 
Starcode251, using sphere clustering with distance set to 3. clustalOmega252 aligned 
the sequences within these clusters and MEME253, under default parameters, 
excepting -dna -maxw 12, generated position weight matrices (PWMs) of these aligned 
clusters. Tomtom254, querying the Jolma 2013, JASPAR Core 2014, and Uniprobe 
mouse databases, identified the top transcription factors corresponding to these 
PWMs, under default parameters excepting -no-ssc -min-overlap 5 -evalue -thresh 
10.0.  
The same procedure was used to identify transcription factors specifically 
conveying regulatory potential in the MB library relative to the FB library, except 
during gkm-SVM training, the positive set was specified as the top 10,000 non-
ubiquitously open MB summits and the negative set was specified to be the top 10,000 




Transcription factor footprinting  
A single MB ATAC-seq library was sequenced on the Illumina HiSeq in Rapid 
Run mode with 2x100bp reads, to a depth of ≥350 million paired-end reads. Analysis 
was performed as described in Chapter 2. CENTIPEDE255 was used to identify 
footprints. Sequences underlying the deeply sequenced MB library peaks, less those 
ubiquitously open, were extracted. FIMO256, with options --text --parse-genomic-coord, 
identified all locations underlying ATAC-seq peaks of the motifs identified above. 
Additionally, conservation data from 30-way vertebrate phastCons was considered in 
the CENTIPEDE calculations; for each PWM site, those with mean conservation score 
greater than 0.9 were considered. Finally, the BAM file read end co-ordinates were 
adjusted in response to the shift in co-ordinates due to the transposase insertion257. 
As such, following the original ATAC-seq method95, reads were adjusted +4bp on the 
positive strand and -5bp on the negative strand.  
Genome-wide read pileup over predicted motif sites 
FIMO, as above, was used to identify all co-ordinates genome wide of the 
identified motifs. deepTools204 “bamCoverage” tool was run under default conditions, 
to convert the deeply sequenced MB library BAM to bigwig format. Following this, a 
matrix file was generated with “computeMatrix”, with options --referencePoint center 
-b 1000 -a 1000 -bs 50 specified. Finally, “plotHeatmap” was used to generate plots 




deltaSVM predictions of variant effect  
Selecting variants  
Lead variants from GWASs on Alzheimer disease243, epilepsy244, PD25, 
progressive supranuclear palsy245, and schizophrenia246 were downloaded from the 
NHGRI-EBI GWAS Catalog258. Proxy variants in high LD (r2 ≥ 0.8) were collected with 
rAggr, querying: 1000 Genomes phase 3 (Oct 2014) CEU+FIN+GBR+IBS+TSI 
populations for variants with minimum minor allele frequency of 0.001 and a 
maximum distance of 500kb from the lead SNP.  
Scoring variants 
 Identified variants were submitted to the deltaSVM perl script169. FASTA files 
were generated containing the 19bp sequence context centred on the variant, either 
containing the reference or alternate allele. The MB DA neuron vocabulary was used 
to score the variants. Vocabularies from GM12878 lymphoblastoid cells247 and melanA 
cells248 were also used to score variants, as negative controls.  
Motif analysis  
 The damaging effect of the variants on TF binding was predicted with 
motifbreakR259. Querying the MotifDb collection of protein-DNA binding motifs260, 




Validation of deltaSVM predictions of effect 
Cloning of prioritized sequences  
Primers (Supplementary Table 3.2) were designed using Primer-BLAST212 
under default parameters with the requirement that the primers fall within 400bp on 
either side of the variant. Sequences were PCR amplified from human genomic DNA 
extracted from lymphoblastoid cell lines that were heterozygous for each variant, 
identified from the 1000 Genomes Project, provided by the Coriell Institute (HG03832, 
HG01883, HG00187, HG03193, and HG03690). PCR amplicons were BP cloned 
(Gateway; Invitrogen #11789020) into pDONR221 (Invitrogen) and transformed. 
Plasmid sequences were confirmed by diagnostic digest (BsrGI) and Sanger 
sequencing. QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent #210518) 
was used to remove unwanted variation and, when necessary, to induce the 
alternative alleles. Sequences were LR cloned (Gateway; Invitrogen #11791020) into 
the E1B promoter luciferase vector77. Final vectors were quantified with the Qubit 
dsDNA Broad Range Assay (Invitrogen) and standardized to 500ng/µL.  
Cell culture of SK-N-SH cells  
 SK-N-SH cells were cultured in EMEM with 10% FBS and 1X penicillin and 
streptomycin for at least three passages before assay. For luciferase assay, cells were 






Each well was lipofected with 500ng of the luciferase reporter plasmid 
containing the putative enhancers and 10ng of CMV-RL renilla expression vector 
(Promega #E2261) using 0.75µl Lipofectamine 3000 per well (Life Technologies 
#L3000015). Three to four biological replicates and two to four technical replicates 
were performed for each construct.  
Luciferase activity assay 
48 hours post-lipofection, cells were lysed and lysates were collected for assay 
with the Dual-Luciferase Reporter Assay System (Promega # E1960). Luciferase and 
renilla activity was measured with the Tecan GENiosPro Microplate Reader (Tecan 
Group Ltd.) luminometer with automatic injectors. Within samples, the luciferase 
activity was normalized to renilla activity. Across samples, luciferase activity was 
further normalized to the average luciferase activity of the empty pE1B plasmids 
(containing a single basepair between the Gateway arms).  
Protein array testing differential binding 
HuProt v3.1 human proteome microarrays printed on the PATH surface 
containing >16,000 unique proteins representing 12,586 genes (CDI laboratories)249 
were blocked with 25mM HEPES pH 8.0, 50mM potassium glutamate, 8mM MgCl2, 
3mM DTT, 10% glycerol, 0.1% Triton X-100, 3% BSA on an orbital shaker at 4oC for 
≥3 hours. Allele specific protein-DNA binding interactions were identified through 
dye-swap competition of major and minor alleles labeled with either Cy3 or Cy5. DNA 
fragments for rs2737024 and rs2583959 were synthesized with the SNP for each allele 
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flanked by 15 nucleotides of the upstream and downstream sequence and a common 
priming site at the 3’ end (Supplementary Table 3.3). 
The dsDNA fragments were created by separately annealing a primer 
containing a Cy3 or Cy5 label and adding Klenow (NEB) with dNTP to fill-in the 
complementary strand for each allele261. Cy3 labeled major allele was mixed with Cy5 
labeled minor allele (each at 40nM) in 1x hybridization buffer (10mM Tris-Cl pH 8.0, 
50mM KCl, 1mM MgCl2, 1mM DTT, 5% glycerol, 10µM ZnCl2, 3mg/mL BSA) and 
added to an array, dyes were then swapped for each allele and the mixture was then 
added to a second array. DNA was allowed to bind overnight at 4oC on an orbital 
shaker with protection from light. Chips were washed once with cold 1xTBST (0.1% 
Triton X-100) for 5 minutes at 4oC, rinsed, and dried in the centrifuge. Cy5 and Cy3 
images were taken separately on a Genepix 4000B scanner and, after alignment to 
the GAL file, individual spot intensities were extracted using the Genepix Pro 
software. 
Allele specific interactions were identified through dye swap analysis. The 
ratio of major/minor allele binding was calculated using the duplicate spot average 
median foreground signal for each protein according to the following equation: 
 
 
Mean intensity was calculated by averaging the foreground signal for the Cy3 
and Cy5 channels of the major and minor alleles. MA plots were made for each allele 







SN4741 characterization  
Cell culture of SN4741 cells  
 SN4741 cells were cultured in high glucose DMEM with 10% FBS and 1X 
penicillin and streptomycin at 37°C. To induce differentiation, 24 hours after the cells 
were passaged, the flask was moved to differentiation media (high glucose DMEM 
with 0.5% FBS) and were cultured at 39°C for 48 hours.  
cDNA synthesis and RT-qPCR for DA neuron markers 
RNA was extracted using the RNeasy Mini Kit (Qiagen). Each RNA sample 
was submitted to first strand cDNA synthesis using the SuperScript III First-Strand 
Synthesis System for RT-PCR (Invitrogen), following the Oligo(dT) method.  
Primers (Supplementary Table 3.4) were designed using Primer-BLAST212 
under default parameters with the requirement for exon-exon junction spanning 
specified. qPCR was performed using Power SYBR Green Master Mix (Applied 
Biosystems). Reactions were run in triplicate, following default SYBR Green Standard 
cycle specifications on the Viia7 Real-Time PCR System (Applied Biosystems). 
Relative quantification followed the 2-ΔΔCT method, normalizing results to Actb in the 
samples at the non-permissive temperature. 
Karyotyping 
G-banded karyotyping was performed by WiCell on twenty cells. Resulting 





 Cells at both the permissive and non-permissive temperatures were 
trypsinized and scRNA-seq libraries were generated following the Chromium 10X 
pipeline. Four replicates at each temperature across 17,000 cells were assayed.  
 scRNA-seq analysis was performed with Seurat. Cells were filtered to remove 
stressed/dying cells (% of reads mapping to the mitochondria > 15%) and empty 
droplets and doublets (number of unique genes detected less than 200 or greater than 
6,000). Cells were normalized using `SCTransform()` and the effect of percent 
mitochondrial reads and the sequence depth was corrected for. Principal component 
(PC) analysis was performed and a PC cut-off was identified using `JackStraw()` and 
`ElbowPlot()`. UMAP clustering using this PC cutoff and a minimum distance of 0.001 
was used for dimensionality reduction.  
 Cells were scored for their stage in the cell cycle using `CellCycleScoring()` on 
cell cycle genes provided by Seurat (`cc.genes`). Expression was plotted on a log scale 
with `VlnPlot()` for a variety of proliferation and DA neuron markers (shown: Mki67, 





3.8 Figures and supplementary materials 
Figure 3.1: Identification of transcription factors (TFs) important to DA 
neurons 
 
(A) The kmer predicted to have the greatest regulatory potential underlying MB 
ATAC-seq peaks corresponds to the Rfx family of TFs. (B) RNA-seq quantification in 
these same cells indicates this enrichment is likely due to Rfx3 or Rfx7 activity. 
Examining the ATAC-seq signal over predicted binding sites reveals a robust TF 
footprint (C) and a general enrichment of reads overlapping Rfx sites genome-wide 
(D). (E-H) Similarly, a kmer corresponding to the TFs Foxa1/2 have similar evidence 
for their activity. (I-J) The third ranked motif likely corresponds to Ascl1, and while 
it fails to leave a robust TF footprint (K), there is clear enrichment of ATAC-seq signal 
overlapping genome-wide predicted Ascl1 binding sites (L). (M, N) Nr4a2, canonically 
associated with DA neuron biology, is identified as a highly expressed TF likely 
contributing to the regulatory potential of the putative CREs however, it fails to leave 
a TF footprint in the cut-site patterns around predicted motif sites (O) and is only 









Figure 3.2: Investigating rs4988232 for an effect on enhancer activity  
 
(A) The distribution of gkm-SVM scores for all disease-associated variants scored in 
the midbrain and forebrain. (B) The schizophrenia-associated variant, rs4988232, is 
the top variant ranked by deltaSVM as highly damaging. (C) This variant is predicted 
to disrupt an RFX binding site. (D) None of the other variants in high LD (r2 ≥ 0.8) 
are predicted to be nearly as damaging as rs4988232. (E, F) When these variants are 
scored with deltaSVM using a different cell type vocabulary, this locus is not predicted 
to be damaging to transcription factor binding. (G) 500bp centred on each variant was 
cloned for luciferase assay (red: top ranked variant). (H) Luciferase activity for the 
reference and alternative alleles of each variant. The top predicted variant does not 
validate, and nine of the ten constructs do not appear to direct reporter activity above 






Figure 3.3: Investigating the top variants falling in midbrain open chromatin 
regions for their effect on enhancer activity 
 
(A) The distribution of gkm-SVM scores for all disease-associated variants that 
overlap an open chromatin region in the midbrain. (B) Summary of the deltaSVM 
scores for the top eleven variants that fall in midbrain open chromatin regions. (C) 
Schematic of the variants, the open chromatin regions and genes that they overlap. 
(D) None of the tested variants, either as the reference or alternate allele, exceed 
background levels of reporter activity (“EMPTY”). (E) Even the enhancer at SNCA, 
containing either the reference sequence (non-risk) or the haplotype containing the 







Figure 3.4: Identification of proteins whose binding is impacted by the 
implicated PD-risk SNPs 
 
(A, B) MA plots for both rs2737024 and rs2583959 indicating the magnitude of the 
effect of the minor and major allele on binding. Cut-off for differential binding: 
log2(major/minor) ≥ 1.5 or ≤ -1.5. (A) NOVA1 and APOBEC3C (green circles) bind at 
rs2737024 with greater affinity for the major allele, while PEG10 and SNRPA (red 
circles) have a greater affinity for the minor allele. (B) CHMP5 (red circle) has a 
greater affinity for the minor allele of rs2583959. (C) Representative images of the 
protein binding for each of the differentially bound proteins. (D) Expression analysis 
in the MB and FB DA neurons for each of the differentially bound proteins indicate 
Nova1, Peg10, Snrpa, and Chmp5 to be highly expressed in these populations, while 
none of the Apobec family member genes are expressed (RPKMs ≤ 1, data not shown). 







Figure 3.5: Initial characterization of the SN4741 cell line suggests it is an 
unstable, triploid cell line that express markers of differentiation but not of 
dopaminergic neurons 
 
(A) RT-qPCR indicates the cells, when shifted a non-permissive temperature, begin to 
express markers of dopaminergic neurons at high levels. (B) A representative 
karyogram of SN4741 cells, indicating the likely triploid nature of the cells. Also 
shown are the marker chromosomes. (C) Summary of the karyotypes of 20 SN4741 
cells demonstrating the instability of aneuploidy in these cells. (D) scRNA-seq at the 
permissive and non-permissive temperature indicates the cells at each temperature 
are transcriptionally distinct. (E, F) Shifting the cells to the non-permissive 
temperature is accompanied by a shift in cell cycle stage from G2M and S phase to 
primarily G1 phase. (G) A marker of proliferation, Mki-67, is only expressed at the 
permissive temperature, corroborating the cell cycle analysis shift. (H) There is no 
detected expression of tyrosine hydroxylase, Th, at either temperature. (I, J) Other 
markers of DA neurons, Nr4a2 (I) and Slc6a3 (J) are also not detected, calling into 







Supplementary Figure 3.1: Motif analysis identifies transcription factors 
(TFs) important specifically for MB regulatory potential 
 
(A-D) The motifs with the greatest regulatory potential specific to the MB and the 
potential TF matching that motif were identified. (E-H) Expression analysis of these 
identified TFs confirm the sequence based analysis for Foxa1 (E), Foxa2 (F), and 
Nr4a2 (H). Foxd3 (G), while prioritized on the basis of sequence composition, is not 
expressed in MB or FB DA neurons (≤1 PKM) and was likely identified as a 




Supplementary Table 3.1: Summarizing the disease-associated variants 
collected for scoring by deltaSVM 
Disorder # of lead SNPs 
# of LD 
friend SNPs PMID 
Alzheimer disease 19 916 24162737 
Epilepsy 4 317 25087078 
Parkinson disease 26 3,700 25064009 
Progressive supranuclear palsy 7 3,304 21685912 






Supplementary Table 3.2: Primer sequences used to clone the constructs for 
luciferase assay (bold: BP Gateway arms) 
  














































































































































Supplementary Table 3.4: RT-qPCR primers for testing expression of 
dopaminergic neuron markers 
Marker Forward Reverse 
Th CTGTCCACGTCCCCAAGGTTCA CAATGGGTTCCCAGGTTCCG 
Actb TGGCTCCTAGCACCATGAAG AGCTCAGTAACAGTCCGCCTA 
Foxa2 CCCTACGCCAAATGAACTCG GTTCTGCCGGTAGAAAGGGA 





Chapter 4: The developmental origins of Parkinson 
disease 
4.1 Investigating the pathogenesis of Parkinson disease by single-cell 
RNA-seq 
Parkinson disease (PD) is the second most common neurodegenerative disease 
and is characterized by progressive motor phenotypes, including resting tremor, 
bradykinesia, rigidity, and postural instability2. These symptoms are largely the effect 
of substantial degeneration of midbrain dopaminergic (DA) neurons, specifically those 
in the substantia nigra4. This preferential degeneration and the appearance of protein 
aggregates of α-synuclein, in the form of Lewy bodies, are the pathological hallmarks 
of PD. How these protein aggregates result in cell death and why these processes 
might preferentially affect the DA neurons of the substantia nigra is not well 
understood.  
 PD can also present with a variety of non-motor phenotypes, including 
anosmia, constipation, and REM sleep disorders, which often precede the motor 
phenotypes by years to decades3,262. This prodromal phase of PD suggests that 
neurodegeneration is occurring long before the clinical presentation of PD. Supporting 
this, by the time that movement phenotypes become apparent and a clinical diagnosis 
is made, up to 40-60% of DA neurons of the substantia nigra have already been lost4. 
It is therefore important to examine early time points, before the neurodegeneration 
has become apparent, in order to elucidate the mechanisms that lead to the 
preferential loss of nigral DA neurons.  
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 Using a mouse model of PD, we set out to characterize populations of midbrain 
DA neurons at an early post-natal time point and identify subpopulations, genes, and 
pathways disrupted in PD. First, to examine the early development of DA neuron cell 
type subpopulations, we performed single-cell RNA-seq (scRNA-seq) on populations of 
wildtype DA neurons at both embryonic day E15.5 and post-natal day P7. This 
analysis defined the heterogeneity of DA populations over developmental time in the 
brain, revealing the development of distinct populations of mature DA neurons by P7. 
Next, at this early post-natal time point, we compared midbrain DA neurons in a 
mouse model of PD and identify differences. We find that, even this early in 
development, there are significant alterations in neural differentiation, gene 
expression, and mitochondrial function. Finally, we present a model to unify these 
observations, suggesting PD is a disorder that begins to manifest during early neuron 
development and maturation. 
4.2 Characterizing E15.5 and P7 dopaminergic neurons in wildtype 
mice4 
In order to characterize DA neuros, we performed scRNA-seq on cells isolated 
from distinct anatomical locations of the mouse brain over developmental time. We 
used fluorescence-activated cell sorting (FACS) to retrieve single DA neurons from the 
Tg(Th-EGFP)DJ76Gsat BAC transgenic mouse line (Th:eGFP), which expresses 
EGFP under the control of the tyrosine hydroxylase locus171. We microdissected both 
midbrain (MB) and forebrain (FB) from E15.5 mice, extending our analyses to MB, 
                                                     
4 This section and associated methods have been published in the American Journal of Human Genetics and 
adapted for use in this thesis. Hook, P. W. et al. Single-Cell RNA-Seq of Mouse Dopaminergic Neurons Informs 
Candidate Gene Selection for Sporadic Parkinson Disease. Am. J. Hum. Genet. 102, 427–446 (2018)151. 
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FB, and olfactory bulb (OB) in P7 mice (Figure 4.1A). Brains from four and five mice 
were pooled for E15.5 and P7, respectively. E15.5 and P7 time points were chosen 
based on their representation of stable MB DA populations, either after neuron birth 
(E15.5) or between periods of programmed cell death (P7)263 (Figure 4.1A). 
To assess the transcriptomes of these tissues and time points, we sequenced 
~95 cells from each, using the Smart-Seq2 protocol138, for a total of 473 single cells 
sequenced to an average depth of ∼8×105 50-bp paired-end fragments per cell. We 
performed standard quality control and filtered cells for total mass, total number of 
mRNAs, and total number of expressed genes per cell. We then used principle 
component analysis (PCA) in order to identify and remove cells representing 
oligodendrocytes and other support cells. After this filtering, 396 cells remained 
for downstream analysis.  
With this data, we set out to identify clusters of single cells within time points 
and anatomical regions. First, to compare embryonic and post-natal DA neuron 
development, we analysed all cells collected. Doing so, we find that E15.5 cells from 
both MB and FB largely cluster together (Figure 4.1B), supporting the notion that 
they are less differentiated. By contrast, cells isolated at P7 mostly cluster by 
anatomical region, suggesting progressive functional divergence with time (Figure 
4.1B). We performed recursive analysis of each of these clusters to identify 
subpopulations therein. This revealed a total of 13 clusters (E15.5 FB1-2, MB1-2; P7 
OB1-3, FB1-2, MB1-4; Figure 4.1C), demonstrating the diversity of DA neuron 
subtypes and their progressive differentiation across developmental time.  
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With subpopulations of DA neurons defined by our data, we set out to assign a 
biological identity to each cluster. To do this, we identified differentially expressed 
genes between clusters within each time point, then identified marker genes for each 
cluster within each time point (summarized in Table 4.1). Among the four clusters 
identified at E15.5, two were represented in t-SNE space as a single large group that 
included cells from both MB and FB (E15.MB1, E15.FB1), leaving two smaller clusters 
that were comprised solely of MB or FB cells (Figure 4.1D). Both E15.MB1 and 
E15.FB1 show markers consistent with neuroblast populations264–272. The isolated MB 
cluster (E15.MB2) specifically expressed Foxa1, Lmx1a, Pitx3, and Nr4a2 and thus 
likely represents a post-mitotic DA neuron population273. Similarly, the discrete 
E15.FB2 cluster expressed markers of post-mitotic FB/hypothalamic neurons, 
including Six3, Six3os1, Sst, and Npy274–278 (Figure 4.1E). These embryonic data did 
not discriminate between cells populating known domains of DA neurons, such as the 
substantia nigra (SN) or ventral tegmental area (VTA). 
By contrast, P7 cells mostly cluster by anatomical region and each region has 
defined subsets (Figure 4.1F). Focusing specifically on the midbrain DA neurons, we 
identified four P7 MB DA subset clusters (Figure 4.1G). Marker gene analysis 
confirmed that three of the clusters correspond to DA neurons from the VTA (Otx2 
and Neurod6279,280; P7.MB1), the periaqueductal gray area (PAG; Vip and Pnoc149,281–
283; P7.MB3), and the SN (Sox6, Aldh1a7, Ndnf, Serpine2, Rbp4, and Fgf20149,279,284,285; 
P7.MB4). These data are consistent with recent scRNA-seq studies of similar 
populations149,283. The only cluster without a readily assigned identity was P7.MB2. 
This population of P7 MB DA neurons is likely a neuroblast-like population based on 
marker gene analysis149,286–290. Like the overlapping E15.MB1 and E15.FB1 clusters, 
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this cluster preferentially expresses markers of neuronal precursors, differentiation, 
or maturation. Additionally, this cluster exhibits gene expression consistent with 
embryonic mouse neuroblast populations149 as well as cell division and neuron 
development286–290. 
These results indicate a unique opportunity; at post-natal day 7 there are DA 
neurons that are mature and present in their ultimate anatomical locations, but there 
also remains a group of still developing neuroblasts. Further investigation at this time 
point would allow us to compare the impact of PD mutations on the mature DA 
neurons and structures that persist through to adulthood, but also consider how the 
PD mutation might impact DA neural development.  
4.3 Characterizing P7 dopaminergic neurons in a mouse model of 
Parkinson disease  
To assess the early developmental origins of PD, we performed scRNA-seq on 
midbrain DA neurons in a mouse model of PD. The A53T mouse model (B6;C3-
Tg(Prnp-SNCA*A53T)83Vle/J; JAX: 004479)291 expresses mutant human SNCA 
under the direction of the mouse prion protein promoter. This mouse model 
recapitulates human PD phenotypes, like progressive movement impairments and α-
synuclein aggregates) and demonstrates an allele-dosage effect, with the age of onset 
earlier for homozygotes (14-15 months) than for hemizygotes (22-28 months)291. We 
bred this allele onto the Th:eGFP background to allow retrieval of DA neurons. On a 
wildtype, hemizygous, and homozygous A53T background (Supplementary Figure 
4.1), we microdissected the midbrain from two litters of P7 pups and collected 13,518 
single cells by FACS for scRNA-seq. 
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Cells from each genotype were processed with the 10X Genomics pipeline for 
cDNA generation and library preparation. Following sequencing, it became apparent 
that our cells had not made it through this process completely intact and exhibited 
high levels of ambient RNA. As a consequence of either FACS, the 10X platform, or a 
combination of subjecting our neurons to both, our libraries exhibited a low fraction 
of reads in cells (~30%). Following sequencing, we captured 2,430 cells, with ~170,000 
reads per cell. We further filtered these cells in order to remove empty droplets, 
doublets and multiplets, and stressed/dying cells by considering the number of unique 
genes, read depth, and percent of reads mapping to the mitochondria. Following 
filtering, 1,357 cells remained for analysis.  
We performed clustering analysis on these cells to identify subpopulations 
present in our samples. Doing so, we identify seven clusters (Figure 4.2A). 
Preliminary expression analysis suggested two of these clusters (clusters 5 and 6) 
display little evidence of Th or eGFP expression (Figure 4.2B, Supplementary 
Figure 4.7) and likely consist of contaminating cell types, with cluster 5 expressing 
high levels of oligodendrocyte and other support cell markers292–297 (Figure 4.2C, 
Supplementary Figure 4.6). Marker analysis of this contaminating cell cluster 
identifies genes enriched in this cluster (eg: Zic1, Nfib, Id2, Tcf4; Figure 4.2D)298–303, 
which in consultation with ISH slides from the Allen Mouse Brain Atlas304, suggest 
these are granule cells, likely from either the hippocampus or cerebellum 
(Supplementary Figure 4.8). Consequently, this cluster and the contaminating 
oligodendrocyte cluster were removed from further analysis.  
Considering only the remaining dopaminergic neurons, we sought to assign 
each cluster to a biological identity or anatomical region. We performed differential 
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gene expression analysis between clusters to identify markers genes for each cluster 
(Figure 4.2E-I, Table 4.2). Comparing these markers with marker genes established 
from the literature149,279–287 and our work on wildtype P7 DA neurons151, we were able 
to assign a cell type to each cluster, identifying clusters corresponding to: the VTA, a 
post-natal neuroblast population, two SN clusters (SN1 and SN2), and the PAG 
(Figure 4.3A, Supplementary Figure 4.9). We have begun to confirm these cluster 
assignments with single molecular RNA fluorescence in situ hybridization (smFISH) 
on brain sections from wildtype P7 mice, using the genes indicated in Figure 4.3B-I.  
Clusters 0, 2, and 4 – tentatively the VTA, SN1 and SN2 – are transcriptionally 
related to each other, sharing high expression of many markers genes (eg: Aldh1a1 
and Ddc, Figure 4.4A; extended in Supplementary Figure 4.9). Clusters 2 and 4 
especially, both assigned to the SN, are highly similar in their expression patterns. 
We had not previously observed a separation of SN DA neurons in our study of 
wildtype P7 MB DA neurons, perhaps due to the relatively few cells sequenced (n = 
80 MB neurons). With a combined 337 cells assigned to the SN clusters here, resolving 
nuanced differences becomes possible. Here, we observe cluster 2 (SN1) to exhibit 
higher expression of DA neuron markers, like Th and Slc6a3 (Figure 4.4A, 
Supplementary Figure 4.9), while cluster 4 (SN2) has restricted expression of DA 
neuron markers, like Pitx3 and Foxa1 (Supplementary Figure 4.9)175,177. We will use 
smFISH against the genes indicated in Figure 4.4B-D to confirm these subtle 
transcriptional differences between clusters 0, 2, and 4, paying particular focus to 




4.4 The Parkinson disease mutation alters cell maturation, gene 
expression and mitochondrial dynamics  
Ultimately, our goal was to examine the effects of the A53T PD mutation on 
the transcriptomes of developing MB DA neurons. Towards this, first, we confirmed 
that the transgene is expressed at P7. Given the transgene incorporates the mouse 
Prnp 3’ and 5’ UTRs291 and the 3’ sequencing method employed by 10X Genomics137, 
reads belonging to the endogenous Prnp gene and the A53T transgene are 
indistinguishable. Thus, if the mutant transgene is active, we expect to see an 
apparent increase in Prnp expression in hemizygote and homozygote cells over 
wildtype. Indeed, we observe an increase in the number of cells with detectable Prnp 
expression between homozygote cells (79.2%) and wildtype cells (40.2%), with 
homozygotic cells expressing significantly higher levels (~3.3 fold increase) of Prnp 
(Figure 4.5A). 
Next, we examined how the presence of the A53T mutation impacts the 
distribution of cells among the subpopulations (Figure 4.5B), particularly focusing on 
alterations to the SN clusters, given the preferential degeneration of these neurons in 
PD. We observe approximately double the number of mutant cells in the two SN 
clusters and interestingly, given the physical interspersion of the post-natal 
neuroblast population with the SN151, we see approximately half as many neuroblast 
cells present in homozygous mutant cells. This alteration could indicate a precocious 
differentiation phenotype, with mutant neurons exiting the neuroblast stage and 
maturing into SN cells, a substantial difference to observe as early as P7. Additionally, 
we observe no apparent changes to the VTA cluster proportions by genotype, but do 
see an unexpected halving of cells in the PAG in homozygotes compared to wildtypes. 
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Quantifying cell proportion differences from scRNA-seq data is fraught with false 
positives, so we will validate these cell population differences by smFISH and quantify 
the number of cells in each cluster, comparing the three genotypes. 
 Finally, we sought to identify transcriptional differences between the 
genotypes resulting from the mutation on a cluster-specific and global basis. The two 
SN clusters had no significantly differentially expressed genes by genotype, however 
the neuroblast population had four genes downregulated, all mitochondrial (mt-Co3, 
mt-Nd1, mt-Atp6, and mt-Cytb; Figure 4.6A), and a single gene, Rtn3, upregulated 
(lnFC = 0.88, adjusted p-value = 0.016; Figure 4.6A, Table 4.3). Reticulon-3, Rtn3, is 
involved in the ER/secretory pathway and is likely involved in ER stress-mediated 
apoptosis via caspase signaling to the mitochondria. It has previously been implicated 
in Alzheimer disease, and it has been demonstrated that knockdown of RTN3 
increases ß-amyloid levels while overexpression decreases ß-amyloid levels305. 
The VTA, while appearing unaffected by the mutation in terms of cellular 
proportions, has 232 genes dysregulated, 27 down- and 185 upregulated (Table 4.3). 
Of the top genes upregulated in the mutant condition, we find many genes that have 
previously been implicated in PD or other neurodegenerative disorders; for example, 
the top upregulated gene is Cck (lnFC = 1.931, adjusted p-value = 3.74 x 10-3; Figure 
4.6B), whose expression has been associated with the visual hallucinations that 
sometimes co-occur with PD306,307. Resp18 is also significantly upregulated (lnFC = 
1.203, adjusted p-value = 8.43 x 10-6; Figure 4.6B), and its expression has previously 
been associated with PD – downregulation of RESP18 protected DA neurons against 
damage by MPTP, a chemical used in the modeling of PD, and its overexpression 
aggravated cell death in similar models308,309. Of the 27 genes downregulated, one, 
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Wsb1 (lnFC = -0.857, adjusted p-value = 1.89 x 10-4; Figure 4.6B) is present in Lewy 
bodies in LRRK2-associated PD and is involved in the ubiquitination and aggregation 
of LRRK2310. Another interesting downregulated gene is Gria2 (lnFC = -0.492, 
adjusted p-value = 1.53 x 10-4; Figure 4.6B), a subunit of an AMPA receptor, whose 
expression is associated with ALS, neurodevelopmental disorders, and addiction 
behaviours311,312. There are also 11 genes involved in the mitochondria and the 
electron transport chain that are significantly downregulated, which includes those 
genes that were downregulated in the neuroblast populations.  
To assess whether this mitochondrial dysregulation is a common phenomenon 
in the mutant cells and to increase our power to detect differences between the 
genotypes, we explored global transcriptomic differences by genotype, regardless of 
cluster. Doing so, we identify 388 dysregulated genes, with 91 downregulated genes 
and 297 genes that are upregulated (Table 4.3). Pathway analysis313 of these genes 
identifies the oxidative phosphorylation pathway as dysregulated with 37 
differentially expressed genes involved in this process. Interestingly, 12 of the 
dysregulated genes in the pathway are downregulated while the other 25 genes are 
upregulated (Figure 4.7A) and strikingly, whether the gene is encoded on the 
mitochondrial or nuclear genome correlates with the direction of dysregulation. Genes 
that are encoded on the mitochondrial genome are downregulated and those that are 
encoded on the nuclear genome are upregulated in the mutant cells. To our knowledge, 
this pattern of expression has not been observed in PD models before. Opposite to 
what we observe here, significant downregulation of nuclear-encoded genes, but not 
mitochondrial-encoded genes, has previously been observed in Alzheimer disease314. 
We will confirm these gene expression changes and those that are cluster-specific 
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through smFISH and will further examine mitochondrial function in the mutant mice. 
We will assess the mtDNA copy number to look for biogenesis defects, and use 
MitoTracker assays and cryoEM to examine mitochondrial size, number, location, and 
assess gross morphological characteristics.  
4.5 Discussion 
 Understanding the timing and predisposing causes of the degeneration of DA 
neurons of the substantia nigra remains challenging. Examination of developing or 
early post-natal neurons could illuminate processes occurring far before the 
neurodegeneration becomes apparent. Understanding these developmental origins of 
PD could yield new insights into PD pathogenesis and help inform early interventions 
for the management or prevention of PD. To this end, we assayed wildtype and mutant 
DA neurons in a mouse model of PD for transcriptional differences occurring at post-
natal day 7. Despite this early developmental stage, we identified a variety of 
subpopulations of midbrain DA neurons, discovered a potential 
maturation/differentiation defect, and uncovered extensive gene expression 
alterations implicating mitochondrial dysfunction. 
 Our strategy focused on assaying specifically the DA neurons of the midbrain, 
given their known role in the movement phenotypes of PD, in a mouse model of 
familial PD using FACS. However, it is not just the DA neurons of the substantia 
nigra that are degenerated in PD – many of the prodromal symptoms of PD are likely 
the result of degeneration of other classes of neurons (eg: serotonergic, GABAergic, 
glutamatergic) in structures throughout the brain315–318. Additionally, the 
degeneration of substantia nigra neurons in PD may not be a cell-autonomous process; 
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LRRK2, the most commonly mutated gene in PD, is expressed in microglia as well as 
DA neurons319–321. Thus, to get a more rich view of the cells that may be dysregulated 
in PD, performing scRNA-seq in unsorted, gross-dissected regions of the brain could 
yield greater insights into the mechanisms by which PD-predisposing mutations exert 
their effects on disease pathogenesis. This strategy would also eliminate the need to 
subject the cells to FACS, which could reduce the ambient RNA background that our 
study design suffered from, improving the yield of cells assessed.  
 In examining the proportions of cells in each cluster stratified by genotype, we 
observed an approximate doubling of cells present in the PAG and the two SN clusters, 
and a halving of cells present in the post-natal neuroblast cluster. It is interesting to 
observe an increase in SN neurons in the mutant mice, given PD is a 
neurodegenerative disease and by the time of presentation, patients have fewer DA 
neurons in the SN. In the development of DA neurons in the mouse, there still remains 
a wave of programmed cell death occurring between P10 and P30263. It may be that 
this precocious differentiation is depleting the neuroblast pool for recovery following 
this wave of cell death. We will be testing this hypothesis by inspecting the various 
cell proportions during and following this programmed cell death, and comparing the 
genotypes for alterations in subpopulation proportions.  
 Given the observed dysregulation of cellular proportions, we expected there to 
be gross changes in gene expression by genotype in a cluster specific- and global 
manner. For example, we see specific upregulation of Cck in mutant DA neurons in 
the VTA cluster and altered expression of a variety of other genes including several 
others already known to PD biology like Resp18 and Wsb1. Despite identifying no 
differentially expressed genes in the SN clusters, we do observe a handful of genes 
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that are up- and downregulated in the precursor neuroblast population, including 
several mitochondrial genes. This dysregulation is reflected in the mutant cells as a 
whole: there is global dysregulation of genes involved in the oxidative phosphorylation 
pathway.  
 Mitochondrial dysfunction has been extensively associated with sporadic, 
familial and environmentally-induced PD322–329. A long standing hypothesis implicates 
aberrant levels of reactive oxygen species with PD, focusing on the high energy 
demands of the substantia nigra as the source of the preferential degeneration of these 
neurons. In particular, disruptions to complex I of the electron transport chain have 
been associated with PD325,330,331. Here, at a very early developmental age, we observe 
a striking pattern of dysregulation of electron transport chain associated genes, 
involving all five complexes, in which the encoding genome determines the direction 
of dysregulation. This is novel, unusual expression pattern that could suggest a 
disconnect in communication between the mitochondria and the cell. One mechanism 
we are particularly interested in is mitochondrial fission and fusion. In a variety of 
models, α-synuclein over-expression has recently been demonstrated to produce 
fragmented mitochondria through disrupted fission and fusion processes332–335. 
Importantly, in the A53T mouse model of PD that we use here, fusion and fission 
defects have been previously observed, but only in late stages of the disease (i.e.: not 
detected at 6 months but present at 12 months)336.  
 A mitochondrial fission or fusion problem during DA neuron development leads 
us to a particularly compelling hypothesis to unify our observations of mitochondrial 
dysregulation and precocious/aberrant maturation of neuroblasts into substantia 
nigra neurons. In the process of neuronal differentiation, there is a switch from 
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glycolysis to oxidative phosphorylation for energy production and this shift is 
accompanied by changes in mitochondrial morphology, dependent on fission and 
fusion (Figure 4.8)337–339. Our observations would then suggest that mutant DA 
neurons early in development suffer from defects in mitochondrial dynamics that 
ultimately result in the precocious maturation of neuroblasts into SN neurons. We are 
actively assaying mitochondria and their dynamics in mutant DA neurons to pursue 
this hypothesis. If this fission/fusion mechanism is at the root of the early 
transcriptional, cellular and maturation defects we observe, it presents a lucrative 
target for modulation in early therapeutics for the prevention of PD.  
 That any differences are observed between PD mutant mice and their wildtype 
littermates at just post-natal day 7 is perhaps the most surprising result of these 
experiments. Despite months remaining before these mice begin to develop PD-related 
phenotypes, there are stark differences already present in midbrain DA neurons. 
These neurons will persist into adulthood, at which point the differences will become 
apparent and manifest in movement phenotypes. We suggest here a possible 





Mouse husbandry  
E15.5 and P7 wildtype mice 
The Th:EGFP BAC transgenic mice (Tg(Th-EGFP)DJ76Gsat) used in this 
study were generated by the GENSAT Project171 and were purchased through the 
Mutant Mouse Resource & Research Centers (MMRRC) Repository. Mice were 
maintained on a Swiss Webster (SW) background with female SW mice obtained from 
Charles River Laboratories. The Tg(Th-EGFP)DJ76Gsat line was primarily 
maintained through matings between Th:EGFP-positive, hemizygous male mice and 
wild-type SW females (dams). Timed matings for cell isolation were similarly 
established between hemizygous male mice and wild-type SW females. The 
observation of a vaginal plug was defined as embryonic day 0.5 (E0.5). 
Mutant A53T mice 
B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J mice (A53T; JAX strain: 004479)291 were 
obtained from Jackson Labs. The colony was maintained with hemizygous-
hemizygous matings. To generate the mouse litters for assay, a series of matings were 
performed. Hemizygous A53T mice were crossed with hemizygous DA neuron reporter 
mice, Tg(Th-EGFP)DJ76Gsat mice (Th-EGFP)171, and pups hemizygous for both 
alleles were retained. These mice were crossed with a homozygous Th-EGFP mouse, 
and male mice hemizygous for the A53T allele and homozygous for the Th-EGFP allele 
were selected. Finally, these male mice were crossed with a female A53T hemizygote, 
such that all pups will be hemizygous for the Th-EGFP allele and all three possible 
combinations of A53T alleles will be present (25% wildtype, 50% hemizygous, 25% 
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homozygous). This mating scheme is summarized in Supplementary Figure 4.1. All 
mouse procedures and husbandry were reviewed and approved by the institutional 
care and use committee.  
Neural dissociation and fluorescence-activated cell sorting (FACS) 
E15.5 and P7 wildtype mice 
At 15.5 days after the timed mating, pregnant dams were euthanized and the 
entire litter of E15.5 embryos were dissected out of the mother and immediately 
placed in chilled Eagle’s Minimum Essential Media (EMEM). Individual embryos 
were then decapitated and heads were placed in fresh EMEM on ice. Embryonic brains 
were removed and placed in Hank’s Balanced Salt Solution (HBSS) without Mg2+ and 
Ca2+ and manipulated while on ice. For P7 samples, the morning the pups were born 
was considered postnatal day 0 (P0). Once the mice were aged to P7, all the mice from 
the litter were euthanized and the brains were then quickly dissected and placed in 
HBSS without Mg2+ and Ca2+ on ice. The brains were immediately observed under a 
fluorescent stereomicroscope and EGFP+ brains were selected. EGFP+ regions of 
interest in the forebrain (hypothalamus) and the midbrain for both time points, and 
the olfactory bulbs at P7 were then dissected and placed in HBSS on ice. This process 
was repeated for each EGFP+ brain. Brain regions from four EGFP+ E15.5 mouse 
pups and from five EGFP+ P7 mice were pooled together for dissociation. 
Resected brain tissues were dissociated using papain (Papain Dissociation 
System, Worthington Biochemical Corporation; Cat#: LK003150) following the 
trehalose-enhanced protocol reported by Saxena et al.340 with the following 
modifications. The dissociation was carried out at 37°C in a sterile tissue culture 
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cabinet and RNase inhibitor was added to all solutions. During dissociation, all tissues 
at all time points were triturated every 10 min using a sterile Pasteur pipette. For 
E15.5 tissues, this was continued for no more than 40 min. For P7, this was continued 
for up to 1.5 hours or until the tissue appeared to be completely dissociated. 
Additionally, for P7 tissues, after dissociation but before cell sorting, the cell 
pellets were passed through a discontinuous density gradient in order to remove cell 
debris that could impede cell sorting. This gradient was adapted from the Worthington 
Papain Dissociation System kit. Briefly, after completion of dissociation according to 
the Saxena protocol340, the final cell pellet was resuspended in DNase dilute albumin-
inhibitor solution, layered on top of 5mL of albumin-inhibitor solution, and 
centrifuged at 70 × g for 6 min. The supernatant was then removed. 
For each time point-region condition, pellets were resuspended in 200μL of 
media without serum comprised of DMEM/F12 without phenol red, 5% trehalose 
(w/v), 25μM AP-V, 100μM kynurenic acid, and 10μL of 40U/μL RNase inhibitor 
(RNasin Plus RNase Inhibitor, Promega) at room temperature. The resuspended cells 
were then passed through a 40μM filter and introduced into a FACS machine 
(Beckman Coulter MoFlo Cell Sorter or Becton Dickinson FACSJazz). Viable cells 
were identified via propidium iodide staining, and individual neurons were sorted 
based on their fluorescence directly into lysis buffer in individual wells of 96-well 
plates for single-cell sequencing (2μL Smart-Seq2 lysis buffer + RNase inhibitor, 1μL 
oligo-dT primer, and 1μL dNTPs) according to Picelli et al138. Blank wells were used 
as negative controls for each plate collected. Upon completion of a sort, the plates were 
briefly spun in a tabletop microcentrifuge and snap-frozen on dry ice. Single-cell 
lysates were subsequently kept at −80°C until cDNA conversion. 
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Mutant A53T mice 
Neural dissociation was carried out using a modified Worthington dissociation 
system (Worthington Biochemical Corporation; Cat#: LK003150) in combination with 
a modified trehalose-enhanced dissociation protocol340, with minor modifications. P7 
pups were decapitated and their brains extracted and placed into Earle's Balanced 
Salt Solution (EBSS) with trehalose individually in a 6-well plate. Midbrain GFP+ 
regions were microdissected under a fluorescent microscope and transferred to 
Worthington papain solution containing DNaseI and an RNase inhibitor. In this 
solution, the tissue was macerated with a scalpel and placed in a 37°C, 5% CO2 
incubator. After 15 minutes, and every subsequent ten minutes for up to an hour, 
using a Pasteur pipette, the tissue in papain was triturated, until the tissue has been 
dissociated, as confirmed under a microscope. The dissociated neurons were pooled on 
the basis of their common A53T genotypes and transferred to a 15mL conical tube. To 
each sample, 75µL EBSS containing albumin-ovomucoid inhibitor, DNaseI, RNase 
inhibitor, and trehalose was added, and were centrifuged for 10 minutes at 100g. The 
supernatant was removed and the cells were resuspended in 150uL of the same EBSS 
solution and mechanically dissociated with a P200 pipette. Another 100uL of EBSS 
solution was added and mechanical dissociation continued with a P1000 pipette. Next, 
2.5mL of DMEM/F12 (without phenol red) with trehalose was added and centrifuged 
as before. The supernatant was discarded and another 200µL of EBSS solution is 
added and a final mechanical dissociation with a P200 pipette was carried out. 
Another 2.5mL of DMEM/F12 with trehalose is added and pelleted by centrifugation 
one final time.  
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These pellets were resuspended in 750μL ice-cold HBSS with calcium and 
magnesium and passed through a 40µm filter. A total of 13,518 GFP+, and therefore 
likely DA neurons, were sorted by FACS, with each genotype being sorted into a single 
well of a 96-well plate (wildtype: 5,314; hemizygous: 5,202; homozygous: 3,002), 
containing 10µL of cold PBS. Before submitting the samples to droplet formation by 
10X Genomics, the total volume in each well was brought to 35µL with PBS.  
Single-cell RNA-seq library preparation and sequencing 
E15.5 and P7 wildtype mice 
Library preparation and amplification of single-cell samples were performed 
using a modified version of the Smart-Seq2 protocol138. Briefly, 96-well plates of single 
cell lysates were thawed to 4°C, heated to 72°C for 3 min, then immediately placed on 
ice. Template switching first-strand cDNA synthesis was performed as described 
above using a 5′-biotinylated TSO oligo. cDNAs were amplified using 20 cycles of 
KAPA HiFi PCR and 5′-biotinylated ISPCR primer. Amplified cDNA was cleaned with 
a 1:1 ratio of Ampure XP beads and approximately 200pg was used for a one-quarter 
standard sized Nextera XT tagmentation reaction. Tagmented fragments were 
amplified for 14 cycles and dual indexes were added to each well to uniquely label 
each library. Concentrations were assessed with Quant-iT PicoGreen dsDNA Reagent 
(Invitrogen) and samples were diluted to ∼2nM and pooled. Pooled libraries were 
sequenced on the Illumina HiSeq 2500 platform to a target mean depth of ∼8.0 × 105 




Mutant A53T mice 
Following FACS, cells were assayed following the Chromium 10X pipeline137. 
Cell capture, cDNA generation, and library preparation were performed with the 
standard protocol for the Chromium Single Cell 3’ V2 reagent kit. Library quality and 
concentration was assessed with the High Sensitivity DNA assay on the Agilent 2100 
Bioanalyzer and the Qubit dsDNA High Sensitivity Assay (Invitrogen).  
Single-cell RNA-sequencing libraries were pooled and sequenced on the 
Illumina HiSeq 2500 and generated ~170,000 reads per cell.  
Preliminary single-cell RNA-seq data analysis  
E15.5 and P7 wildtype mice 
For all libraries, paired-end reads were aligned to the mouse reference genome 
(mm10) supplemented with the Th-EGFP+ transgene contig, using HISAT2205 with 
default parameters except: -p 8. Aligned reads from individual samples were 
quantified against a reference transcriptome (GENCODE vM8)209 supplemented with 
the addition of the EGFP transcript. Quantification was performed using cuffquant341 
with default parameters and the following additional arguments: --no-update-check -
p 8. Normalized expression estimates across all samples were obtained using 
cuffnorm341 with default parameters. 
Gene-level and isoform-level FPKM (fragments per kilobase of transcript per 
million) values produced by cuffquant341 and the normalized FPKM matrix from 
cuffnorm were used as input for the Monocle 2 single-cell RNA-seq framework342 in 
R/Bioconductor207. Genes were annotated using the Gencode vM8 release. A 
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CellDataSet (cds) was then created using Monocle 2 (v2.2.0)342 containing the gene 
FPKM table, gene annotations, and all available metadata for the sorted cells. All cells 
labeled as negative controls and empty wells were removed from the data. Relative 
FPKM values for each cell were converted to estimates of absolute mRNA counts per 
cell (RPC) using the Monocle 2 Census algorithm343 using the Monocle function 
“relative2abs().” After RPCs were inferred, a new cds was created using the estimated 
RNA copy numbers with the expression Family set to “negbinomial.size()” and a lower 
detection limit of 0.1 RPC. 
After expression estimates were inferred, the cds containing a total of 473 cells 
was run through Monocle 2's “detectGenes()” function with the minimum expression 
level set at 0.1 transcripts. The following filtering criteria were then imposed on the 
entire dataset: (1) Number of expressed genes: The number of expressed genes 
detected in each cell in the dataset was plotted and the high and low expressed gene 
thresholds were set based on observations of each distribution. Only those cells that 
expressed between 2,000 and 10,000 genes were retained. (2) Cell mass: Cells were 
then filtered based on the total mass of RNA in the cells calculated by Monocle 2. 
Again, the total mass of the cell was plotted and mass thresholds were set based on 
observations from each distribution. Only those cells with a total cell mass between 
100,000 and 1,300,000 fragments mapped were retained. (3) Total RNA copies per cell: 
Cells were then filtered based on the total number of RNA transcripts estimated for 
each cell. Again, the total RNA copies per cell was plotted and RNA transcript 
thresholds were set based on observations from each distribution. Only those cells 
with a total mRNA count between 1,000 and 40,000 RPCs were retained. 
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A total of 410 individual cells passed these initial filters. Outliers found in 
subsequent, reiterative analyses described below were analyzed and removed, 
resulting in a final cell number of 396. 
Mutant A53T mice 
Sequences were aligned to a modified mm10 genome using the CellRanger 
v3.0.1 pipeline. The mm10 genome was modified using `cellranger mkref` to include a 
custom GFP construct to allow for quantification of the dopaminergic fluorescent 
marker expression. Unique molecular identifier (UMI) counts were quantified per 
gene per cell (`cellranger count`) and aggregated (`cellranger aggr`) across samples 
with no normalization. Our data had a high background level of reads not in cells, 
possibly from the combination of FACS and the microfluidics of the 10X Genomics 
platform, and as such, our capture efficiency was low, with only 2,430 cells captured 
(wildtype: 896; hemizygous: 1,059; homozygous: 475). 
Using Seurat v3.1.1.9021, cells were examined for the number of genes 
expressed per cell, number of UMIs, and number of reads to identify empty droplets 
and doublets/multiplets (Supplementary Figure 4.2). Cells with less than 600 or 
more than 2,700 genes, those with greater than 10,000 UMIs assigned to the cell, and 
those with more than 40% of reads originating from the mitochondria were removed. 





Normalization and cluster analysis 
E15.5 and P7 wildtype mice 
After initial filtering described above, the entire cds as well as subsets of the 
cds based on “age” and “region” of cells were created for recursive analysis. Regardless 
of how the data were subdivided, all data followed a similar downstream analysis 
workflow. 
The genes to be analyzed for each iteration were filtered based on the number 
of cells that expressed each gene. Genes were retained if they were expressed in >5% 
of the cells in the dataset being analyzed. These were designated “expressed_genes.” 
For example, when analyzing all cells collected together (n = 410), a gene had to be 
expressed in 20.5 cells (410 × 0.05 = 20.5) to be included in the analysis. In contrast, 
when analyzing P7 MB cells (n = 80), a gene had to be expressed in just four cells (80 
× 0.05 = 4). This was done to include genes that may define rare populations of cells 
that could be present in any given population. 
The data were prepared for Monocle analysis by retaining only the expressed 
genes that passed the filtering described above. Size factors were estimated using the 
Monocle 2 “estimateSizeFactors()” function. Dispersions were estimated using the 
“estimateDispersions()” function. 
Genes that have a high biological coefficient of variation (BCV) were identified 
by first calculating the BCV by dividing the standard deviation of expression for each 
expressed gene by the mean expression of each expressed gene. A dispersion table was 
then extracted using the “dispersionTable()” function from Monocle 2. Genes with a 
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mean expression > 0.5 transcripts and a “dispersion_empirical” ≥ 1.5∗dispersion_fit or 
2.0∗dispersion_fit were identified as “high variance genes.” 
PCA was run using the R “prcomp()” function on the centered and scaled log2 
expression values of the “high variance genes.” PC1 and PC2 were visualized to scan 
the data for outliers as well as bias in the PCs for age, region, or plates on which the 
cells were sequenced. If any visual outliers in the data were observed, those cells were 
removed from the original subsetted cds and all filtering steps above were repeated. 
Once there were no visual outliers in PC1 or PC2, a screeplot was used to determine 
the number of PCs that contributed most significantly to the variation in the data. 
This was manually determined by inspecting the screeplot and including only those 
PCs that occur before the leveling-off of the plot. 
Once the number of significant PCs was determined, t-SNE142 was used to 
embed chosen PC dimensions in a 2D space for visualization. This was done using the 
“tsne()” function available through the tsne package (v.0.1-3) in R with “whiten = 
FALSE.” The parameters “perplexity” and “max_iter” were tested with various values 
and set according to what was deemed to give the cleanest clustering of the data. 
After dimensionality reduction via t-SNE, the number of clusters was 
determined in an unbiased manner by fitting multiple Gaussian distributions over 
the 2D t-SNE projection coordinates using the R package ADPclust344. t-SNE plots 
were visualized using a custom R script. The number of genes expressed and the total 




Mutant A53T mice 
Single-cell RNA-seq data was processed using `SCTransform()` to normalize, 
find variable genes, and scale the data on each genotype separately. Doing so, we 
regressed out the effects of the proportion of reads mapping to the mitochondria and 
the replicate. To integrate the data, 3,000 variable features were selected 
(`SelectIntegrationFeatures()`) and integrated with the `PrepSCTIntegration()`, 
`FindIntegrationAnchors()`, and `IntegrateData()` functions.  
Principal component (PC) analysis was performed and the distribution of 
replicates and genotypes were examined to confirm the success of SCTransform and 
integration (Supplementary Figure 4.3). `JackStraw()` and `ElbowPlot()` were used 
in combination to determine the PC cut-off, PC21, for inclusion into further 
dimensionality reduction.  
t-SNE reduction was used to project the cell relationships onto two dimensions, 
using ̀ RunTSNE()` with perplexity = 50, ̀ FindNeighbors()`, and ̀ FindClusters()` with 
resolution = 0.2. Seven clusters were identified with 441, 220, 192, 181, 145, 139, and 
39 cells. Clusters were examined for whether they contained cells collected from both 
replicates and all genotypes (Supplementary Figure 4.4). Clusters were also 
examined for bias in percent mitochondrial reads, number of genes expressed, and 
sequencing depth (Supplementary Figure 4.5). Following confirmation of unbiased 
clustering, the active assay was changed to RNA and expression was normalized with 
`NormalizeData()`.   
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Estimating cell types 
E15.5 and P7 wildtype mice 
In order to find differentially expressed genes between brain DA populations 
at each age, the E15.5 and P7 datasets were annotated with regional cluster identity 
(“subset cluster”). Differential expression analysis was performed using the 
“differentialGeneTest()” function from Monocle 2 that uses a likelihood ratio test to 
compare a vector generalized additive model (VGAM) using a negative binomial 
family function to a reduced model in which one parameter of interest has been 
removed. In practice, the following model was fit: “∼subset.cluster” for E15.5 or P7 
dataset. Genes were called as significantly differentially expressed if they had a q 
value (Benjamini-Hochberg corrected p value) < 0.05. 
Mutant A53T mice 
 Clusters were examined for expression of general marker genes, including pan-
neuronal markers, oligodendrocyte/support cell markers (Supplementary Figure 
4.6), and markers of a variety of different neuronal subtypes (Supplementary 
Figure 4.7). Expression of a variety of known marker genes151 was evaluated and 
clusters were assigned to anatomical locations (Supplementary Figure 4.9). New 
markers of each region were identified using `FindMarkers()` where only positive 
markers present in over 25% of cells of that cluster, with an adjusted p-value less than 
0.05 under a Wilcoxon rank sum test, were considered (Table 4.2). To find markers 
specific to each cluster, these lists of differential genes were sorted by `pct.2`, so as to 
identify those differentially expressed genes not present in other clusters. These lists 
of genes in consultation with ISH data from the Allen Mouse Brain Atlas304 were used 
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to confirm the likely anatomical locations of the clusters, and in the case of 
contaminating cells (cluster 6), suggest the cells are granule cells (Supplementary 
Figure 4.8, Supplementary Figure 4.9).  
 Clusters not corresponding to dopaminergic neurons were removed from 
further analysis, leaving 1,179 dopaminergic neurons for analysis. 
Examining the effect of the mutant allele 
Mutant transgene expression 
 Expression of the endogenous mouse Prnp was evaluated and visualized. The 
A53T transgene was randomly inserted into the mouse genome and is bound by the 
UTRs of the mouse prion protein (Prnp)291. Since 10X Genomics technologies sequence 
from the 3’ end of the transcript, reads originating from the transgene and the 
endogenous mouse Prnp gene are indistinguishable. Were the transgene included in 
the genome assembly during alignment, multimapping reads from either of these loci 
would fail to align and no expression of either the transgene or the endogenous locus 
would be detected. As such, by not including the transgene in the reference assembly, 
reads mapping to both the transgene and the endogenous locus are assigned to the 
endogenous mouse Prnp locus. To confirm transgene expression, we simply look for 
an increase of reads mapping to the Prnp gene in the mutant cells over the levels 






Effect on cell proportions 
The percent of cells per genotype per cluster was calculated by dividing the 
number of cells in a cluster-genotype by the total number of cells in that genotype. 
Stacked barplots were generated. 
Differential gene analysis between genotypes 
 To identify differentially expressed genes between the genotypes, wildtype 
cells were compared against homozygous cells, using the `FindMarkers()` function on 
a per cluster basis and globally and significant genes with an adjusted p-value less 
than 0.1 under a Wilcoxon rank sum test were identified (Table 4.3).  
Pathway analysis 
 All genes up and downregulated overall were submitted to KEGG Search and 
Color Pathway Mapper313. Querying the mouse genome for associated pathways, all 
dysregulated genes were submitted and colour coded such that genes that are 
downregulated in the mutant cells are red, and those that are upregulated in the 
mutant cells are green.  
Data availability and sharing  
Single-cell RNA-sequencing data will be available at the Gene Expression 
Omnibus (GEO). All code and related documentation will be made available in a 
GitHub repository at https://github.com/sarahmcclymont/A53T_scRNAseq. An 




4.7 Figures and supplementary materials 
Figure 4.1: scRNA-seq identifies subpopulations of dopaminergic neurons at 
E15.5 and P7 
 
(A) A schematic of the scRNA-seq experimental procedures for isolating and 
sequencing EGFP+ cells from E15.5 and P7 DA neurons of the MB, FB and OB. 
Timeline adapted from Barallobre et al.263 (B) A t-distributed stochastic neighbour 
embedding (t-SNE) plot of all collected cells that passed quality control measures 
colored by regional identity. E15.5 cells cluster together while P7 cells cluster 
primarily by regional identity. (C) A t-SNE plot of all collected cells coloured by subset 
cluster identity. Through iterative analysis, time point-regions collected can be 
separated into 13 total subpopulations. (D) Focusing specifically on all E15.5 cells, 
coloured by regional identity, we observe an overlap of MB and FB clusters. (E) With 
marker gene analysis, we can assign functions to these clusters. There are two clusters 
made each solely of MB and FB neurons, which represent post-mitotic DA neurons 
however, there also remains a neuroblasts population, composed of both MB and FB 
cells. (F) Focusing on all P7 neurons collected, coloured by cluster identity, we observe 
nine subpopulations of cells that mostly cluster by regional identity. (G) Examining 
specifically the P7 MB neurons, there are four subpopulations of cells: the substantia 










Figure 4.2: Seven transcriptionally distinct clusters of cells are identified 
 
(A) A tSNE plot indicating the seven clusters of neural subpopulations identified post-
filtering and quality control measures. (B) Clusters 0 through 4 have detectable levels 
of Th expression, indicating their dopaminergic functioning. Clusters 5 and 6 do not 
appear to express Th and are therefore likely to be contaminating cells. (C-I) The 
clusters are transcriptionally distinct from each other and marker genes can be 




Figure 4.3: All clusters are assigned a biological identity and marker genes of 
each are identified for functional validation by single-molecule RNA FISH 
(smFISH) 
 
(A) The seven clusters are assigned to be the ventral tegmental area (VTA), a post-
natal neuroblast population, two substantia nigra (SN) clusters, the periaqueductal 
grey area (PAG), and two contaminating cell types: support cells, like oligodendrocytes 
and microglia, and granule cells. (B) After removing these contaminating cells from 
analysis, the remaining clusters are all dopaminergic, with detectable Th expression. 
(C-I) Marker genes for each cluster that will be tested in wildtype P7 mice brain slices 






Figure 4.4: The VTA and two SN clusters are transcriptionally related and 
smFISH will be performed to assess their spatial relationships 
 
(A) All three clusters share elevated expression of Th, Ddc, and Aldh1a1. The 
expression of these three genes will be probed with smFISH to confirm the location of 
all three clusters. (B-D) Aldh1a1 will be used as a probe, along with each pair of genes 
plotted here, to isolate the locations of each cluster specifically. (B) The VTA cluster 
is expected to be Aldh1a1+, Meg3+, and Meis2-, to help separate the VTA expression 
patterns from the nearby neuroblast population that also has high expression of Meg3. 
(C) The SN1 cluster is expected to be Aldh1a1+, Slitrk4+, and Usp29-. Usp29 was 
selected as a probe in order to distinguish this cluster from the VTA, neuroblast and 
SN2 populations. (D) The SN2 cluster is expected to be positive for expression of 
Aldh1a1 and Lix1, but is not expected to express Chrnb3. This combination of probes 
should allow us to resolve the SN2 population while separating it from the VTA and 








Figure 4.5: The mutant α-synuclein transgene is expressed at post-natal day 
7 and alters dopaminergic neuron population proportions  
 
(A) The mutant transgene is expressed in increasing levels commensurate with the 
number of mutant alleles. (B) The proportions of cells in each cluster are altered in 
the mutant state. Importantly, the post-natal neuroblast population has half as many 
cells in the homozygous state as in the wildtype controls, and there is an approximate 
doubling of the populations of substantia nigra cells in the mutant mice, perhaps 
indicating a precocious maturation phenotype. The periaqueductal grey area 




Figure 4.6: There is cluster-specific gene dysregulation of genes previously 
implicated in neurodegeneration  
 
(A) Rtn3, a gene previously implicated in ß-amyloid levels in Alzheimer disease, is the 
only significantly upregulated gene in mutant post-natal neuroblasts. Additionally 
four genes, like mt-Atp6, all involved in oxidative phosphorylation are downregulated 
in mutant neuroblasts. (B) The VTA has 232 significantly dysregulated genes. Cck 
and Resp18 are two upregulated genes in the mutant neurons and both are genes 
previously implicated in PD307–309. Only 27 genes are significantly downregulated, 
including Wsb1 and Gria2, which are interesting genes given their roles in Lewy body 






Figure 4.7: There is striking and extensive transcriptional dysregulation of 
the oxidative phosphorylation pathway in the mutant dopaminergic neurons  
 
(A) A schematic indicating the genes downregulated (red) and upregulated (green) in 
the mutant state at each complex of the electron transport chain. 37 genes are 
dysregulated, including 12 downregulated and 25 upregulated genes. Strikingly, the 
genes that are downregulated are all mitochondrial-encoded while the genes that are 
upregulated are nuclear-encoded. (B) Examples of oxidative phosphorylation pathway 
genes that are significantly dysregulated in the mutant condition. mt-Nd5 and mt-
Cytb, encoded on the mitochondria, have lower expression in mutants, while Cox5a 








Figure 4.8: A mitochondrial fission or fusion defect could underlie the 
observed precocious maturation phenotype involving the neuroblasts and 
substantia nigra populations 
 
In the process of neural differentiation there is a switch in energy production from 
glycolysis to oxidative phosphorylation. This change is accompanied by changes in 
mitochondrial conformation – from long, branched mitochondria to small, fragmented 
mitochondria, and back again337–339. This morphological change is predicated on 
fission and fusion processes and therefore alterations to these dynamics could explain 




Table 4.1: Marker gene expression analysis is used to assign identities to each 
of the clusters identified at E15.5 and P7 
 
Age Cluster Identity Selected markers  
E15.5 
FB1 Forebrain neuroblast Rnd3, Dlx1, Dlx2 
FB2 Post-mitotic forebrain DA neurons Six3, Six3os1, Sst, Npy 
MB1 Midbrain neuroblast Lhx9, Ebf1, Pax5, Nrg1 
MB2 Post-mitotic midbrain DA neurons Foxa1, Lmx1a, Pitx3, Nr4a2 
P7  
MB1 Ventral tegmental area (VTA) Otx2, Neurod6 
MB2 Post-natal neuroblast 
Fam19a2, Lhx9, Ldb2, Mab21l1, 
Tmem163, Meis1, Rmst, Crnde, 
Gm2694 
MB3 Periaqueductal grey area (PAG) Vip, Pnoc 









foldchange   
Percent 
of cells in 
cluster 
Percent of 










A Slc18a2 0.982  80.3% 33.3% 5.82E-61 
Epha5 0.950  88.4% 47.2% 1.72E-64 
Cck 0.928  69.4% 41.2% 6.58E-20 
Tenm1 0.921  89.6% 40.1% 2.36E-74 
Cadm1 0.809  95.7% 66.2% 1.09E-46 












Meis2 1.869  67.3% 5.5% 1.94E-121 
Sst 1.311  30.5% 8.3% 1.92E-17 
Rmst 1.149  90.0% 36.4% 8.32E-61 
Rbfox1 1.083  46.8% 5.5% 3.92E-62 
Cntn5 1.028  45.0% 5.3% 1.16E-60 







1 Slc6a3 1.420  66.7% 39.2% 2.79E-27 
Tuba1b 1.052  93.8% 76.2% 2.07E-47 
Hsp90aa1 0.979  97.9% 90.9% 2.52E-49 
Tubb2a 0.967  99.5% 91.8% 1.36E-47 
Th 0.964  76.6% 61.3% 5.79E-19 








 Vip 2.947  98.3% 33.0% 1.72E-108 
Ebf1 2.029  99.4% 32.1% 2.96E-106 
Fam19a1 1.201  90.6% 30.4% 3.65E-66 
Crhbp 1.130  39.8% 2.8% 1.31E-63 
Gipr 1.128  47.5% 2.0% 3.60E-93 







2 Tmsb10 1.984  100.0% 91.2% 9.92E-79 
Atp5g1 1.802  97.9% 47.1% 1.16E-78 
Selenow 1.694  97.9% 55.6% 3.50E-73 
Atp5k 1.620  93.8% 34.2% 3.21E-70 
Cox6b1 1.589  97.2% 47.8% 8.80E-72 








o Apoe 4.325  71.9% 7.7% 3.98E-102 
Fabp7 3.091  59.7% 4.6% 7.32E-95 
Bcan 2.873  70.5% 0.7% 3.96E-183 
Atp1a2 2.588  58.3% 2.0% 2.82E-122 
Sparcl1 2.458  35.3% 4.7% 9.59E-36 












 Nfib 2.137  100.0% 11.7% 4.82E-57 
Zic1 1.921  74.4% 1.4% 2.99E-130 
Fgfr1 1.721  79.5% 13.7% 2.14E-31 
Id2 1.641  79.5% 14.7% 2.43E-27 
Arpp21 1.619  79.5% 14.2% 1.48E-28 




Table 4.3: Genes up- and downregulated globally and in a cluster-specific 
manner 





Percent of cells 





Prnp 1.191  79.2% 40.2% 9.82E-30 
Pgrmc1 0.960  88.0% 71.7% 5.54E-18 
Stmn4 0.910  86.3% 73.8% 8.29E-11 
Serinc1 0.876  87.4% 60.3% 2.50E-21 
Stmn3 0.851  96.7% 93.9% 6.68E-23 
Scg5 0.847  82.0% 76.5% 1.08E-07 
Atp6v0e2 0.840  77.0% 44.0% 6.85E-17 
Cst3 0.829  74.9% 62.8% 2.15E-07 
Fxyd6 0.824  87.4% 71.9% 1.41E-17 
Bsg 0.816  83.6% 69.8% 3.19E-13    …   
mt-Atp8 -0.683  73.2% 87.1% 6.62E-14 
Arglu1 -0.698  33.9% 64.3% 8.36E-10 
Ogt -0.755  33.3% 66.2% 6.27E-12 
Rmst -0.782  28.4% 58.6% 2.27E-08 
Gm42418 -0.784  32.2% 66.4% 1.03E-12 
Malat1 -0.787  69.9% 86.0% 1.20E-13 
Tia1 -0.793  25.7% 62.2% 4.82E-14 
AC149090.1 -0.868  45.4% 78.0% 4.81E-17 
Snhg11 -0.953  47.0% 80.8% 1.21E-22 
Meg3 -0.974  55.7% 84.8% 6.27E-25 
VTA 
Cck 1.931   82.5% 62.0% 3.74E-03 
Pgrmc1 1.422  93.7% 74.5% 6.04E-11 
Cst3 1.383  81.0% 62.0% 5.89E-06 
Stmn4 1.368  87.3% 78.3% 9.63E-08 
Bsg 1.315  87.3% 69.6% 1.70E-09 
Stmn3 1.297  95.2% 93.5% 2.58E-06 
Scg5 1.259  90.5% 76.1% 3.77E-08 
Fxyd6 1.227  90.5% 70.7% 5.46E-08 
Ly6h 1.224  96.8% 92.4% 3.20E-04 
Ndufc2 1.218  71.4% 39.7% 2.41E-06 
   …   
Tia1 -0.661  42.9% 78.8% 2.83E-03 
Snhg11 -0.667  77.8% 100.0% 4.40E-11 
Rbm5 -0.678  41.3% 74.5% 1.64E-03 
Carmil3 -0.704  30.2% 65.2% 9.82E-03 
Meg3 -0.745  84.1% 100.0% 1.06E-15 
Prpf4b -0.782  30.2% 61.4% 8.93E-03 
AC149090.1 -0.801  73.0% 95.1% 5.06E-07 
Arglu1 -0.844  38.1% 77.2% 5.60E-05 
Wsb1 -0.857  28.6% 66.8% 1.89E-04 
Gm42418 -0.896   39.7% 76.6% 4.27E-05 
Neuroblast 
Prnp 1.433   90.9% 48.0% 0.0004 
Rtn3 0.882  95.5% 68.6% 0.016 
mt-Co3 -0.644  95.5% 100.0% 0.063 
mt-Nd1 -0.680  90.9% 100.0% 0.034 
mt-Atp6 -0.734  95.5% 100.0% 0.005 
mt-Cytb -0.750  81.8% 99.0% 0.017 
PAG 
Nsg1 1.166   100.0% 63.2% 0.092 
Ctsl 1.086  87.5% 31.0% 0.023 
Tomm20 1.056  75.0% 21.8% 0.074 
Dlk1 0.968  100.0% 92.0% 0.005 
Cd24a 0.869  56.2% 5.7% 0.003 
AU040320 0.755  31.2% 1.1% 0.091 
Mtfp1 0.616  25.0% 0.0% 0.074 
Gm9803 0.590  37.5% 1.1% 0.005 
Cbr4 0.568  25.0% 0.0% 0.074 
SN 1 NA NA   NA NA NA 
SN2 Prnp 1.552   75.0% 34.0% 0.055 






Supplementary Figure 4.1: Mating scheme to generate litters with 
fluorescently-labelled dopaminergic neurons and all three A53T genotypes  
 
Successive generations of matings were performed such that the final generation for 
assay were all hemizygous for the Th-GFP allele (green font) and were either wildtype 






Supplementary Figure 4.2: Quality control metrics used to filter scRNA-seq 
data 
 
(A) The number of unique genes in each cell, the number of molecules in a cell, and 
the percent of reads mapping to the mitochondria are plotted and filtering cut-offs are 
identified to exclude empty droplets, doublets, and low quality cells. (B) Following 
filtering using these empirically derived cut-offs, the distributions are again examined 





Supplementary Figure 4.3: Replicates and genotypes are well distributed 
across PC1 and PC2  
 
(A) PC1 and PC2 are visualized. (B) PC1 and PC2 are examined for bias in replicate 





Supplementary Figure 4.4: Replicates and genotypes are present in each 
cluster  
 
(A) The clusters as projected onto PC1 and PC2 indicate that cluster 5 represents the 
group of cells that is separated from the main mass of cells. (B) The replicates are 






Supplementary Figure 4.5: Assessing the clusters for bias in percent 
mitochondrial reads, number of reads and number of genes expressed per cell  
 
(A) Cluster 4 and the outlier cluster 5 have few cells with a high proportion of 
mitochondrial reads. (B) Number of reads and (C) unique genes expressed per cell are 
well distributed across the clusters, with clusters 2 and 5 having a lower number of 




Supplementary Figure 4.6: Cluster 5 displays markers of support cells, like 
oligodendrocytes and astrocytes 
 
(A) Cluster 0, 1, 2, 3, 4, and 6 express pan-neuronal markers. Cluster 5 does not, 
instead expressing (B) markers of oligodendrocytes, (C) microglia, (D) astrocytes, and 






Supplementary Figure 4.7: Cluster 6 is not dopaminergic and likely 
represents a contaminating cell type 
 
(A) Cluster 0 through 4 express Th and eGFP, which was the marker upon which the 
cells were sorted by FACS, at robust levels. Cluster 5, oligodendrocytes, and cluster 6 
appear to be contaminating cell types, which do not express eGFP. All clusters were 
evaluated for expression of markers of (B) dopaminergic345–348, (C) glutamatergic349–
351, (D) GABAergic352–354, (E) serotonergic355–357, and (F) cholinergic neurons358–360. 
Cluster 6 does not appear to be exclusively any one of these subtypes, but does express 








Supplementary Figure 4.8: The contaminating cluster 6 is likely to be 
granule cells  
 
Consulting the Allen Mouse Brain Atlas for in situ hybridization experiments on some 
of the top marker genes, Fgfr1, Tcf4, Id2, and Nfib, all display increased expression 
in granule cell layers, either in the hippocampus (Fgfr1, Tcf4) or in the cerebellum 
(Id2, Nfib). Experiment and slide identifiers in Supplementary Table 4.6. 
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Supplementary Figure 4.9: Expression of previously established marker 
genes was used to assign biological identities to each of the remaining clusters  
 
(A, B) Marker gene analysis easily identifies these clusters as (A) the periaqueductal 
grey area (PAG) and (B) a post-natal neuroblast population. (C, D) Discriminating the 
ventral tegmental area (VTA) from the remaining two clusters is challenging given 
some of the marker genes have shared expression patterns, but key genes like (C) 
Oprk1 and Lpl distinguish this cluster as the VTA. (D) The remaining two clusters 
are likely substantia nigra clusters (SN1 and SN2), as demonstrated by the high 
expression of Aldh1a1, Chrna6, and Slc6a3. Specific to the two SN clusters is Caln1 
and Gch1 expression. Distinguishing SN1 from SN2 is more difficult. However, we 
can detect differences like genes specific to SN2, like Pitx3 and Foxa1, while SN1 more 






Supplementary Table 4.1: Experiment and image identifiers for the Allen Mouse Brain Atlas in situ hybridization 
slides used in assigning cluster six as granule neurons 
Gene Experiment ID Image ID URL 
Fgfr3 79588290 79593744 https://mouse.brain-map.org/experiment/siv?id=79588290&imageId=79593744 
Id2 71836806 71681421 https://mouse.brain-map.org/experiment/siv?id=71836806&imageId=71681421 
Tcf4 79488927 79454916 https://mouse.brain-map.org/experiment/siv?id=79488927&imageId=79454916 





Chapter 5: Conclusions 
5.1 Summary of significant findings  
Comprehensive evaluation of midbrain dopaminergic (DA) neurons is 
required for an improved understanding of the molecular mechanisms of Parkinson 
disease (PD) risk and progression. Here, we have examined the chromatin and 
transcriptional landscapes of midbrain DA neurons to extensively catalogue 
putative enhancers, identify transcription factors (TFs) important to gene 
expression regulation, uncover variants that disrupt enhancer functioning and TF 
binding, and detect significant alterations in gene expression, neuronal maturation, 
and mitochondrial function in the early disease state.  
 To identify and prioritize non-coding variants associated with PD, we first 
queried the chromatin of 50,000 midbrain and forebrain DA neurons. We identified 
>100,000 open chromatin regions that we assessed for functionality using in silico 
and in vivo means. One such region, in an intron of the familial PD gene, SNCA, 
directs reporter expression in catecholaminergic neurons throughout the mouse life 
course in key regions affected in PD. Not only does this enhancer direct disease-
appropriate expression, but in sequencing ~1,000 PD cases and controls, we 
demonstrate it to contain disease-associated variation. Two tightly linked common 
variants, rs2737024 and rs2583959, that fall in this enhancer are significantly 
associated with PD risk (odds ratio ~1.25, p-value = 0.002). 
 This finding is intriguing, not only because we identify novel disease-
associated enhancer variants near to a familial PD gene, but this also represents 
the possible benefit of a paradigm shift in how common disease variants are 
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identified. Typically, large genome-wide association studies uncover loci associated 
with disease but do not indict any one variant. Functional fine-mapping, in which 
these results are intersected with functional annotations, like those generated by 
ChIP-seq experiments, can be employed to prioritize variants that likely disrupt 
functional elements. Our strategy flips this paradigm – starting with a high quality, 
disease-relevant annotation dataset, we query these annotations and identify 
disease-associated variants by sequencing a relatively small number of cases and 
controls. 
 To uncover how these and other common variants associated with 
neurodegeneration and neuropsychiatric disorders disrupt gene expression and 
ultimately modulate disease risk, we employed a machine learning algorithm, gkm-
SVM, to learn the regulatory vocabulary of midbrain DA neurons. In combination 
with TF footprinting and bulk RNA-seq, we identify TFs that are actively engaging 
the DNA to influence gene expression in MB DA neurons. We identify Rfx3/5, 
Foxa1/2, Ascl1, and Nr4a2 as important to MB DA neurons. We use this regulatory 
vocabulary to predict how >7,000 disease-associated variants might impact TF and 
protein binding. These predictions have been challenging to validate given the cell-
type restricted activity of enhancers and the reliance on common validation 
strategies using in vitro cell surrogates. Prevented, as we were, from using standard 
luciferase assays to validate our predictions, we shifted our focus to protein-binding 
arrays and have identified four proteins, NOVA1, PEG10, SNRPA, and CHMP5, 
whose binding may be impacted by the SNCA enhancer variants.  
 The challenge of finding appropriate in vitro cellular surrogates for in vivo-
derived data is not unique to this study. Enhancer usage can be excessively 
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restricted by cell type, developmental time point, or environmental perturbation. As 
the field moves forward in querying increasingly more refined populations in vivo, 
the validity of using an in vitro cell surrogate not matched for those characteristics 
becomes untenable. One strategy to combat this limitation is to perform validation 
experiments in vivo, in the same cells as were queried. This strategy would be ideal 
in terms of the biological validity of the results but is not always feasible given the 
low throughput nature of many in vivo assays and the cell number requirements of 
many enhancer reporter assays. An alternative strategy is to find more appropriate 
in vitro cell surrogates. Here, we use ATAC-seq and bulk and single-cell RNA-seq 
(scRNA-seq) to judge the suitability of an immortalized mouse substantia nigra cell 
line, SN4741. Karyotyping suggests these cells are triploid and highly genetically 
complex. Preliminary scRNA-seq fails to confirm these cells as necessarily DA 
neurons, calling into question their suitability. We continue to assess these cells but 
also continue to search for alternative surrogates and may turn our focus to 
differentiated iPSCs.  
 Finally, we investigated the mechanisms underlying the preferential 
degeneration of DA neurons of the substantia nigra. We performed scRNA-seq in 
~1,300 midbrain DA neurons at an early post-natal time point in a mouse model of 
PD to assess the effects of the mutation on the transcriptomes of developing neurons. 
We identify five clusters of MB DA neurons, including a novel separation of two 
substantia nigra populations. The mutant allele has significant effects on the 
distribution of cells within the clusters, with half as many neuroblasts present in 
the homozygous mutant mice. This halving appears to be accompanied by a 
commensurate doubling of the number of mutant cells in the substantia nigra 
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clusters, likely indicating a precocious maturation defect of DA neurons in relevant 
and key populations in the pathogenesis of PD.  
 There is also significant cluster-specific and global gene dysregulation in the 
mutant state. Genes known to be involved in neurodegenerative diseases, including 
PD, are among the hundreds of genes identified as differentially expressed, but 
perhaps most strikingly, there is extensive dysregulation of genes involved in the 
oxidative phosphorylation pathway. Most interestingly, this dysregulated 
expression of mitochondria is dependent on the genome on which the implicated 
gene is encoded on. The mitochondrial-encoded genes of the electron transport chain 
are all downregulated, while the upregulated genes are all encoded in the nucleus. 
This is a novel pattern of transcriptional dysregulation in PD and we hypothesize 
this may indicate a mitochondrial fission or fusion dysfunction that underlies the 
neuronal maturation defect of neuroblasts into substantia nigra neurons. These 
observations suggest a developmental origin to the preferential degeneration of 
substantia nigra DA neurons in PD.  
5.2 Future directions 
We are eager to continue investigating each of these exciting results. In 
regards to the enhancer at SCNA containing disease-associated variants, we look 
forward to characterizing the enhancer-deletion mouse for molecular and gross 
motor phenotypes. To supplement these deletion studies, it would be worthwhile to 
study the reverse phenomenon and attempt an over-expression assay at the 
enhancer, perhaps through recruiting activating TFs or chromatin remodellers to 
the locus with CRISPR-activation experiments. Additionally, the chromatin assay 
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of midbrain DA neurons yielded a catalogue of over 100,000 open chromatin regions. 
We have examined six of these. There remains a myriad of information still to be 
explored in these catalogues, either through further single locus investigations, 
looking at any one of the other 100 some odd regions that we already know to overlap 
PD associated variation, or we are moving to massively parallel reporter assays 
(MPRA) to test many disease associated variants for function simultaneously. We 
are also exploring using promoter capture HiC (pcHiC) to assign open chromatin 
regions to their cognate genes.  
 Both MPRA and pcHiC have high cell number requirements for assay and as 
such, usually rely on in vitro modelling. We continue to search for accurate cell 
surrogates for our cell types of interest. We have focused our efforts on 
characterizing SN4741 cells with ATAC-seq, bulk RNA-seq, and scRNA-seq. This 
characterization strategy can be applied to a variety of cell lines to allow an 
empirical judgement as to the relatedness of the chromatin, TFs, and transcriptome 
to the in vivo system. While SN4741 cells are perhaps not as proximal to a DA state 
as we had hoped, we are currently investigating methods to improve the 
differentiation process, including longer differentiation time or supplementation 
with differentiation factors like retinoic acid.  
 Although we have examined the transcriptomes of midbrain DA neurons in 
a mouse model of PD, we have not yet examined the chromatin landscape of these 
neurons or how the disease state might alter this. We have presently optimized 
small-scale ATAC-seq to facilitate analysis of these neurons. This will allow us to 
assay enhancer usage and develop a TF vocabulary at post-natal time point and will 
also allow us to assess how changes in the chromatin are related to changes in the 
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transcriptome. This would be a rich source of data however it would likely be unable 
to elaborate on the mitochondrial phenotype, given the lack of nucleosomes in the 
mitochondrial genome. We have begun employing a variety of assays to examine the 
mitochondria in our mouse model of PD however, these are static evaluations of 
mitochondria. To investigate mitochondrial dynamics in an in vivo model, we can 
employ mouse models like the MitoMouse lines361, wherein the mitochondria are 
fluorescently-labelled for in vivo imaging. Ultimately, we hope an improved 
understanding of these mechanisms will allow us to modulate the progression or 
risk of PD.  
 Assaying the chromatin and transcriptomic landscapes of wildtype and 
mutant mice has proven effective for increasing our understanding of the biology of 
DA neurons and PD. We plan to extend these assays to other time points, cell types, 
and perturbations in order to expand our understanding. These strategies represent 
powerful paradigms for assaying restricted populations of cells in the wildtype and 
disease states. We believe that these approaches can be applied to a biological 





Chapter 6: Appendices 
6.1 The transcriptional targets of SOX9 in Type II Diabetes5 
Ultimately, both Type I and Type II diabetes result in a loss of functioning 
beta-cells. Current treatments, including insulin injections, transplantation of 
donor beta cells, and differentiation of stem cells are compromised by systemic 
complications, scarcity of donor tissues, and cost, respectively. An effective 
treatment for these diseases would ideally involve an increase in beta-cell mass. 
Thus exploring the induction of beta-cells endogenously from pancreatic progenitors 
is an alluring treatment target. However, the capacity for beta-cell neogenesis in 
mammals is controversial. Neogenesis of beta cells after partial ductal ligation has 
been seen in mice in some studies but not others362–367, and targeted ablation of beta 
cells in mice is resolved by proliferation and transdifferentiation368–372. Analysis of 
islets of adult humans with Type I diabetes that died from diabetic ketoacidosis 
showed that while beta cells continuously apoptosed, there remained beta cells 
present at death and no markers of proliferation, suggesting some capacity for 
neogenesis373,374. Conversely, zebrafish have an extraordinary capacity to regenerate 
beta cells by neogenesis after targeted ablation375,376 and we have identified the 
progenitor cell that contributes to beta-cell neogenesis in the zebrafish: centroacinar 
cells (CACs)377. 
CACs are terminal intercalated duct cells – they exist in acini, have long 
extensions, are connected by tight junctions so they can successfully line pancreatic 
ducts, and are Notch responsive377,378. In addition, they are known to express sox9b, 
                                                     
5 This work was performed jointly by Hannah E. Edelman and Sarah A. McClymont and is in preparation for 
submission for publication. 
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a homologue of human SOX9, and we have shown that following beta-cell ablation, 
these sox9b-expressing CACs are a source of regenerated beta cells379. Humans also 
have CACs – terminal intercalated duct cells that express SOX9380 and are Notch 
responsive381 – but their role in beta-cell neogenesis is unknown. Given the 
similarities between these cells in humans and zebrafish, by understanding the 
mechanisms behind beta-cell neogenesis via CACs in zebrafish, we may be able to 
exploit these same mechanisms in humans for use in diabetes treatment. 
Towards this end, an intriguing target to begin unravelling the mechanisms 
of beta-cell regeneration is SOX9. The importance of SOX9 in pancreatic identity382, 
ductal cell identity383, and pancreatic progenitor identity380 has already been 
established in mammals. Additionally, we recently found that Sox9b helps maintain 
the progenitor identity of CACs in zebrafish in that heterozygous loss of sox9b 
results in more efficient differentiation of CACs into beta cells after ablation379. 
Given its important role in pancreatic progenitor status across species, we are 
interested in understanding the transcriptional targets of SOX9 (and Sox9b) to 
elucidate the genetic program behind pancreatic progenitors and beta-cell 
neogenesis.  
We set out to identify effectors of SOX9 transcriptional activity in human 
pancreatic cells to reveal molecular mechanisms that drive beta-cell neogenesis 
using high-throughput sequencing methods. To do so, we utilized a human 
pancreatic adenocarcinoma line, PANC-1, that represents an undifferentiated, 
ductal pancreas cell population that can be induced to differentiate toward an 
endocrine fate384. To query the mechanisms of SOX9 regulation in these cells, we 
integrated RNA-seq and ChIP-seq to identify direct transcriptional targets of SOX9. 
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We found that SOX9 directly regulates EPCAM, which encodes a transmembrane 
protein expressed in stem and progenitor cells in many epithelial tissues385–388 and 
is an interesting target of future studies about pancreatic progenitor function. 
SOX9 modulates the transcription of proliferation and cilia genes in 
PANC-1 cells 
We took a two-step approach to identify direct transcriptional targets of 
SOX9 in PANC-1 cells; namely, RNA-seq following SOX9 knockdown and then 
ChIP-seq to identify SOX9 binding sites. To identify transcripts that are regulated 
by SOX9 activity, we performed RNA-seq in PANC-1 cells that had been transfected 
with either a SOX9 siRNA or a control siRNA. Following SOX9 siRNA transfection, 
SOX9 knockdown was confirmed using both Western blotting (Appendix Figure 
6.1A) and immunofluorescence of fixed cells (Appendix Figure 6.1B). To identify 
genes regulated by SOX9, we sequenced total RNA extracted from PANC-1 cells 
transfected with either control or SOX9 siRNA and identified genes that are 
differentially expressed between knockdown conditions. We identified 93 
differentially expressed genes with 60 genes upregulated and 33 downregulated 
(Appendix Figure 6.1C; Appendix Table 6.1).  
To confirm the identity of the top differentially expressed genes, we 
performed qRT-PCR in siRNA-treated PANC-1 cells for the top five up- and down-
regulated genes. In doing so, we confirmed the differential expression of these ten 
genes, except the downregulated gene SKIV2L (Appendix Figure 6.1D). While 
SKIV2L demonstrated the largest fold change of the downregulated genes, it was 
also nearest the acceptable p-value cut-off and thus may be a false positive.  
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In order to further validate the differential gene expression results, we 
analyzed publicly available RNA-seq data from 178 pancreatic adenocarcinoma 
samples in The Cancer Genome Atlas. In these samples, SOX9 is highly expressed 
and as such, we expected to observe directions of effect opposite to those observed in 
our induced knockdown experiments. We clustered our differentially expressed 
genes based on their expression patterns in the tumor samples and observe that in 
general, corroborating our knockdown studies, upregulated genes clustered together 
and were lowly expressed in the tumor samples, and downregulated genes clustered 
together and with SOX9 and are highly expressed (Appendix Figure 6.2A). 
Furthermore, at an individual gene level, we correlated SOX9 expression with each 
differentially expressed gene to examine how closely the genes are co-regulated in 
these tumor samples and observed there to be a high degree of correlation between 
the differentially expressed genes and SOX9 expression (Appendix 
Supplementary Table 6.1). For example, the upregulated gene with the strongest 
degree of negative correlation with SOX9 expression is CCDC13 (r = -0.50), 
bolstering our observation that SOX9 negatively regulates this gene (Appendix 
Figure 6.2B). Conversely, expression of the downregulated gene, ESRP1, is 
strongly positively correlated with SOX9 expression (r = 0.67), further suggesting 
that SOX9 positively regulates this gene’s expression (Appendix Figure 6.2C). 
Overall, these data serve to validate observations from our genome wide RNA-seq 
analyses and provide additional support for our observed transcriptional targets of 
SOX9. 
Finally, to assess the biological consequences of these differentially 
expressed genes, we explored their individual functions and gene ontology (GO) 
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terms. Genes that are down-regulated following SOX9 knockdown include genes 
with established roles in cancer motility (ESRP1389), cell-cell adhesion 
(TINAGL1390,391), obesity and insulin resistance (RGCC392), and cancer stem cell 
maintenance (EPCAM393). Down-regulated genes were collectively enriched for 
biological processes associated with Notch signaling and the negative regulation of 
proliferation (Appendix Figure 6.1E), suggesting a role for SOX9 in negatively 
regulating proliferation.  
As a whole, upregulated genes were enriched for processes associated with 
cilia development, assembly, and movement (Appendix Figure 6.1F), suggesting 
that SOX9 typically suppresses these processes. Interestingly, the most highly 
upregulated genes following SOX9 knockdown are LRRC6 and SPEF1, which have 
known roles in regulating primary cilia, important features of ductal epithelial 
cells394–396. In all, these observations may indicate that SOX9 serves to restrict the 
differentiation of pancreas progenitor cells toward an epithelial fate by promoting 
the expression of genes important for maintaining a progenitor status.  
SOX9 binding occurs primarily at transcription start sites and regulates 
pancreatic functions 
We next set out to identify putative SOX9-responsive regulatory regions, 
undertaking anti-SOX9 ChIP-seq. Following pull-down, sequencing, and alignment, 
our analysis identified 47,858 SOX9 binding sites in PANC-1 cells. We then analyzed 
the sequence underlying the top 1000 most significant SOX9 binding events to 
identify transcription factor motifs present at these sites. The top enriched motif 
was a “tail-to-tail” palindrome with high similarity to the SOX9 consensus motif 
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(Appendix Figure 6.3A). This result supports previous observations in 
chondrocytes that SOX9 can function as a homodimer397. The second highest 
enriched motif matched the binding sequence for FOS::JUN (Appendix Figure 
6.3B) which has been previously reported to bind in conjunction with SOX9 in 
chondrocytes398. Similar to findings from other groups399,400, we observe an 
enrichment of SOX9 binding events at gene promoters (8.8% of SOX9 peaks; 
Appendix Figure 6.3C), with diminishing proportions of SOX9 binding events 
occurring as the distance to the transcriptional start site increases (Appendix 
Figure 6.3D).  
Next, we sought to interrogate the potential functional outcome of SOX9 
binding in PANC-1 cells. We performed functional annotation of the genes proximal 
to SOX9 binding sites and found many GO biological processes that match with 
SOX9’s known roles (Appendix Figure 6.3E). These include: 1) endocrine pancreas 
development, reflecting the known function of SOX9 activity in the pancreas; 2) stem 
cell maintenance, reflecting the participation of SOX9 in maintaining pancreatic 
progenitor identity379 and; 3) ossification and osteoblast differentiation, which 
reflects known functions of SOX9 in bone development401,402. Taken collectively, 
these data suggest that SOX9 acts in PANC-1 cells to regulate target genes 
important to pancreas biology, in a manner consistent with previously reported 
modes of action in chondrocytes. 
Direct targets of SOX9 overlap with known pancreatic ductal genes 
 To narrow down the list of differentially expressed genes to those most 
biologically relevant, we combined three datasets: 1) SOX9 binding events from our 
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ChIP-seq experiment to identify direct binding targets of SOX9; 2) genes with 
enriched expression in ductal cells (versus acinar or endocrine cells) of the adult 
zebrafish pancreas403 and; 3) genes enriched in zebrafish CACs which can be used 
as CAC markers377. By combining these three data sets we sought to find genes that 
were not only direct targets of SOX9 – i.e. those that were differentially expressed 
following SOX9 knockdown and had a SOX9 binding site proximal to their promoter 
– but also relevant to the biology of the zebrafish pancreatic ductal cells, and 
specifically CACs, not just the molecular underpinnings of human PANC-1 cells. 
 We observed that the majority of genes upregulated with SOX9 knockdown 
are not direct targets of SOX9 (57% of all upregulated genes and 70% of the top ten 
are not bound by SOX9), while all but one of the top ten genes downregulated with 
SOX9 knockdown are direct targets (Appendix Table 6.2), and 64% of 
downregulated genes overall are bound. Several downregulated genes have enriched 
expression in pancreatic ductal cells while the only upregulated gene with ductal 
expression is LRRC6. Finally, EPCAM appears to be a promising candidate gene for 
further investigation because it is a direct target of SOX9, has enriched expression 
in zebrafish ductal cells, and is a marker of CACs (Appendix Table 6.2). 
SOX9 directly regulates expression of EPCAM 
 Given its promising expression in zebrafish pancreatic ductal cells, 
specifically CACs, we examined the relationship between SOX9 and EPCAM. 
EPCAM is a gene encoding a transmembrane protein that is a well-known marker 
of epithelium and has roles in the regulation of pancreas progenitor differentiation 
and cell adhesion385,393. Traces from our RNA-seq and ChIP-seq display the 
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decreased expression of EPCAM with SOX9 knockdown and a large SOX9 binding 
peak centered on the EPCAM transcriptional start site and promoter (Appendix 
Figure 6.4A). Additionally, we performed EPCAM and SOX9 antibody staining in 
PANC-1 cells transfected with either control or SOX9 siRNA. In control-transfected 
cells, SOX9 was expressed in all cell nuclei and EPCAM was expressed at the plasma 
membrane in all cells, albeit with varying intensity. Following SOX9 knockdown, 
SOX9 expression was reduced or absent in nuclei, and EPCAM expression was 
reduced or absent (Appendix Figure 6.4B). These results support the conclusion 
that SOX9 directly regulates EPCAM expression in PANC-1 cells. 
 Furthermore, as a preliminary validation of the relevance of this relationship 
in vivo, we examined the co-regulation of SOX9 and EPCAM in the TCGA pancreatic 
adenocarcinoma samples, as above. In doing so, we observe a strong positive 
correlation of SOX9 and EPCAM expression (r = 0.58; Appendix Figure 6.4C), 
suggesting that in vivo, as well as in vitro, SOX9 is a positive regulator of EPCAM 
expression.  
Discussion 
We previously demonstrated that Sox9b functions downstream of both Notch 
signaling and Retinoic Acid signaling in CACs379. All of these pathways are 
responsible for maintaining the progenitor identity of CACs. Because understanding 
the balance between progenitor maintenance and endocrine differentiation is 
central to characterizing beta-cell neogenesis, we sought to further elucidate the 
differentiation process by finding the downstream targets of Sox9b to better 
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understand how it functions as a central transcription factor in CAC progenitor 
identity. 
By performing RNA-seq and ChIP-seq on PANC-1 cells we were able to 
identify both direct targets (change in expression with SOX9 knockdown and SOX9 
binding peak near promoter) and indirect targets (change in expression with SOX9 
knockdown but no SOX9 binding peak) of SOX9. Because a number of the direct 
targets – like EpCAM and ESRP1 – are associated with epithelial cells, we wondered 
if a decrease in these genes results in an epithelial-to-mesenchymal transition 
(EMT) and this change in cell state alters the overall transcriptional profile of the 
PANC-1 cells. But simple EMT induction does not explain the changes in 
transcription we saw - looking at EMT markers by Western, IF, and qPCR showed 
that not only was there no EMT, but PANC-1 cells are already mesenchymal in 
nature before SOX9 knockdown (Appendix Supplementary Figure 6.1). So a 
change to a more mesenchymal phenotype is not responsible for the transcriptional 
differences seen in SOX9 knockdown. Because Sox9b is known to help CACs 
maintain their progenitor identity379, it is possible that knockdown of SOX9 in 
PANC-1 cells induces differentiation. This idea fits with our RNA-seq results – 
knockdown of SOX9 caused an increase in the expression of many ciliary genes 
which is a known consequence of differentiation404.  
GO analysis of genes downregulated with SOX9 knockdown showed that 
SOX9 is important for the positive regulation of Notch receptor targets. This aligns 
well with previous research, as the role of SOX9 in mediating the expression of 
downstream Notch signaling targets is well-established404–407. Understanding this 
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intricate cross-talk between SOX9 and Notch will be important to being able to 
manipulate progenitor differentiation to endocrine cells379,408.  
In comparison to previous work in other cell systems, we were able to easily 
see the SOX9 binding consensus sequence by pulling out the most enriched sequence 
at binding peaks – unlike the results of ChIP-seq performed in hair follicle stem 
cells400. They found that SOX9 was promiscuous in the sequences it bound to and 
never saw the consensus sequence. In addition, we saw that SOX9 preferentially 
bound to promoters, no matter the target gene, unlike what was seen in developing 
chondrocytes where SOX9 bound promoters for normal cellular functions and 
enhancers for chondrocyte-specific transcription409. These differences suggest that 
SOX9 may vary in how it acts as a transcription factor between different cell types. 
The direct targets of SOX9 that we found have some interesting connotations 
for both the ductal nature of CACs and their progenitor role. TINAGL1 is a 
matricellular protein that is known to bind integrins and laminins and is involved 
in both post-implantation development in the uterus391,410 and vascular smooth 
muscle adhesion390,411,412. Its homolog TINAG is important in tubulogenesis in the 
kidney413. CACs are known to line the branching ducts of the pancreas, so an 
extracellular molecule important for cell-adhesion (and the cell-cell signaling that 
goes along with it) makes biological sense for having an important SOX9-mediated 
role. ESRP1 is a regulator of splicing and is known for predicting favorable outcomes 
in cancer – i.e. its expression (and therefore splicing patterns of things like FGFR2) 
is thought to suppress cancer cell motility and therefore metastasis389,414–416. This 
would make biological sense in the context of CACs and regeneration – expression 
of Sox9b and therefore ESRP1 could promote the epithelial nature of CACs while 
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loss of these proteins would promote a more migratory, mesenchymal nature which 
is necessary for CACs to move to ablated islets and become endocrine cells. All of 
these genes would be interesting targets to follow up on by examining their 
expression in the zebrafish pancreas, developing knockouts, and assessing their 
importance in CAC maintenance and biology. 
Finally, we showed that SOX9 regulates the expression of EpCAM, a gene 
that encodes a single-pass transmembrane glycoprotein that localizes to tight 
junctions385. In addition to its role in cell adhesion, EpCAM can also undergo 
proteolytic cleavage to produce intra- and extracellular fragments that participate 
in signaling and transcriptional activation393. Although EpCAM is expressed 
broadly in epithelial tissues, higher expression is found in cells that are actively 
undergoing proliferation and differentiation events. Thus, EpCAM serves as a 
marker of stem and progenitor cell populations in the intestine, liver, and salivary 
gland386–388. It is also expressed in human and murine embryonic stem cells, where 
it may function upstream of the well-known pluripotency factors OCT4 and 
SOX2417,418. In the human fetal pancreas, EpCAM expression is enhanced in 
progenitor cells that are budding from the ductal epithelium to form new endocrine 
cells385. In the adult pancreas, it is most highly expressed in intercalated ducts385, 
which closely resemble CACs and have been proposed to serve as an endocrine 
progenitor population during regeneration378. Intriguingly, transgenic over-
expression of EpCAM in the mouse pancreas provokes the development of large 
endocrine islets419. Within the developing zebrafish liver EpCAM is expressed in 
Notch responsive progenitor cells called Biliary Epithelial Cells (BECs) that act as 
progenitors for hepatocytes during liver damage and development420,421. Many 
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parallels can be drawn between BECs and the CACs of the pancreas. These cell 
types both line ducts, and Notch signaling as well as Sox9 play an important role in 
maintaining the progenitor status of both. Using CRISPR-Cas9, we are developing 
our own EpCam knockout zebrafish with the same mutation as humans with 
congenital tufting enteropathy. We are hoping to use this knockout to examine the 
pancreatic and CAC phenotype when EpCam is lost. Because EpCAM is expressed 
in the mammalian pancreas and in the CACs of zebrafish, understanding how 
EpCAM acts downstream of Sox9 in the maintenance and identity of endocrine 
progenitor cells will help us better define the mechanisms behind endogenous 
increases in beta-cell mass. 
Materials and Methods 
RNA-seq library preparation and sequencing 
PANC-1 cells were transfected in 24-well plates with either 25 nM of control 
siRNA (Dharmacon catalog # D-001210-03-05) or 25 nM of SOX9 siRNA 
(Dharmacon catalog # M-021507-00-0005) using Lipofectamine 3000 (Thermo). 
After 48 hours, transfected cells were pooled (4 wells per replicate) and harvested, 
two replicates from each siRNA condition, and total RNA was isolated using a 
Qiagen RNeasy kit. RNA-seq libraries were created using the Illumina TruSeq 
Stranded Total RNA Sample Prep Kit. RNA-seq libraries were pooled and sequenced 





RNA-seq alignment, quantification, and analysis 
Reads were aligned to hg19 genome with HISAT2 (v2.0.5)205 and visualized 
with the Integrative Genomics Viewer172,173. Statistical analyses were performed 
using R221. Gene expression was quantified using the “featureCount” function of the 
Rsubread package (v1.28.1)206 to count read overlap with RefSeq genes. Genes with 
greater than one read across all four samples were submitted to DESeq2 (v1.18.1)422 
to identify genes differentially expressed across conditions 
(absolute(log2(foldchange)) > 1, adjusted p-value < 0.05). To generate the volcano 
plot, each gene’s log2(fold change) was plotted against the –log10(adjusted p-value), 
with genes meeting our criteria for significantly differentially expressed being 
plotted in red (upregulated) or blue (downregulated). Genes significantly up- and 
down-regulated were submitted to Enrichr423,424. The GO Biological Process was 
ranked on the basis of the combined score. Differentially expressed genes were 
annotated as being directly bound by SOX9 if there was a SOX9 binding event 
within 1kb (upstream or downstream) of the transcriptional start site (RefSeq, 
hg19).  
ChIP-seq library preparation and sequencing 
PANC-1 cells were grown in DMEM supplemented with 10% FBS at 37°C 
with 5.0% CO2 and passaged at 70-80% confluency. 2 biological replicates of ChIP-
seq were performed essentially as in Lee et al., 2006425. Briefly; approximately 2.0 X 
108 cells were crosslinked in 11% formaldehyde and stopped with 2.5 M glycine 
before being washed in 1X PBS, lysed, and sonicated for 35 minutes in a Bioruptor 
at 4°C to achieve a fragment size of approximately 200 bp. An input fraction was set 
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aside and the rest of the lysate was then incubated with 10 µg anti-SOX9 (AB5535, 
Millipore) overnight at 4°C. Antibody-bound chromatin was then purified using 
Protein G Dynabeads (Thermo) and crosslinking was reversed overnight at 65°C. 
ChIP-seq libraries were created using the Illumina TruSeq DNA Sample Prep Kit 
and quantified using Quant-iT PicoGreen dsDNA assay (Invitrogen). ChIP-seq 
libraries were pooled and sequenced on the Illumina HiSeq to a minimum depth of 
59 million, 1x50bp reads per library. 
ChIP-seq alignment, peak calling, and analysis 
Reads were aligned to hg19 with Bowtie2 (v2.2.5)198 in --local mode following 
TruSeq adapter removal and quality filtering with fastx toolkit (v0.0.14). Following 
alignment, reads with mapping score < MAPQ30, reads aligning to the 
mitochondria, and duplicate reads were removed with SAMtools (v1.3.1)199. ChIP-
seq replicates were combined and peaks were called on this joint file with MACS2 
(v2.1.1.20160309)200 using “callpeak”. Peaks with q-value >10-3 and those 
overlapping ENCODE blacklists were removed195. These peaks were annotated for 
their genomic location using CEAS (v1.0.0)201 of the Cistrome analysis pipeline202 
and the distance of each peak to the nearest gene’s transcriptional start site was 
quantified. The top 1000 most significant SOX9 peaks by q-value were submitted to 
SeqPos (v1.0.0) under default parameters. The top resulting position weight 
matrices were matched to motifs in the JASPAR database426. These same 1000 
peaks were submitted to GREAT (v3.0.0)218 under default settings except that the 
association rule was expanded such that “proximal” was defined as 5kb both 
upstream and downstream. The top 20 GO Biological Process terms by binomial 
rank were chosen for display and manually grouped by function. 
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Western blot confirmation of SOX9 knockdown 
PANC-1 cells were cultured in 6-well plates and transfected with 100 nM 
control siRNA (catalogue number above) or 100 nM SOX9 siRNA (catalogue number 
above). After 48 hours, cells were washed with PBS, isolated in RIPA buffer with 
complete, EDTA-free protease inhibitor (Roche) and vortexed. Supernatant was 
collected after centrifugation. Protein concentration was determined using the 
Pierce BCA Protein Assay Kit (Thermo Scientific) and 10 µg of protein was run on 
an Any kD Mini-PROTEAN TGX Precast Protein Gel (Bio-Rad). Transferred at 45V 
for 90 minutes. Membrane blocked for 1 hour and incubated overnight in primary 
antibody (Rabbit anti-Sox9 Santa Cruz sc-20095 1:500; N-Cadherin D4R1H XP 
Rabbit mAb Cell Signaling Technology 13116 1:1000; E-Cadherin 24E10 Rabbit 
mAb Cell Signaling Technology 3195 1:1000), washed 3 times, and incubated in anti-
rabbit HRP (Cell Signaling 7074S 1:2500) for 1 hour. Developed using SuperSignal 
West Dura Extended Duration Substrate (Thermo Scientific) and exposed on a 
ChemiDoc-It2. Stripped membrane using Restore Western Blot Stripping Buffer 
(Thermo Scientific) and repeated staining and development as above using rabbit 
anti-beta-tubulin (Cell Signaling 2128 1:1000) primary.  
Antibody staining 
PANC-1 cells were grown on gelatin-coated coverslips for 48 hours after 
siRNA transfection and fixed in 4% paraformaldehyde buffered in 1X PBS. 
Following 4X5 min washes in 1X PBS, coverslips were blocked in PBST + 10% FBS 
for 1 hour at room temperature and permeablized in 0.5% Triton in PBS for 20 
minutes, incubated with primary antibodies (rabbit anti-SOX9 Santa Cruz sc-20095 
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1:250; mouse anti-EPCAM Santa Cruz sc-66020 1:100; vimentin D21H3 XP Rabbit 
mAb Cell Signaling Technology 5741 1:100) at 4°C overnight. Coverslips were 
washed 4X5 min in blocking, then incubated in secondary antibody (Alexa Fluor 488 
donkey anti-rabbit, Alexa Fluor 488 donkey anti-mouse, Cy3 donkey anti-rabbit, 
Alexa Fluor 647 donkey anti-rabbit, all 1:500, Jackson ImmunoResearch 711-546-
152, 715-456-150, 711-166-152, 711-606-152 respectively) at 4°C overnight before 
4X5 min final PBST washes and a brief DAPI (1:2500 in PBS) stain. Images were 
collected using a Nikon A1-si Laser Scanning Confocal microscope.  
Quantitative PCR confirmation of differentially expressed genes 
PANC-1 cells were cultured in 12-well plates and transfected with 100 nM 
control siRNA (catalogue number above) or 100 nM SOX9 siRNA (catalogue number 
above). After 48 hours, RNA was isolated using Qiagen RNeasy Kit (with DNase 
digestion step) and cDNA was synthesized using Superscript III (Thermo) with 
random hexamer primers. 3 biological replicates of the quantitative PCR reactions 
were run in technical triplicate following the default SYBR green cycling conditions 
on an Applied Biosystems Viia 7 using 2x Power SYBR Green Master Mix (Applied 
Biosystems). Expression was calculated using the ΔΔCT method normalized to 
GAPDH expression and control siRNA transfected cells. Primer sequences can be 
found in Appendix Supplementary Table 6.2389,427,428.  
Correlation with TCGA pancreatic adenocarcinoma expression patterns 
mRNA-sequencing from 178 pancreatic adenocarcinoma samples from the 
TCGA was accessed and downloaded on March 2, 2018. Read-counts were log2 
normalized after addition of a pseudocount and a heatmap429 was generated for all 
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significantly upregulated and downregulated genes and SOX9’s expression patterns 
in these samples, using hierarchical clustering to group these selected genes into 
three clusters, and scaling the expression values by column. Individual gene 
correlation with SOX9 expression was calculated using the Pearson correlation 




Figures and supplementary materials 
 
Appendix Figure 6.1: Knockdown of SOX9 results in an increase of ciliary 
gene expression and a decrease in expression of genes negatively regulating 
proliferation 
 
(A) Western blot and (B) immunofluorescence confirms knockdown of SOX9 protein 
following SOX9 siRNA treatment. Scale bar is 100 um. (C) A volcano plot of adjusted 
p-value versus fold change upon SOX9 knockdown indicates that 93 genes exhibit 
significantly altered expression (33 decreased and 60 increased). (D) Quantitative 
PCR confirms all but one (SKIV2L) of the top five upregulated and top five 
downregulated genes observed with RNA-seq. 3 biological replicates per gene, error 
bars represent standard deviation (E) GO analysis of downregulated genes reveals 
a role for SOX9 in Notch signaling as well as in the regulation of proliferation. (F) 
GO analysis of upregulated genes is enriched for ciliary development and function. 









Appendix Figure 6.2: Expression data from pancreatic adenocarcinoma 
samples corroborate the expression patterns seen in PANC-1 cells 
 
(A) Expression analysis of the TCGA pancreatic adenocarcinoma sample data set 
indicate that upregulated genes identified by RNA-seq in PANC-1 cells tend to 
cluster together and are lowly expressed in these samples. Further, downregulated 
genes identified by RNA-seq in PANC-1 cells tend to cluster together and with SOX9 
and are highly expressed. (B) At an individual gene level, CCDC13, a gene that is 
upregulated following SOX9 knockdown, is negatively correlated with SOX9 
expression, suggesting that SOX9 negatively regulates this gene. (C) Conversely, 
ESRP1, a gene that is downregulated following SOX9 knockdown, is positively 









Appendix Figure 6.3: Characteristics of SOX9 gene regulation include 
promoter proximal binding and regulation of genes important to pancreatic 
biology 
 
(A) The most common motif seen at SOX9 binding sites is a homodimer of the 
forward and reverse known SOX9 binding sequences (tail to tail). (B) The second 
most common motif at SOX9 binding sites is recognized by FOS::JUN. (C) SOX9 
binding is enriched at promoters (≤1000 base-pairs upstream of a transcription start 
site). (D) As distance from the transcriptional start site increases, the proportion of 
SOX9 binding events decreases. (E) The nearest genes to SOX9 binding sites are 










Appendix Figure 6.4: RNA-seq and ChIP-seq in combination reveal 
EPCAM to be a direct target of SOX9 
 
(A) Traces corresponding to RNA-seq and ChIP-seq reads near the EPCAM gene 
confirm SOX9 knockdown and reveal SOX9 binding at the EPCAM transcription 
start site. (B) Immunofluorescence staining of PANC-1 cells confirms knockdown of 
both SOX9 and EPCAM protein by siSOX9. Scale bar is 100 um. (C) Expression of 
EPCAM and SOX9 in TCGA pancreatic adenocarcinoma samples are positively 
correlated, suggesting that EPCAM expression is upregulated by SOX9.   
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Appendix Table 6.1: Top 10 upregulated and downregulated genes 
















LRRC6  3.332 1.98E-02 
SPEF1  3.158 2.36E-04 
CASC1  2.809 4.45E-02 
DNAH7  2.663 1.85E-05 
C9orf116  2.583 3.86E-06 
CFAP69  2.358 2.09E-03 
CCDC13  2.191 4.77E-03 
AXIN2  2.175 1.59E-03 
C6orf165  2.169 1.64E-06 









TUB -1.437 1.09E-02 
LIN7C -1.470 2.28E-05 
SLC45A3 -1.475 1.23E-02 
DDAH1 -1.522 7.86E-06 
CENPM -1.550 2.91E-05 
EPCAM -1.762 1.85E-05 
RGCC -2.006 7.30E-03 
TINAGL1 -2.264 1.33E-05 
ESRP1 -2.307 2.52E-03 






Appendix Table 6.2: Assessing the top differentially expressed genes for 
evidence of direct SOX9 regulation, expression in pancreatic ductal cells, and 


















LRRC6 Yes Yes No 
SPEF1 Yes No No 
CASC1 No No No 
DNAH7 No No No 
C9orf116 No No No 
CFAP69 Yes No No 
CCDC13 No No No 
AXIN2 No No No 
C6orf165 No No No 









TUB Yes No No 
LIN7C Yes No No 
SLC45A3 Yes No No 
DDAH1 Yes No No 
CENPM Yes No No 
EPCAM Yes Yes Yes 
RGCC No Yes No 
TINAGL1 Yes Yes No 
ESRP1 Yes Yes No 





Appendix Supplementary Figure 6.1: Changes in gene expression from 
SOX9 knockdown do not correspond with changes in cell state 
 
(A) Immunofluorescence for the mesenchymal marker vimentin is present uniformly 
in PANC-1 cells. (B) There is no change in N-cadherin or E-cadherin expression by 
Western blot between PANC-1 cells treated with siControl versus siSOX9. (C) 
Quantitative PCR shows that while there is a general decrease in expression of 
FGFR2 with SOX9 knockdown, there is no change in the ratio between its splice 
isoforms or the splice isoforms of FGFR3, indicative of no EMT.60,61 Three biological 
replicates per gene, error bars represent standard deviation. 
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Appendix Supplementary Table 6.1: Correlation of SOX9 expression with 














































Appendix Supplementary Table 6.2: List of primers used for qPCR 
 
Gene Forward Reverse Source 
GAPDH GCACCGTCAAGGCTGAGAAC ATGGTGGTGAAGACGCCAGT Ishii et al. 2014 
SOX9 GGGCACCGGCCTCTACTCCA TCCCAGTGCTGGGGGCTGT  
LRRC6 CGCCATGGGCTGGATCACAGAA ATGCAACGAGAGTTCCTCCAGGG  
SPEF1 AGCGATGGAGTCCTTGTTGCAGAG TGGAGAGAGTTGGCGGGGACA  
CASC1 AGGTGTTTTCCTGAAGCAGAGA AGGATCAGGACTCCCATCACA  
DNAH7 TGCCTCTATCGTCCTAGGGG GCTGGCCGATTTATCCTGCT  
C9orf116 GGAGAGGACCAGCGACTACT ACAGCCTTCTGGGTCCTGTA  
SKIV2L CGGGAGCGAATGCAGATACA GTTCGGAGCACCTCTACTCG  
ESRP1 CAATATTGCCAAGGGAGGTG GTCCCCATGTGATGTTTGTG Ishii et al. 2014 
TINAGL1 TCCCAAACAGCAGTTGGATGTA GGTTCTTGGTCACACTGCCA  
RGCC GCACCTGGAGCGCATGAAGC TGAATCTGCACTCTCCGAGTCGCT  
EPCAM CGCGTTCGGGCTTCTGCTTG ATTTGGCAGCCAGCTTTGAGCA  
FGFR2-IIIb CGTGGAAAAGAACGGCAGTAAATA GAACTATTTATCCCCGAGTGCTTG Ranieri et al. 2015 
FGFR2-IIIc TGAGGACGCTGGGGAATATACG TAGTCTGGGGAAGCTGTAATCTCCT Ranieri et al. 2015 
FGFR3-IIIb TCAAGTCCTGGATCAGTGAGAGT AGGAAGAAGCCCACCCCG Tomlinson et al. 2005 
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